{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 1339, "items": [{"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T21:26:31Z", "timestamp": 1574371591291}, "publisher-location": "Weinheim, Germany", "reference-count": 0, "publisher": "Wiley-VCH Verlag GmbH", "isbn-type": [{"value": "9783527312375", "type": "print"}, {"value": "9783527619665", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9783527619665.ch40", "type": "book-chapter", "created": {"date-parts": [[2008, 5, 26]], "date-time": "2008-05-26T10:48:00Z", "timestamp": 1211798880000}, "page": "1014-1032", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Histone Deacetylase Inhibitors: Development as Anticancer Agents"], "prefix": "10.1002", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}], "member": "311", "container-title": ["Apoptosis and Cancer Therapy"], "deposited": {"date-parts": [[2013, 12, 16]], "date-time": "2013-12-16T23:08:32Z", "timestamp": 1387235312000}, "score": 58.86979, "issued": {"date-parts": [[null]]}, "ISBN": ["9783527619665", "9783527312375"], "references-count": 0, "URL": "http://dx.doi.org/10.1002/9783527619665.ch40"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T08:36:07Z", "timestamp": 1575189367181}, "reference-count": 93, "publisher": "Informa Healthcare", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Opinion on Investigational Drugs"], "published-print": {"date-parts": [[2005, 12]]}, "DOI": "10.1517/13543784.14.12.1497", "type": "journal-article", "created": {"date-parts": [[2005, 11, 25]], "date-time": "2005-11-25T10:01:46Z", "timestamp": 1132912906000}, "page": "1497-1511", "source": "Crossref", "is-referenced-by-count": 179, "title": ["Histone deacetylase inhibitors: discovery and development as anticancer agents"], "prefix": "10.1517", "volume": "14", "author": [{"given": "Paul A", "family": "Marks", "sequence": "first", "affiliation": []}, {"given": "Milos", "family": "Dokmanovic", "sequence": "additional", "affiliation": []}], "member": "3197", "published-online": {"date-parts": [[2005, 11, 25]]}, "reference": [{"key": "CIT0001", "DOI": "10.1016/S0065-230X(02)86002-X", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1038/35106079", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1038/nature02017", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1172/JCI0216547", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1101/gad.927301", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1038/nature01411", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1016/S0092-8674(04)00044-3", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1016/S0955-0674(03)00013-9", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "DOI": "10.1016/S0065-230X(04)91004-4", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "DOI": "10.1042/bj20021321", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1146/annurev.biochem.73.011303.073651", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "author": "MET S", "first-page": "1509", "year": "2004", "journal-title": "Int. J. OncoL"}, {"key": "CIT0016", "DOI": "10.1200/JCO.2005.16.600", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1016/j.jmb.2004.02.006", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1146/annurev.pharmtox.45.120403.095825", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1016/S1535-6108(03)00165-X", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1007/s00726-004-0087-3", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1073/pnas.182372299", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1073/pnas.0307708100", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.1002/jcb.20179", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1074/jbc.M105993200", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1073/pnas.191375098", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "DOI": "10.1016/S0168-9525(03)00073-8", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1073/pnas.140199597", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "author": "LI X", "volume": "279", "first-page": "34201", "year": "2004", "journal-title": "Chem."}, {"key": "CIT0037", "DOI": "10.1016/j.molcel.2005.04.021", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1016/S0092-8674(03)00939-5", "doi-asserted-by": "publisher"}, {"key": "CIT0040", "DOI": "10.1006/bbrc.1999.1389", "doi-asserted-by": "publisher"}, {"key": "CIT0041", "DOI": "10.1073/pnas.96.9.4868", "doi-asserted-by": "publisher"}, {"key": "CIT0042", "author": "KAO HY", "volume": "14", "first-page": "55", "year": "2000", "journal-title": "Genes Den"}, {"key": "CIT0043", "DOI": "10.1016/S1074-7613(03)00109-2", "doi-asserted-by": "publisher"}, {"key": "CIT0044", "DOI": "10.1074/jbc.M108931200", "doi-asserted-by": "publisher"}, {"key": "CIT0045", "DOI": "10.1074/jbc.M111871200", "doi-asserted-by": "publisher"}, {"key": "CIT0046", "DOI": "10.1016/j.cell.2004.10.024", "doi-asserted-by": "publisher"}, {"key": "CIT0047", "DOI": "10.1128/MCB.24.19.8467-8476.2004", "doi-asserted-by": "publisher"}, {"key": "CIT0048", "DOI": "10.1016/S0092-8674(02)00861-9", "doi-asserted-by": "publisher"}, {"key": "CIT0050", "DOI": "10.1074/jbc.274.34.23977", "doi-asserted-by": "publisher"}, {"key": "CIT0051", "DOI": "10.1016/j.bbrc.2003.09.043", "doi-asserted-by": "publisher"}, {"key": "CIT0052", "DOI": "10.1016/S1535-6108(04)00114-X", "doi-asserted-by": "publisher"}, {"key": "CIT0053", "DOI": "10.1074/jbc.M908066199", "doi-asserted-by": "publisher"}, {"key": "CIT0054", "author": "TOU L", "volume": "24", "first-page": "3132", "year": "2004", "journal-title": "Cell. Biol."}, {"key": "CIT0055", "DOI": "10.1074/jbc.M402475200", "doi-asserted-by": "publisher"}, {"key": "CIT0056", "author": "HUANG Y", "volume": "62", "first-page": "2913", "year": "2002", "journal-title": "Cancer Res"}, {"key": "CIT0058", "DOI": "10.1517/13543784.13.1.21", "doi-asserted-by": "publisher"}, {"key": "CIT0059", "DOI": "10.1111/j.1349-7006.2001.tb02153.x", "doi-asserted-by": "publisher"}, {"key": "CIT0060", "DOI": "10.1002/pros.20022", "doi-asserted-by": "publisher"}, {"key": "CIT0061", "DOI": "10.4161/cc.3.6.927", "doi-asserted-by": "publisher"}, {"key": "CIT0062", "DOI": "10.1002/ijc.21240", "doi-asserted-by": "publisher"}, {"key": "CIT0063", "DOI": "10.1002/ijc.20395", "doi-asserted-by": "publisher"}, {"key": "CIT0064", "author": "SCANLAN MJ WELTS", "volume": "62", "first-page": "4041", "year": "2002", "journal-title": "Cancer Res."}, {"key": "CIT0065", "DOI": "10.1158/1078-0432.CCR-04-0455", "doi-asserted-by": "publisher"}, {"key": "CIT0066", "DOI": "10.1016/S0092-8674(00)81664-5", "doi-asserted-by": "publisher"}, {"key": "CIT0067", "DOI": "10.1111/j.1349-7006.2004.tb03239.x", "doi-asserted-by": "publisher"}, {"key": "CIT0068", "DOI": "10.1021/jm0303094", "doi-asserted-by": "publisher"}, {"key": "CIT0070", "DOI": "10.1073/pnas.95.6.3003", "doi-asserted-by": "publisher"}, {"key": "CIT0071", "DOI": "10.1016/j.bmcl.2004.08.016", "doi-asserted-by": "publisher"}, {"key": "CIT0072", "DOI": "10.2174/0929867033456576", "doi-asserted-by": "publisher"}, {"key": "CIT0073", "author": "YOSHIDA M", "volume": "10", "first-page": "2351", "year": "2003", "journal-title": "Med. Chem."}, {"key": "CIT0075", "DOI": "10.1002/ijc.20372", "doi-asserted-by": "publisher"}, {"key": "CIT0076", "DOI": "10.1158/1078-0432.CCR-03-0709", "doi-asserted-by": "publisher"}, {"key": "CIT0077", "DOI": "10.1073/pnas.0430973100", "doi-asserted-by": "publisher"}, {"key": "CIT0079", "DOI": "10.1038/43710", "doi-asserted-by": "publisher"}, {"key": "CIT0081", "DOI": "10.1016/j.str.2004.04.012", "doi-asserted-by": "publisher"}, {"key": "CIT0083", "author": "GRAY SG", "volume": "24", "first-page": "773", "year": "2004", "journal-title": "Int. J. Oncol"}, {"key": "CIT0085", "author": "PEART MJ", "volume": "102", "first-page": "3697", "year": "2005", "journal-title": "VAN LAAR RK et al.: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA"}, {"key": "CIT0086", "DOI": "10.1073/pnas.2536759100", "doi-asserted-by": "publisher"}, {"key": "CIT0087", "DOI": "10.1128/MCB.23.12.4162-4173.2003", "doi-asserted-by": "publisher"}, {"key": "CIT0088", "author": "VAN LINT C", "volume": "5", "first-page": "245", "year": "1996", "journal-title": "Gene Exp."}, {"key": "CIT0090", "DOI": "10.1016/S0959-8049(03)00072-8", "doi-asserted-by": "publisher"}, {"key": "CIT0091", "DOI": "10.1073/pnas.180316197", "doi-asserted-by": "publisher"}, {"key": "CIT0092", "author": "WARRENER R", "volume": "17", "first-page": "1550", "year": "2003", "journal-title": "FASEB J.", "DOI": "10.1096/fj.02-1003fje", "doi-asserted-by": "crossref"}, {"key": "CIT0093", "DOI": "10.4161/cc.3.10.1195", "doi-asserted-by": "publisher"}, {"key": "CIT0094", "DOI": "10.1038/sj.onc.1207893", "doi-asserted-by": "publisher"}, {"key": "CIT0096", "DOI": "10.1073/pnas.0408732102", "doi-asserted-by": "publisher"}, {"issue": "17", "key": "CIT0099", "doi-asserted-by": "crossref", "first-page": "7832", "DOI": "10.1158/0008-5472.CAN-04-4608", "volume": "65", "author": "XU W-S, PEREZ G, NGO L, GUI C-Y, MARKS", "year": "2005", "journal-title": "Cancer Res."}, {"key": "CIT0100", "DOI": "10.1073/pnas.0408345102", "doi-asserted-by": "publisher"}, {"key": "CIT0101", "author": "ROSATO RR", "volume": "2", "first-page": "1273", "year": "2003", "journal-title": "Mol. Cancer Ther."}, {"key": "CIT0102", "DOI": "10.1016/S0891-5849(00)00313-0", "doi-asserted-by": "publisher"}, {"key": "CIT0103", "DOI": "10.1089/ars.2000.2.4-811", "doi-asserted-by": "publisher"}, {"key": "CIT0104", "DOI": "10.1089/152308604771978336", "doi-asserted-by": "publisher"}, {"key": "CIT0105", "DOI": "10.1046/j.1432-1327.2000.01701.x", "doi-asserted-by": "publisher"}, {"key": "CIT0107", "author": "PIEKARZ R", "volume": "10", "first-page": "2289", "year": "2004", "journal-title": "Pharm. Des."}, {"key": "CIT0108", "DOI": "10.1158/0008-5472.CAN-03-2629", "doi-asserted-by": "publisher"}, {"key": "CIT0109", "author": "COFFEY DC", "volume": "61", "first-page": "3591", "year": "2001", "journal-title": "Cancer Res."}, {"key": "CIT0110", "DOI": "10.1532/IJH97.04032", "doi-asserted-by": "publisher"}, {"key": "CIT0111", "author": "PEI XY", "volume": "10", "first-page": "3839", "year": "2004", "journal-title": "Cancer Res."}, {"key": "CIT0112", "author": "GEORGE P", "volume": "2005", "first-page": "1768", "journal-title": "Blood"}, {"key": "CIT0117", "DOI": "10.1038/sj.onc.1205777", "doi-asserted-by": "publisher"}, {"key": "CIT0118", "DOI": "10.1182/blood-2003-09-3068", "doi-asserted-by": "publisher"}, {"key": "CIT0119", "DOI": "10.1038/ncponc0106", "doi-asserted-by": "publisher"}, {"key": "CIT0121", "DOI": "10.1182/blood-2003-12-4333", "doi-asserted-by": "publisher"}, {"key": "CIT0122", "author": "NERVI C", "volume": "104", "first-page": "1805", "year": "2004", "journal-title": "ASH Annual Meeting Abstracts"}, {"key": "CIT0123", "DOI": "10.1002/jcb.20532", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Investigational Drugs"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1517/13543784.14.12.1497", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 7]], "date-time": "2019-04-07T21:18:06Z", "timestamp": 1554671886000}, "score": 52.663788, "issued": {"date-parts": [[2005, 11, 25]]}, "references-count": 93, "journal-issue": {"published-online": {"date-parts": [[2005, 11, 25]]}, "published-print": {"date-parts": [[2005, 12]]}, "issue": "12"}, "alternative-id": ["10.1517/13543784.14.12.1497"], "URL": "http://dx.doi.org/10.1517/13543784.14.12.1497", "relation": {"cites": []}, "ISSN": ["1354-3784", "1744-7658"], "issn-type": [{"value": "1354-3784", "type": "print"}, {"value": "1744-7658", "type": "electronic"}], "subject": ["Pharmacology (medical)", "Pharmacology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T20:09:58Z", "timestamp": 1574453398394}, "reference-count": 166, "publisher": "Informa Healthcare", "issue": "9", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Opinion on Investigational Drugs"], "published-print": {"date-parts": [[2010, 9]]}, "DOI": "10.1517/13543784.2010.510514", "type": "journal-article", "created": {"date-parts": [[2010, 8, 5]], "date-time": "2010-08-05T13:08:58Z", "timestamp": 1281013738000}, "page": "1049-1066", "source": "Crossref", "is-referenced-by-count": 167, "title": ["The clinical development of histone deacetylase inhibitors as targeted anticancer drugs"], "prefix": "10.1517", "volume": "19", "author": [{"given": "Paul A", "family": "Marks", "sequence": "first", "affiliation": [{"name": "Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Cell Biology and Genetics Program, 1275 York Ave, New York, NY 10065, USA"}]}], "member": "3197", "published-online": {"date-parts": [[2010, 8, 5]]}, "reference": [{"issue": "1", "key": "CIT0001", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1016/j.molmed.2009.11.003", "volume": "16", "author": "Handel AE", "year": "2009", "journal-title": "Trends Mol Med"}, {"key": "CIT0002", "DOI": "10.1242/jeb.019752", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1016/S0959-437X(03)00015-7", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1146/annurev.biochem.76.052705.162114", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1126/science.1063127", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1002/jcb.22185", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1126/science.1175371", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1038/nrg2485", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1016/j.jmb.2004.02.006", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1093/emboj/21.11.2672", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1158/1541-7786.MCR-07-0324", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "DOI": "10.1101/gad.1563807", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "DOI": "10.1158/1535-7163.MCT-08-0985", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1016/j.molcel.2008.02.030", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1126/science.1166226", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1126/science.1181046", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1016/j.cell.2006.05.040", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1073/pnas.0430973100", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1073/pnas.0803749105", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.1016/j.molcel.2007.05.033", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1016/j.molcel.2005.04.021", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1016/S0092-8674(03)00939-5", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1038/sj.emboj.7601210", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.1038/ni.1673", "doi-asserted-by": "publisher"}, {"issue": "4", "key": "CIT0025", "first-page": "245", "volume": "5", "author": "Van Lint C", "year": "1996", "journal-title": "Gene Expr"}, {"key": "CIT0026", "DOI": "10.1073/pnas.2536759100", "doi-asserted-by": "publisher"}, {"issue": "4", "key": "CIT0027", "first-page": "773", "volume": "24", "author": "Gray SG", "year": "2004", "journal-title": "Int J Oncol"}, {"key": "CIT0028", "DOI": "10.1073/pnas.0500369102", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1158/1535-7163.MCT-07-0251", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1002/jcb.20179", "doi-asserted-by": "publisher"}, {"issue": "6749", "key": "CIT0031", "doi-asserted-by": "crossref", "first-page": "188", "DOI": "10.1038/43710", "volume": "401", "author": "Finnin MS", "year": "1999", "journal-title": "Nature"}, {"key": "CIT0032", "DOI": "10.1016/j.str.2004.04.012", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1073/pnas.0404603101", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "author": "Bottomley MJ", "first-page": "M803514200", "year": "2008", "journal-title": "J Biol Chem"}, {"key": "CIT0035", "DOI": "10.2174/156802609788085304", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "DOI": "10.1038/ng1773", "doi-asserted-by": "publisher"}, {"key": "CIT0037", "DOI": "10.1126/science.1133427", "doi-asserted-by": "publisher"}, {"key": "CIT0038", "DOI": "10.1158/1535-7163.MCT-08-0860", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1016/j.cell.2007.01.029", "doi-asserted-by": "publisher"}, {"issue": "4", "key": "CIT0040", "first-page": "769", "volume": "18", "author": "Nakagawa M", "year": "2007", "journal-title": "Oncol Rep"}, {"key": "CIT0041", "DOI": "10.1007/s10549-005-6001-1", "doi-asserted-by": "publisher"}, {"key": "CIT0042", "DOI": "10.1016/j.oraloncology.2008.08.011", "doi-asserted-by": "publisher"}, {"key": "CIT0043", "DOI": "10.1111/j.1365-2141.2009.07887.x", "doi-asserted-by": "publisher"}, {"key": "CIT0044", "DOI": "10.1517/14728220903241658", "doi-asserted-by": "publisher"}, {"key": "CIT0045", "DOI": "10.1038/sj.onc.1204853", "doi-asserted-by": "publisher"}, {"key": "CIT0046", "DOI": "10.1038/sj.onc.1204639", "doi-asserted-by": "publisher"}, {"key": "CIT0047", "DOI": "10.1038/nbt1272", "doi-asserted-by": "publisher"}, {"key": "CIT0048", "DOI": "10.1517/13543770903393789", "doi-asserted-by": "publisher"}, {"key": "CIT0049", "DOI": "10.1016/j.canlet.2009.01.040", "doi-asserted-by": "publisher"}, {"key": "CIT0050", "DOI": "10.1021/jm701384x", "doi-asserted-by": "publisher"}, {"key": "CIT0051", "DOI": "10.2174/187152009788679976", "doi-asserted-by": "publisher"}, {"issue": "6", "key": "CIT0052", "doi-asserted-by": "crossref", "first-page": "505", "DOI": "10.2174/138161208783885353", "volume": "14", "author": "Butler KV", "year": "2008", "journal-title": "Curr Pharm Des"}, {"key": "CIT0053", "DOI": "10.1016/j.canlet.2009.02.013", "doi-asserted-by": "publisher"}, {"key": "CIT0054", "DOI": "10.1021/jm800988r", "doi-asserted-by": "publisher"}, {"key": "CIT0055", "DOI": "10.1073/pnas.191208598", "doi-asserted-by": "publisher"}, {"key": "CIT0056", "DOI": "10.1073/pnas.0408732102", "doi-asserted-by": "publisher"}, {"key": "CIT0057", "DOI": "10.1016/j.canlet.2008.06.005", "doi-asserted-by": "publisher"}, {"key": "CIT0058", "DOI": "10.1073/pnas.182372299", "doi-asserted-by": "publisher"}, {"key": "CIT0059", "DOI": "10.1158/1541-7786.MCR-06-0111", "doi-asserted-by": "publisher"}, {"key": "CIT0060", "DOI": "10.1073/pnas.0707828104", "doi-asserted-by": "publisher"}, {"key": "CIT0061", "DOI": "10.1158/1078-0432.CCR-04-2088", "doi-asserted-by": "publisher"}, {"key": "CIT0062", "DOI": "10.1016/j.canlet.2009.02.042", "doi-asserted-by": "publisher"}, {"key": "CIT0063", "DOI": "10.1158/0008-5472.CAN-06-3996", "doi-asserted-by": "publisher"}, {"key": "CIT0064", "DOI": "10.1073/pnas.0307342101", "doi-asserted-by": "publisher"}, {"key": "CIT0065", "DOI": "10.1158/1535-7163.MCT-06-0022", "doi-asserted-by": "publisher"}, {"key": "CIT0066", "DOI": "10.1073/pnas.180316197", "doi-asserted-by": "publisher"}, {"key": "CIT0067", "DOI": "10.1073/pnas.0307708100", "doi-asserted-by": "publisher"}, {"key": "CIT0068", "DOI": "10.1128/MCB.23.12.4162-4173.2003", "doi-asserted-by": "publisher"}, {"key": "CIT0069", "DOI": "10.1038/sj.onc.1207654", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "CIT0070", "first-page": "45", "volume": "24", "author": "Lee E-M", "year": "2009", "journal-title": "Intl J Mol Med"}, {"key": "CIT0071", "DOI": "10.1158/0008-5472.CAN-09-2327", "doi-asserted-by": "publisher"}, {"key": "CIT0072", "DOI": "10.1517/14728222.9.4.809", "doi-asserted-by": "publisher"}, {"key": "CIT0073", "DOI": "10.1073/pnas.0505585102", "doi-asserted-by": "publisher"}, {"key": "CIT0074", "DOI": "10.1038/sj.onc.1207893", "doi-asserted-by": "publisher"}, {"key": "CIT0075", "DOI": "10.1038/sj.onc.1207830", "doi-asserted-by": "publisher"}, {"key": "CIT0076", "DOI": "10.1038/nm1160", "doi-asserted-by": "publisher"}, {"key": "CIT0077", "DOI": "10.1073/pnas.0607518103", "doi-asserted-by": "publisher"}, {"key": "CIT0078", "DOI": "10.1146/annurev.biochem.73.011303.073706", "doi-asserted-by": "publisher"}, {"issue": "9", "key": "CIT0079", "first-page": "3591", "volume": "61", "author": "Coffey DC", "year": "2001", "journal-title": "Cancer Res"}, {"key": "CIT0080", "DOI": "10.1038/onc.2009.306", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "CIT0081", "first-page": "216", "volume": "69", "author": "Rosato RR", "year": "2006", "journal-title": "Mol Pharmacol"}, {"issue": "4", "key": "CIT0082", "first-page": "425", "volume": "3", "author": "Zhang XD", "year": "2004", "journal-title": "Mol Cancer Ther"}, {"key": "CIT0083", "DOI": "10.1073/pnas.0408345102", "doi-asserted-by": "publisher"}, {"issue": "17", "key": "CIT0084", "doi-asserted-by": "crossref", "first-page": "7832", "DOI": "10.1158/0008-5472.CAN-04-4608", "volume": "65", "author": "Xu WS", "year": "2005", "journal-title": "Cancer Res"}, {"key": "CIT0085", "DOI": "10.1091/mbc.E03-01-0860", "doi-asserted-by": "publisher"}, {"key": "CIT0086", "DOI": "10.1038/35055010", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "CIT0087", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.4161/cbt.4.2.1441", "volume": "4", "author": "Dowling M", "year": "2005", "journal-title": "Cancer Biol Ther"}, {"key": "CIT0088", "DOI": "10.4161/cc.4.5.1690", "doi-asserted-by": "publisher"}, {"issue": "13", "key": "CIT0089", "first-page": "3637", "volume": "63", "author": "Rosato RR", "year": "2003", "journal-title": "Cancer Res"}, {"key": "CIT0090", "DOI": "10.1089/ars.2007.9.25", "doi-asserted-by": "publisher"}, {"key": "CIT0091", "DOI": "10.1016/j.semcancer.2006.09.005", "doi-asserted-by": "publisher"}, {"key": "CIT0092", "DOI": "10.1074/jbc.274.31.21645", "doi-asserted-by": "publisher"}, {"key": "CIT0093", "DOI": "10.1074/jbc.M512719200", "doi-asserted-by": "publisher"}, {"issue": "5", "key": "CIT0094", "doi-asserted-by": "crossref", "first-page": "2401", "DOI": "10.1074/jbc.C500241200", "volume": "281", "author": "Zhang YY", "year": "2006", "journal-title": "J Biol Chem"}, {"key": "CIT0095", "DOI": "10.1074/jbc.C500186200", "doi-asserted-by": "publisher"}, {"key": "CIT0096", "DOI": "10.1128/MCB.22.22.7982-7992.2002", "doi-asserted-by": "publisher"}, {"key": "CIT0097", "DOI": "10.1074/jbc.M505733200", "doi-asserted-by": "publisher"}, {"key": "CIT0098", "DOI": "10.2174/156802606777812068", "doi-asserted-by": "publisher"}, {"key": "CIT0099", "DOI": "10.1016/j.canlet.2008.11.012", "doi-asserted-by": "publisher"}, {"key": "CIT0100", "DOI": "10.4161/cc.5.21.3409", "doi-asserted-by": "publisher"}, {"key": "CIT0101", "DOI": "10.1128/MCB.26.6.2019-2028.2006", "doi-asserted-by": "publisher"}, {"key": "CIT0102", "DOI": "10.1158/0008-5472.CAN-05-4598", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "CIT0103", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1007/s10637-006-9000-0", "volume": "25", "author": "Kano Y", "year": "2007", "journal-title": "Invest New Drugs"}, {"key": "CIT0104", "DOI": "10.1210/me.2008-0179", "doi-asserted-by": "publisher"}, {"key": "CIT0105", "DOI": "10.1016/j.canlet.2009.01.002", "doi-asserted-by": "publisher"}, {"key": "CIT0106", "DOI": "10.1158/1078-0432.CCR-08-1587", "doi-asserted-by": "publisher"}, {"key": "CIT0107", "DOI": "10.1016/j.canlet.2009.02.019", "doi-asserted-by": "publisher"}, {"key": "CIT0108", "DOI": "10.1158/1078-0432.CCR-08-2786", "doi-asserted-by": "publisher"}, {"key": "CIT0109", "DOI": "10.1158/1078-0432.CCR-08-2788", "doi-asserted-by": "publisher"}, {"key": "CIT0110", "DOI": "10.1200/JCO.2008.21.6150", "doi-asserted-by": "publisher"}, {"key": "CIT0111", "DOI": "10.2165/11315680-000000000-00000", "doi-asserted-by": "publisher"}, {"key": "CIT0112", "DOI": "10.1038/sj.bjc.6604557", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "CIT0113", "first-page": "1123", "volume": "109", "author": "Jennifer LB", "year": "2007", "journal-title": "Blood"}, {"key": "CIT0114", "DOI": "10.1038/sj.bjp.0707166", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "CIT0115", "doi-asserted-by": "crossref", "first-page": "157", "DOI": "10.1038/onc.2009.334", "volume": "29", "author": "Villagra A", "year": "2009", "journal-title": "Oncogene"}, {"key": "CIT0116", "DOI": "10.2174/156802609788085313", "doi-asserted-by": "publisher"}, {"issue": "10", "key": "CIT0117", "first-page": "854", "volume": "7", "author": "Kazantsev AG", "year": "2008", "journal-title": "Nat Rev"}, {"issue": "34", "key": "CIT0118", "doi-asserted-by": "crossref", "first-page": "3940", "DOI": "10.2174/138161209789649349", "volume": "15", "author": "Antonello M", "year": "2009", "journal-title": "Curr Pharm Des"}, {"key": "CIT0119", "DOI": "10.1073/pnas.0437870100", "doi-asserted-by": "publisher"}, {"key": "CIT0120", "DOI": "10.1016/j.exphem.2005.08.007", "doi-asserted-by": "publisher"}, {"key": "CIT0121", "DOI": "10.1038/sj.bjp.0707165", "doi-asserted-by": "publisher"}, {"key": "CIT0122", "DOI": "10.2174/092986707780362880", "doi-asserted-by": "publisher"}, {"key": "CIT0123", "DOI": "10.1111/j.1365-2184.2009.00633.x", "doi-asserted-by": "publisher"}, {"key": "CIT0124", "DOI": "10.1016/j.jss.2009.04.012", "doi-asserted-by": "publisher"}, {"key": "CIT0125", "DOI": "10.1016/j.canlet.2009.02.027", "doi-asserted-by": "publisher"}, {"key": "CIT0126", "DOI": "10.1038/ncponc0106", "doi-asserted-by": "publisher"}, {"key": "CIT0127", "DOI": "10.1517/13543784.16.7.1111", "doi-asserted-by": "publisher"}, {"key": "CIT0128", "DOI": "10.1158/1078-0432.CCR-06-0511", "doi-asserted-by": "publisher"}, {"key": "CIT0129", "DOI": "10.1016/j.canlet.2009.03.016", "doi-asserted-by": "publisher"}, {"key": "CIT0130", "DOI": "10.1158/1078-0432.CCR-07-2114", "doi-asserted-by": "publisher"}, {"key": "CIT0131", "DOI": "10.1016/S0891-5849(00)00313-0", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "CIT0132", "first-page": "1129", "volume": "21", "author": "Chung YM", "year": "2001", "journal-title": "Anticancer Res"}, {"key": "CIT0133", "DOI": "10.1158/1541-7786.MCR-08-0296", "doi-asserted-by": "publisher"}, {"key": "CIT0134", "DOI": "10.1200/JCO.2005.14.167", "doi-asserted-by": "publisher"}, {"key": "CIT0135", "DOI": "10.1111/j.1349-7006.2009.01237.x", "doi-asserted-by": "publisher"}, {"key": "CIT0136", "DOI": "10.1016/j.ygyno.2008.01.009", "doi-asserted-by": "publisher"}, {"key": "CIT0137", "DOI": "10.1007/s10637-008-9131-6", "doi-asserted-by": "publisher"}, {"key": "CIT0138", "DOI": "10.1007/s10637-007-9075-2", "doi-asserted-by": "publisher"}, {"key": "CIT0139", "DOI": "10.1158/1078-0432.CCR-07-0162", "doi-asserted-by": "publisher"}, {"key": "CIT0140", "DOI": "10.1158/1078-0432.CCR-08-0122", "doi-asserted-by": "publisher"}, {"key": "CIT0141", "DOI": "10.1210/jc.2008-1631", "doi-asserted-by": "publisher"}, {"key": "CIT0142", "DOI": "10.1200/JCO.2008.19.0694", "doi-asserted-by": "publisher"}, {"key": "CIT0143", "DOI": "10.1111/j.1349-7006.2009.01360.x", "doi-asserted-by": "publisher"}, {"key": "CIT0144", "DOI": "10.1200/JCO.2005.01.9679", "doi-asserted-by": "publisher"}, {"key": "CIT0145", "DOI": "10.1093/annonc/mdn031", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "CIT0146", "doi-asserted-by": "crossref", "first-page": "1060", "DOI": "10.1182/blood-2007-06-098061", "volume": "111", "author": "Garcia-Manero G", "year": "2008", "journal-title": "Blood"}, {"key": "CIT0147", "DOI": "10.1097/JTO.0b013e318191520c", "doi-asserted-by": "publisher"}, {"key": "CIT0148", "DOI": "10.1158/1078-0432.CCR-07-1786", "doi-asserted-by": "publisher"}, {"issue": "15", "key": "CIT0149", "first-page": "8580", "volume": "27", "author": "Zain JM", "year": "2009", "journal-title": "J Clin Oncol"}, {"key": "CIT0150", "DOI": "10.1038/sj.leu.2404860", "doi-asserted-by": "publisher"}, {"key": "CIT0151", "author": "Evens AM", "volume": "114", "first-page": "2726", "year": "2009", "journal-title": "Am Society Hematol"}, {"key": "CIT0152", "DOI": "10.1158/1078-0432.CCR-09-0547", "doi-asserted-by": "publisher"}, {"key": "CIT0153", "DOI": "10.1158/1535-7163.MCT-09-0689", "doi-asserted-by": "publisher"}, {"key": "CIT0154", "DOI": "10.1158/1078-0432.CCR-07-0135", "doi-asserted-by": "publisher"}, {"key": "CIT0155", "DOI": "10.1158/1078-0432.CCR-05-2689", "doi-asserted-by": "publisher"}, {"key": "CIT0156", "DOI": "10.1200/JCO.2006.06.4964", "doi-asserted-by": "publisher"}, {"key": "CIT0157", "DOI": "10.1158/1078-0432.CCR-05-2095", "doi-asserted-by": "publisher"}, {"issue": "14", "key": "CIT0158", "doi-asserted-by": "crossref", "first-page": "7279", "DOI": "10.1200/jco.2004.22.14_suppl.7279", "volume": "22", "author": "Reid T", "year": "2004", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "CIT0159", "first-page": "3047", "volume": "7", "author": "Carducci MA", "year": "2001", "journal-title": "Clin Cancer Res"}, {"issue": "8", "key": "CIT0160", "first-page": "2292", "volume": "7", "author": "Gilbert J", "year": "2001", "journal-title": "Clin Cancer Res"}, {"key": "CIT0161", "DOI": "10.1215/S1152851704000183", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "CIT0162", "doi-asserted-by": "crossref", "first-page": "131", "DOI": "10.1007/s10637-006-9017-4", "volume": "25", "author": "Camacho LH", "year": "2007", "journal-title": "Invest New Drugs"}, {"key": "CIT0163", "DOI": "10.1158/1078-0432.CCR-07-0791", "doi-asserted-by": "publisher"}, {"key": "CIT0164", "DOI": "10.1038/sj.bjc.6603851", "doi-asserted-by": "publisher"}, {"key": "CIT0165", "DOI": "10.1158/1078-0432.CCR-07-1461", "doi-asserted-by": "publisher"}, {"key": "CIT0166", "DOI": "10.1200/JCO.2007.14.5730", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Investigational Drugs"], "language": "en", "link": [{"URL": "https://www.tandfonline.com/doi/pdf/10.1517/13543784.2010.510514", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 9, 6]], "date-time": "2018-09-06T16:21:32Z", "timestamp": 1536250892000}, "score": 42.096237, "issued": {"date-parts": [[2010, 8, 5]]}, "references-count": 166, "journal-issue": {"published-online": {"date-parts": [[2010, 8, 5]]}, "published-print": {"date-parts": [[2010, 9]]}, "issue": "9"}, "alternative-id": ["10.1517/13543784.2010.510514"], "URL": "http://dx.doi.org/10.1517/13543784.2010.510514", "relation": {"cites": []}, "ISSN": ["1354-3784", "1744-7658"], "issn-type": [{"value": "1354-3784", "type": "print"}, {"value": "1744-7658", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T07:03:52Z", "timestamp": 1575183832990}, "publisher-location": "Berlin/Heidelberg", "reference-count": 177, "publisher": "Springer-Verlag", "isbn-type": [{"value": "1402036418", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/1-4020-3642-6_12", "type": "book-chapter", "created": {"date-parts": [[2005, 10, 27]], "date-time": "2005-10-27T18:25:56Z", "timestamp": 1130437556000}, "page": "269-305", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Histone Deacetylase Inhibitors: Novel Targeted Anti-Cancer Agents"], "prefix": "10.1007", "author": [{"given": "Paul", "family": "Marks", "sequence": "first", "affiliation": []}, {"given": "William Kevin", "family": "Kelly", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "12_CR1", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7", "volume": "184", "author": "W. D. Cress", "year": "2000", "unstructured": "Cress W. D. and Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol, 2000; 184: 1\u201316.", "journal-title": "J Cell Physiol"}, {"key": "12_CR2", "doi-asserted-by": "publisher", "first-page": "1695", "DOI": "10.1517/13543784.11.12.1695", "volume": "11", "author": "W. K. Kelly", "year": "2002", "unstructured": "Kelly W. K., O'Connor O. A., and Marks P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs, 2002;11: 1695\u20131713.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "12_CR3", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.1038/35106079", "volume": "1", "author": "P. Marks", "year": "2001", "unstructured": "Marks P., Rifkind R. A., Richon V. M., Breslow R., Miller T. and Kelly W. K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer, 2001; 1: 194\u2013202.", "journal-title": "Nat Rev Cancer"}, {"key": "12_CR4", "doi-asserted-by": "publisher", "first-page": "737", "DOI": "10.1042/BJ20021321", "volume": "370", "author": "A. J. Ruijter de", "year": "2003", "unstructured": "de Ruijter A. J., van Gennip A. H., Caron H. N., Kemp S. and van Kuilenburg A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 2003; 370: 737\u2013749.", "journal-title": "Biochem J"}, {"key": "12_CR5", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1038/nrg962", "volume": "3", "author": "P. A. Jones", "year": "2002", "unstructured": "Jones P. A. and Baylin S. B. The fundamental role of epigenetic events in cancer. Nat Rev Genet, 2002; 3: 415\u2013428.", "journal-title": "Nat Rev Genet"}, {"key": "12_CR6", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.1016/S1535-6108(03)00165-X", "volume": "4", "author": "R. W. Johnstone", "year": "2003", "unstructured": "Johnstone R. W. and Licht J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell, 2003; 4: 13\u201318.", "journal-title": "Cancer Cell"}, {"key": "12_CR7", "doi-asserted-by": "publisher", "first-page": "2373", "DOI": "10.2174/0929867033456576", "volume": "10", "author": "M. Curtin", "year": "2003", "unstructured": "Curtin M. and Glaser K. Histone deacetylase inhibitors: the abbott experience. Curr Med Chem, 2003; 10: 2373\u20132392.", "journal-title": "Curr Med Chem"}, {"key": "12_CR8", "doi-asserted-by": "publisher", "first-page": "5097", "DOI": "10.1021/jm0303094", "volume": "46", "author": "T. A. Miller", "year": "2003", "unstructured": "Miller T. A., Witter D. J. and Belvedere S. Histone deacetylase inhibitors. J Med Chem, 2003; 46: 5097\u20135116.", "journal-title": "J Med Chem"}, {"key": "12_CR9", "first-page": "137", "volume": "91", "author": "P. A. Marks", "year": "2004", "unstructured": "Marks P. A., Richon V. M., Miller T. and Kelly W. K. Histone deacetylase inhibitors. Adv Cancer Res, 2004; 91: 137\u2013168.", "journal-title": "Adv Cancer Res"}, {"key": "12_CR10", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1517/13543784.13.1.21", "volume": "13", "author": "R. R. Rosato", "year": "2004", "unstructured": "Rosato R. R. and Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs, 2004; 13: 21\u201338.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "12_CR11", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.2174/1568009043481560", "volume": "4", "author": "D. M. Vigushin", "year": "2004", "unstructured": "Vigushin D. M. and Coombes R. C. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets, 2004; 4: 205\u2013218.", "journal-title": "Curr Cancer Drug Targets"}, {"key": "12_CR12", "doi-asserted-by": "publisher", "first-page": "461", "DOI": "10.1016/j.ctrv.2004.04.006", "volume": "30", "author": "R. Somech", "year": "2004", "unstructured": "Somech R., Izraeli S. and J. Simon A. Histone deacetylase inhibitors\u2014a new tool to treat cancer. Cancer Treat Rev, 2004; 30: 461\u2013472.", "journal-title": "Cancer Treat Rev"}, {"key": "12_CR13", "doi-asserted-by": "crossref", "first-page": "779", "DOI": "10.4161/cc.3.6.927", "volume": "3", "author": "R. K. Lindemann", "year": "2004", "unstructured": "Lindemann R. K., Gabrielli B. and Johnstone R. W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle, 2004; 3: 779\u2013788.", "journal-title": "Cell Cycle"}, {"key": "12_CR14", "doi-asserted-by": "crossref", "first-page": "30", "DOI": "10.4161/cbt.190", "volume": "2", "author": "R. R. Rosato", "year": "2003", "unstructured": "Rosato R. R. and Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther, 2003; 2: 30\u201337.", "journal-title": "Cancer Biol Ther"}, {"key": "12_CR15", "first-page": "1422", "volume": "4", "author": "J. P. Secrist", "year": "2003", "unstructured": "Secrist J. P., Zhou X., and Richon V. M. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs, 2003; 4: 1422\u20131427.", "journal-title": "Curr Opin Investig Drugs"}, {"key": "12_CR16", "doi-asserted-by": "publisher", "first-page": "1074", "DOI": "10.1126/science.1063127", "volume": "293", "author": "T. Jenuwein", "year": "2001", "unstructured": "Jenuwein T. and Allis C. D. Translating the histone code. Science, 2001; 293: 1074\u20131080.", "journal-title": "Science"}, {"key": "12_CR17", "doi-asserted-by": "publisher", "first-page": "577", "DOI": "10.1172/JCI200216547", "volume": "110", "author": "H. T. Spotswood", "year": "2002", "unstructured": "Spotswood H. T. and Turner B. M. An increasingly complex code. J Clin Invest, 2002; 110: 577\u2013582.", "journal-title": "J Clin Invest"}, {"key": "12_CR18", "doi-asserted-by": "publisher", "first-page": "836", "DOI": "10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X", "volume": "22", "author": "B. M. Turner", "year": "2000", "unstructured": "Turner B. M. Histone acetylation and an epigenetic code. Bioessays, 2000; 22: 836\u2013845.", "journal-title": "Bioessays"}, {"key": "12_CR19", "doi-asserted-by": "publisher", "first-page": "2343", "DOI": "10.1101/gad.927301", "volume": "15", "author": "Y. Zhang", "year": "2001", "unstructured": "Zhang Y. and Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev, 2001; 15: 2343\u20132360.", "journal-title": "Genes Dev"}, {"key": "12_CR20", "doi-asserted-by": "publisher", "first-page": "381", "DOI": "10.1016/S0092-8674(02)01077-2", "volume": "111", "author": "T. Agalioti", "year": "2002", "unstructured": "Agalioti T., Chen G. and Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. Cell, 2002; 111: 381\u2013392.", "journal-title": "Cell"}, {"key": "12_CR21", "doi-asserted-by": "publisher", "first-page": "489", "DOI": "10.1016/S0092-8674(02)00644-X", "volume": "108", "author": "E. J. Richards", "year": "2002", "unstructured": "Richards E. J. and Elgin S. C. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell, 2002; 108: 489\u2013500.", "journal-title": "Cell"}, {"key": "12_CR22", "doi-asserted-by": "publisher", "first-page": "1176", "DOI": "10.1093/emboj/19.6.1176", "volume": "19", "author": "T. Kouzarides", "year": "2000", "unstructured": "Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo J, 2000; 19: 1176\u20131179.", "journal-title": "Embo J"}, {"key": "12_CR23", "doi-asserted-by": "publisher", "first-page": "58", "DOI": "10.1016/0168-9525(96)81401-6", "volume": "12", "author": "A. P. Wolffe", "year": "1996", "unstructured": "Wolffe A. P. and Pruss D. Deviant nucleosomes: the functional specialization of chromatin. Trends Genet, 1996; 12: 58\u201362.", "journal-title": "Trends Genet"}, {"key": "12_CR24", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1038/38444", "volume": "389", "author": "K. Luger", "year": "1997", "unstructured": "Luger K., Mader A. W., Richmond R. K., Sargent D. F. and Richmond T. J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 1997; 389: 251\u2013260.", "journal-title": "Nature"}, {"key": "12_CR25", "doi-asserted-by": "publisher", "first-page": "475", "DOI": "10.1038/nature02017", "volume": "425", "author": "W. Fischle", "year": "2003", "unstructured": "Fischle W., Wang Y. and Allis C. D. Binary switches and modification cassettes in histone biology and beyond. Nature, 2003; 425: 475\u2013479.", "journal-title": "Nature"}, {"key": "12_CR26", "doi-asserted-by": "publisher", "first-page": "3971", "DOI": "10.1093/nar/gkg473", "volume": "31", "author": "P. Trojer", "year": "2003", "unstructured": "Trojer P., Brandtner E. M., Brosch G., Loidl P., Galehr J., Linzmaier R., Haas H., Mair K., Tribus M. and Graessle S. Histone deacetylases in fungi: novel members, new facts. Nucleic Acids Res, 2003; 31: 3971\u20133981.", "journal-title": "Nucleic Acids Res"}, {"key": "12_CR27", "doi-asserted-by": "publisher", "first-page": "162", "DOI": "10.1016/S0959-437X(00)00174-X", "volume": "11", "author": "S. Khochbin", "year": "2001", "unstructured": "Khochbin S., Verdel A., Lemercier C. and Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev, 2001; 11: 162\u2013166.", "journal-title": "Curr Opin Genet Dev"}, {"key": "12_CR28", "doi-asserted-by": "publisher", "first-page": "25748", "DOI": "10.1074/jbc.M111871200", "volume": "277", "author": "L. Gao", "year": "2002", "unstructured": "Gao L., Cueto M. A., Asselbergs F. and Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem, 2002; 277: 25748\u201325755.", "journal-title": "J Biol Chem"}, {"key": "12_CR29", "doi-asserted-by": "publisher", "first-page": "1990", "DOI": "10.1007/s00018-003-3090-z", "volume": "60", "author": "S. Kyrylenko", "year": "2003", "unstructured": "Kyrylenko S., Kyrylenko O., Suuronen T. and Salminen A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci, 2003; 60: 1990\u20131997.", "journal-title": "Cell Mol Life Sci"}, {"key": "12_CR30", "doi-asserted-by": "publisher", "first-page": "75", "DOI": "10.1006/excr.2000.5080", "volume": "262", "author": "S. G. Gray", "year": "2001", "unstructured": "Gray S. G. and Ekstrom T. J. The human histone deacetylase family. Exp Cell Res, 2001; 262: 75\u201383.", "journal-title": "Exp Cell Res"}, {"key": "12_CR31", "doi-asserted-by": "publisher", "first-page": "4868", "DOI": "10.1073/pnas.96.9.4868", "volume": "96", "author": "C. M. Grozinge", "year": "1999", "unstructured": "Grozinge, C. M., Hassig C. A. and Schreiber S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A, 1999; 96: 4868\u20134873.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR32", "doi-asserted-by": "publisher", "first-page": "17", "DOI": "10.1016/j.jmb.2004.02.006", "volume": "338", "author": "I. V. Gregoretti", "year": "2004", "unstructured": "Gregoretti I. V., Lee Y. M. and Goodson H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol, 2004; 338: 17\u201331.", "journal-title": "J Mol Biol"}, {"key": "12_CR33", "first-page": "245", "volume": "5", "author": "C. Lint Van", "year": "1996", "unstructured": "Van Lint C., Emiliani S. and Verdin E. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expr, 1996; 5: 245\u2013254.", "journal-title": "Gene Expr"}, {"key": "12_CR34", "doi-asserted-by": "publisher", "first-page": "286", "DOI": "10.1016/S0168-9525(03)00073-8", "volume": "19", "author": "E. Verdin", "year": "2003", "unstructured": "Verdin E., Dequiedt F. and Kasler H. G. Class II histone deacetylases: versatile regulators. Trends Genet, 2003; 19: 286\u2013293.", "journal-title": "Trends Genet"}, {"key": "12_CR35", "doi-asserted-by": "publisher", "first-page": "1241", "DOI": "10.1073/pnas.0307708100", "volume": "101", "author": "C. Y. Gui", "year": "2004", "unstructured": "Gui C. Y., Ngo L., Xu W. S., Richon V. M. and Marks P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A, 2004; 101: 1241\u20131246.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR36", "doi-asserted-by": "publisher", "first-page": "455", "DOI": "10.1038/417455a", "volume": "417", "author": "C. Hubbert", "year": "2002", "unstructured": "Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X. F. and Yao T. P. HDAC6 is a microtubule-associated deacetylase. Nature, 2002; 417: 455\u2013458.", "journal-title": "Nature"}, {"key": "12_CR37", "first-page": "87", "volume": "12", "author": "S. Voelter-Mahlknecht", "year": "2003", "unstructured": "Voelter-Mahlknecht S. and Mahlknecht U. Cloning and structural characterization of the human histone deacetylase 6 gene. Int J Mol Med, 2003; 12: 87\u201393.", "journal-title": "Int J Mol Med"}, {"key": "12_CR38", "doi-asserted-by": "publisher", "first-page": "1168", "DOI": "10.1093/emboj/cdg115", "volume": "22", "author": "Y. Zhang", "year": "2003", "unstructured": "Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S. and Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J, 2003; 22: 1168\u20131179.", "journal-title": "EMBO J"}, {"key": "12_CR39", "doi-asserted-by": "publisher", "first-page": "14329", "DOI": "10.1073/pnas.250494697", "volume": "97", "author": "X. Zhou", "year": "2000", "unstructured": "Zhou X., Richon V. M., Wang A. H., Yang X. J., Rifkind R. A. and Marks P. A. Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. Proc Natl Acad Sci U S A, 2000; 97: 14329\u201314333.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR40", "doi-asserted-by": "publisher", "first-page": "16059", "DOI": "10.1074/jbc.M212935200", "volume": "278", "author": "K. Petrie", "year": "2003", "unstructured": "Petrie K., Guidez F., Howell, L., Healy L., Waxman S., Greaves M. and Zelent A. The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem, 2003; 278: 16059\u201316072.", "journal-title": "J Biol Chem"}, {"key": "12_CR41", "doi-asserted-by": "publisher", "first-page": "6656", "DOI": "10.1074/jbc.M108055200", "volume": "277", "author": "D. D. Fischer", "year": "2002", "unstructured": "Fischer D. D., Cai R., Bhatia U., Asselbergs F. A., Song C., Terry R., Trogani N., Widmer R., Atadja P. and Cohen D. Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem, 2002; 277: 6656\u20136666.", "journal-title": "J Biol Chem"}, {"key": "12_CR42", "doi-asserted-by": "publisher", "first-page": "1114", "DOI": "10.1093/nar/30.5.1114", "volume": "30", "author": "J. J. Tong", "year": "2002", "unstructured": "Tong J. J., Liu J., Bertos N. R. and Yang X. J. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res, 2002; 30: 1114\u20131123.", "journal-title": "Nucleic Acids Res"}, {"key": "12_CR43", "doi-asserted-by": "crossref", "first-page": "2343", "DOI": "10.2174/0929867033456657", "volume": "10", "author": "J. Arts", "year": "2003", "unstructured": "Arts J., de Scheppe, S. and Van Emelen K. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem, 2003; 10: 2343\u20132350.", "journal-title": "Curr Med Chem"}, {"key": "12_CR44", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.1016/j.bbrc.2003.09.043", "volume": "310", "author": "K. B. Glaser", "year": "2003", "unstructured": "Glaser K. B., Li J., Staver M. J., Wei R. Q., Albert D. H. and Davidsen S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun, 2003; 310: 529\u2013536.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR45", "doi-asserted-by": "publisher", "first-page": "5992", "DOI": "10.1128/MCB.21.17.5992-6005.2001", "volume": "21", "author": "A. H. Wang", "year": "2001", "unstructured": "Wang A. H. and Yang X. J. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol Cell Biol, 2001; 21: 5992\u20136005.", "journal-title": "Mol Cell Biol"}, {"key": "12_CR46", "doi-asserted-by": "publisher", "first-page": "1735", "DOI": "10.1073/pnas.0437843100", "volume": "100", "author": "A. Mal", "year": "2003", "unstructured": "Mal A. and Harter M. L. MyoD is functionally linked to the silencing of a muscle-specific regulatory gene prior to skeletal myogenesis. Proc Natl Acad Sci U S A, 2003;100: 1735\u20131739.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR47", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1095/biolreprod.102.005991", "volume": "68", "author": "S. McGraw", "year": "2003", "unstructured": "McGraw S., Robert C., Massicotte L. and Sirard M. A. Quantification of histone acetyltransferase and histone deacetylase transcripts during early bovine embryo development. Biol Reprod, 2003; 68: 383\u2013389.", "journal-title": "Biol Reprod"}, {"key": "12_CR48", "doi-asserted-by": "publisher", "first-page": "2672", "DOI": "10.1093/emboj/21.11.2672", "volume": "21", "author": "G. Lagger", "year": "2002", "unstructured": "Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T. and Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. The EMBO Journal, 2002; 21: 2672\u20132681.", "journal-title": "The EMBO Journal"}, {"key": "12_CR49", "doi-asserted-by": "publisher", "first-page": "1841", "DOI": "10.1074/jbc.M206528200", "volume": "278", "author": "Y. D. Wen", "year": "2003", "unstructured": "Wen Y. D., Cress W. D., Roy A. L. and Seto E. Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I. J Biol Chem, 2003; 278: 1841\u20131847.", "journal-title": "J Biol Chem"}, {"key": "12_CR50", "doi-asserted-by": "crossref", "first-page": "497", "DOI": "10.1016/S0959-437X(00)00224-0", "volume": "11", "author": "T. A. McKinsey", "year": "2001", "unstructured": "McKinsey T. A., Zhang C. L. and Olson E. N. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev, 2001; 11: 497\u2013504.", "journal-title": "Curr Opin Genet Dev"}, {"key": "12_CR51", "doi-asserted-by": "publisher", "first-page": "1711", "DOI": "10.1073/pnas.0337639100", "volume": "100", "author": "M. P. Czubryt", "year": "2003", "unstructured": "Czubryt M. P., McAnally J., Fishman G. I. and Olson E. N. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha ) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A, 2003; 100: 1711\u20131716.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR52", "doi-asserted-by": "publisher", "first-page": "763", "DOI": "10.1016/S0955-0674(02)00389-7", "volume": "14", "author": "T. A. McKinsey", "year": "2002", "unstructured": "McKinsey T. A., Zhang C. L. and Olson E. N. Signaling chromatin to make muscle. Curr Opin Cell Biol, 2002; 14: 763\u2013772.", "journal-title": "Curr Opin Cell Biol"}, {"key": "12_CR53", "doi-asserted-by": "publisher", "first-page": "5122", "DOI": "10.1128/MCB.23.15.5122-5131.2003", "volume": "23", "author": "T. Ishizuka", "year": "2003", "unstructured": "Ishizuka T. and Laza, M. A. The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol Cell Biol, 2003; 23: 5122\u20135131.", "journal-title": "Mol Cell Biol"}, {"key": "12_CR54", "doi-asserted-by": "crossref", "first-page": "17625", "DOI": "10.1074/jbc.M301646200", "volume": "278", "author": "I. Berger", "year": "2003", "unstructured": "Berger I., Bieniossek C., Schaffitzel C., Hassle, M., Santelli E. and Richmond T. J. Direct interaction of Ca2+/calmodulin inhibits histone deacetylase 5 repressor core binding to myocyte enhancer factor 2. J Biol Chem, 2003; 278: 17625\u201317635.", "journal-title": "J Biol Chem"}, {"key": "12_CR55", "doi-asserted-by": "publisher", "first-page": "687", "DOI": "10.1016/S1074-7613(03)00109-2", "volume": "18", "author": "F. Dequiedt", "year": "2003", "unstructured": "Dequiedt F., Kasler H., Fischle W., Kiermer V., Weinstein M., Herndier B. G. and Verdin E. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity, 2003; 18: 687\u2013698.", "journal-title": "Immunity"}, {"key": "12_CR56", "doi-asserted-by": "publisher", "first-page": "4074", "DOI": "10.1093/emboj/19.15.4074", "volume": "19", "author": "F. D. Urnov", "year": "2000", "unstructured": "Urnov F. D., Yee J., Sachs L., Collingwood T. N., Bauer A., Beug H., Shi Y. B. and Wolffe A. P. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein verbA yields a chromatin infrastructure-dependent transcriptional repression pathway. EMBO J, 2000; 19: 4074\u20134090.", "journal-title": "EMBO J"}, {"key": "12_CR57", "doi-asserted-by": "publisher", "first-page": "1336", "DOI": "10.1093/emboj/cdg120", "volume": "22", "author": "H. G. Yoon", "year": "2003", "unstructured": "Yoon H. G., Chan D. W., Huang Z. Q., Li J., Fondell J. D., Qin J. and Wong J. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J, 2003; 22: 1336\u20131346.", "journal-title": "EMBO J"}, {"key": "12_CR58", "doi-asserted-by": "crossref", "first-page": "728", "DOI": "10.1007/PL00000896", "volume": "58", "author": "S. Timmermann", "year": "2001", "unstructured": "Timmermann S., Lehrmann H., Polesskaya A. and Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci, 2001; 58: 728\u2013736.", "journal-title": "Cell Mol Life Sci"}, {"key": "12_CR59", "doi-asserted-by": "publisher", "first-page": "1321", "DOI": "10.1172/JCI200111537", "volume": "108", "author": "L.-Z. He", "year": "2001", "unstructured": "He L.-Z., Tolentino T., Grayson P., Zhong S., Warrell R. P., Jr., Rifkind R. A., Marks P. A., Richon V. M. and Pandolfi P. P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin Invest, 2001; 108: 1321\u20131330.", "journal-title": "J. Clin Invest"}, {"key": "12_CR60", "doi-asserted-by": "publisher", "first-page": "10860", "DOI": "10.1073/pnas.95.18.10860", "volume": "95", "author": "J. Wang", "year": "1998", "unstructured": "Wang J., Hoshino T., Redner R. L., Kajigaya S. and Liu J. M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A, 1998; 95: 10860\u201310865.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR61", "doi-asserted-by": "publisher", "first-page": "353", "DOI": "10.1002/ijc.11403", "volume": "107", "author": "H. Kawai", "year": "2003", "unstructured": "Kawai H., Li H., Avraham S., Jiang S. and Avraham H. K. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer, 2003; 107: 353\u2013358.", "journal-title": "Int J Cancer"}, {"key": "12_CR62", "doi-asserted-by": "publisher", "first-page": "667", "DOI": "10.1038/35083062", "volume": "3", "author": "H. M. Chan", "year": "2001", "unstructured": "Chan H. M., Krstic-Demonacos M., Smith L., Demonacos C. and La Thangue N. B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol, 2001; 3: 667\u2013674.", "journal-title": "Nat Cell Biol"}, {"key": "12_CR63", "doi-asserted-by": "publisher", "first-page": "601", "DOI": "10.1038/35410", "volume": "391", "author": "L. Magnaghi-Jaulin", "year": "1998", "unstructured": "Magnaghi-Jaulin L., Groisman R., Naguibneva I., Robin P., Lorain S., Le Villain J. P., Troalen F., Trouche D. and Harel-Bellan A. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature, 1998; 391: 601\u2013605.", "journal-title": "Nature"}, {"key": "12_CR64", "doi-asserted-by": "publisher", "first-page": "2490", "DOI": "10.1101/gad.13.19.2490", "volume": "13", "author": "M. Murphy", "year": "1999", "unstructured": "Murphy M., Ahn J., Walker K. K., Hoffman W. H., Evans R. M., Levine A. J. and George D. L. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev, 1999; 13: 2490\u20132501.", "journal-title": "Genes Dev"}, {"key": "12_CR65", "doi-asserted-by": "publisher", "first-page": "4983", "DOI": "10.1073/pnas.96.9.4983", "volume": "96", "author": "R. I. Yarden", "year": "1999", "unstructured": "Yarden R. I. and Brody L. C. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A, 1999; 96: 4983\u20134988.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR66", "doi-asserted-by": "publisher", "first-page": "1430", "DOI": "10.1182/blood-2002-07-2073", "volume": "101", "author": "S. Skov", "year": "2003", "unstructured": "Skov S., Rieneck K., Bovin L. F., Skak K., Tomra S., Michelsen B. K. and Odum N. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal-pathway essential for CD154 expression. Blood, 2003; 101: 1430\u20131438.", "journal-title": "Blood"}, {"key": "12_CR67", "doi-asserted-by": "publisher", "first-page": "300", "DOI": "10.1038/73536", "volume": "24", "author": "S. A. Gayther", "year": "2000", "unstructured": "Gayther S. A., Batley S. J., Linger L., Bannister A., Thorpe K., Chin S. F., Daigo Y., Russell P., Wilson A., Sowter H. M., Delhanty J. D., Ponder B. A., Kouzarides T. and Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat Genet, 2000; 24: 300\u2013303.", "journal-title": "Nat Genet"}, {"key": "12_CR68", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.1002/(SICI)1097-4644(1998)72:30/31+<194::AID-JCB24>3.0.CO;2-H", "volume": "30\u201331", "author": "R. Fenrick", "year": "1998", "unstructured": "Fenrick R. and Hiebert S. W. Role of histone deacetylases in acute leukemia. J Cell Biochem Suppl, 1998; 30\u201331: 194\u2013202.", "journal-title": "J Cell Biochem Suppl"}, {"key": "12_CR69", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.1006/viro.1999.0181", "volume": "268", "author": "D. A. Smirnov", "year": "2000", "unstructured": "Smirnov D. A., Hou S. and Ricciardi R. P. Association of histone deacetylase with COUP-TF in tumorigenic Ad12-transformed cells and its potential role in shut-off of MHC class I transcription. Virology, 2000; 268: 319\u2013328.", "journal-title": "Virology"}, {"key": "12_CR70", "doi-asserted-by": "crossref", "first-page": "1300", "DOI": "10.1111/j.1349-7006.2001.tb02153.x", "volume": "92", "author": "J. H. Choi", "year": "2001", "unstructured": "Choi J. H., Kwon H. J., Yoon B. I., Kim J. H., Han S. U., Joo H. J. and Kim D. Y. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res, 2001; 92: 1300\u20131304.", "journal-title": "Jpn J Cancer Res"}, {"key": "12_CR71", "first-page": "333", "volume": "10", "author": "Y. Toh", "year": "2003", "unstructured": "Toh Y., Yamamoto M., Endo K., Ikeda Y., Baba H., Kohnoe S., Yonemasu H., Hachitanda Y., Okamura T. and Sugimachi K. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep, 2003; 10: 333\u2013338.", "journal-title": "Oncol Rep"}, {"key": "12_CR72", "doi-asserted-by": "publisher", "first-page": "1475", "DOI": "10.1016/S1357-2725(02)00079-1", "volume": "34", "author": "P. Neumeister", "year": "2002", "unstructured": "Neumeister P., Albanese C., Balent B., Greally J. and Pestell R. Senescence and epigenetic dysregulation in cancer. Int J Biochem Cell Biol, 2002; 34: 1475.", "journal-title": "Int J Biochem Cell Biol"}, {"key": "12_CR73", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1016/S0065-230X(02)86002-X", "volume": "86", "author": "H. Lehrmann", "year": "2002", "unstructured": "Lehrmann H., Pritchard L. L. and Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res, 2002; 86: 41\u201365.", "journal-title": "Adv Cancer Res"}, {"key": "12_CR74", "doi-asserted-by": "publisher", "first-page": "1071", "DOI": "10.1093/hmg/10.10.1071", "volume": "10", "author": "T. Murata", "year": "2001", "unstructured": "Murata T., Kurokawa R., Krones A., Tatsumi K., Ishii M., Taki T., Masuno M., Ohashi H., Yanagisawa M., Rosenfeld M. G., Glass C. K. and Hayashi Y. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet, 2001; 10: 1071\u20131076.", "journal-title": "Hum Mol Genet"}, {"key": "12_CR75", "doi-asserted-by": "publisher", "first-page": "178", "DOI": "10.1016/S0168-9525(98)01438-3", "volume": "14", "author": "R. H. Giles", "year": "1998", "unstructured": "Giles R. H., Peters D. J. and Breuning M. H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet, 1998; 14: 178\u2013183.", "journal-title": "Trends Genet"}, {"key": "12_CR76", "doi-asserted-by": "publisher", "first-page": "2351", "DOI": "10.2174/0929867033456602", "volume": "10", "author": "M. Yoshida", "year": "2003", "unstructured": "Yoshida M., Matsuyama A., Komatsu Y. and Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem, 2003; 10: 2351\u20132358.", "journal-title": "Curr Med Chem"}, {"key": "12_CR77", "doi-asserted-by": "publisher", "first-page": "223", "DOI": "10.1002/jcb.20045", "volume": "92", "author": "D. C. Marchion", "year": "2004", "unstructured": "Marchion D. C., Bicaku E., Daud A. I., Richon V., Sullivan D. M. and Munster P. N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem, 2004; 92: 223\u2013237.", "journal-title": "J Cell Biochem"}, {"key": "12_CR78", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.2174/138620704773120784", "volume": "7", "author": "R. S. Sabet", "year": "2004", "unstructured": "Sabet, R. S., Marcotte, P., Glaser, K., Burns, D. J., Warrior, U., and Groebe, D. R. Screening for inhibitors of histone deacetylase by incorporating a spraying method to micro-arrayed compound screening. Comb Chem High Throughput Screen, 2004; 7: 93\u2013100.", "journal-title": "Comb Chem High Throughput Screen"}, {"key": "12_CR79", "first-page": "17174", "volume": "265", "author": "M. Yoshida", "year": "1990", "unstructured": "Yoshida M., Kijima M., Akita M. and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem, 1990; 265: 17174\u201317179.", "journal-title": "J Biol Chem"}, {"key": "12_CR80", "doi-asserted-by": "publisher", "first-page": "3003", "DOI": "10.1073/pnas.95.6.3003", "volume": "95", "author": "V. M. Richon", "year": "1998", "unstructured": "Richon V. M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R. A. and Marks P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A, 1998; 95: 3003\u20133007.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR81", "doi-asserted-by": "publisher", "first-page": "5705", "DOI": "10.1073/pnas.93.12.5705", "volume": "93", "author": "V. M. Richon", "year": "1996", "unstructured": "Richon V. M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R. A. and Marks P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A, 1996; 93: 5705\u20135708.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR82", "doi-asserted-by": "publisher", "first-page": "2393", "DOI": "10.2174/0929867033456675", "volume": "10", "author": "S. W. Remiszewski", "year": "2003", "unstructured": "Remiszewski S. W. The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem, 2003; 10: 2393\u20132402.", "journal-title": "Curr Med Chem"}, {"key": "12_CR83", "doi-asserted-by": "publisher", "first-page": "689", "DOI": "10.1158/0008-5472.CAN-03-2043", "volume": "64", "author": "P. Atadja", "year": "2004", "unstructured": "Atadja P., Gao L., Kwon P., Trogani N., Walker H., Hsu M., Yeleswarapu L., Chandramouli N., Perez L., Versace R., Wu A., Sambucetti L., Lassota P., Cohen D., Bair K., Wood A. and Remiszewski S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res, 2004; 64: 689\u2013695.", "journal-title": "Cancer Res"}, {"key": "12_CR84", "first-page": "3137", "volume": "60", "author": "G. H. Su", "year": "2000", "unstructured": "Su G. H., Sohn T. A., Ryu B. and Kern S. E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res, 2000; 60: 3137\u20133142.", "journal-title": "Cancer Res"}, {"key": "12_CR85", "doi-asserted-by": "publisher", "first-page": "2461", "DOI": "10.1038/sj.onc.1202564", "volume": "18", "author": "Y. B. Kim", "year": "1999", "unstructured": "Kim Y. B., Lee K. H., Sugita K., Yoshida M. and Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 1999; 18: 2461\u20132470.", "journal-title": "Oncogene"}, {"key": "12_CR86", "first-page": "4916", "volume": "62", "author": "R. Furumai", "year": "2002", "unstructured": "Furumai R., Matsuyama A., Kobashi N., Lee K. H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M. and Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res, 2002; 62: 4916\u20134921.", "journal-title": "Cancer Res"}, {"key": "12_CR87", "doi-asserted-by": "publisher", "first-page": "87", "DOI": "10.1073/pnas.011405598", "volume": "98", "author": "R. Furumai", "year": "2001", "unstructured": "Furumai R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., and Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A, 2001; 98: 87\u201392.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR88", "doi-asserted-by": "publisher", "first-page": "107", "DOI": "10.1016/S0960-894X(00)00604-1", "volume": "11", "author": "S. L. Colletti", "year": "2001", "unstructured": "Colletti S. L., Myers R. W., Darkin-Rattray S. J., Gurnett A. M., Dulski P. M., Galuska S., Allocco J. J., Ayer M. B., Li C., Lim J., Crumley T. M., Cannova C., Schmatz D. M., Wyvratt M. J., Fisher M. H. and Meinke P. T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg Med Chem Lett, 2001; 11: 107\u2013111.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "12_CR89", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1016/S0960-894X(00)00605-3", "volume": "11", "author": "S. L. Colletti", "year": "2001", "unstructured": "Colletti S. L., Myers R. W., Darkin-Rattray S. J., Gurnett A. M., Dulski P. M., Galuska S., Allocco J. J., Ayer M. B., Li C., Lim J., Crumley T. M., Cannova C., Schmatz D. M., Wyvratt M. J., Fisher M. H. and Meinke P. T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2. Bioorg Med Chem Lett, 2001; 11: 113\u2013117.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "12_CR90", "doi-asserted-by": "publisher", "first-page": "815", "DOI": "10.1021/jo016088w", "volume": "67", "author": "S. B. Singh", "year": "2002", "unstructured": "Singh S. B., Zink D. L., Liesch J. M., Mosley R. T., Dombrowski A. W., Bills G. F., Darkin-Rattray S. J., Schmatz D. M. and Goetz M. A. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J Org Chem, 2002; 67: 815\u2013825.", "journal-title": "J Org Chem"}, {"key": "12_CR91", "first-page": "4459", "volume": "61", "author": "Y. Komatsu", "year": "2001", "unstructured": "Komatsu Y., Tomizaki K. Y., Tsukamoto M., Kato T., Nishino N., Sato S., Yamori T., Tsuruo T., Furumai R., Yoshida M., Horinouchi S. and Hayashi H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res, 2001; 61: 4459\u20134466.", "journal-title": "Cancer Res"}, {"key": "12_CR92", "doi-asserted-by": "publisher", "first-page": "36734", "DOI": "10.1074/jbc.M101287200", "volume": "276", "author": "C. J. Phiel", "year": "2001", "unstructured": "Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A. and Klein P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem, 2001; 276: 36734\u201336741.", "journal-title": "J Biol Chem"}, {"key": "12_CR93", "doi-asserted-by": "publisher", "first-page": "869", "DOI": "10.1097/00001813-200209000-00013", "volume": "13", "author": "A. J. Boivin", "year": "2002", "unstructured": "Boivin A. J., Momparler L. F., Hurtubise A, and Momparler R. L. Antineoplastic action of 5-aza-2\u2032-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs, 2002; 13: 869\u2013874.", "journal-title": "Anticancer Drugs"}, {"key": "12_CR94", "doi-asserted-by": "publisher", "first-page": "1079", "DOI": "10.1158/0008-5472.CAN-03-0799", "volume": "64", "author": "N. Gurvich", "year": "2004", "unstructured": "Gurvich N., Tsygankova O. M., Meinkoth J. L. and Klein P. S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res, 2004; 64: 1079\u20131086.", "journal-title": "Cancer Res"}, {"key": "12_CR95", "doi-asserted-by": "publisher", "first-page": "737", "DOI": "10.1111/j.0013-9580.2004.00104.x", "volume": "45", "author": "S. Eyal", "year": "2004", "unstructured": "Eyal S., Yagen B., Sobol E., Altschuler Y., Shmuel M. and Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia, 45: 737\u2013744, 2004.", "journal-title": "Epilepsia"}, {"issue": "Suppl 1", "key": "12_CR96", "first-page": "S91", "volume": "83", "author": "M. Gottlicher", "year": "2004", "unstructured": "Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol, 2004; 83Suppl 1: S91\u201392.", "journal-title": "Ann Hematol"}, {"key": "12_CR97", "doi-asserted-by": "publisher", "first-page": "4592", "DOI": "10.1073/pnas.96.8.4592", "volume": "96", "author": "A. Saito", "year": "1999", "unstructured": "Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T. and Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A, 1999; 96: 4592\u20134597.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR98", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1023/A:1006489328324", "volume": "19", "author": "S. Prakash", "year": "2001", "unstructured": "Prakash S., Foster B. J., Meyer M., Wozniak A., Heilbrun L. K., Flaherty L., Zalupski M., Radulovic L., Valdivieso M. and LoRusso P. M. Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs, 2001; 19: 1\u201311.", "journal-title": "Invest New Drugs"}, {"key": "12_CR99", "doi-asserted-by": "publisher", "first-page": "4351", "DOI": "10.1016/j.bmc.2004.06.020", "volume": "12", "author": "T. Maeda", "year": "2004", "unstructured": "Maeda T., Nagaoka Y., Kuwajima H., Seno C., Maruyama S., Kurotaki M. and Uesato S. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities. Bioorg Med Chem, 2004; 12: 4351\u20134360.", "journal-title": "Bioorg Med Chem"}, {"key": "12_CR100", "doi-asserted-by": "publisher", "first-page": "3909", "DOI": "10.1016/j.bmcl.2003.09.007", "volume": "13", "author": "A. Vasudevan", "year": "2003", "unstructured": "Vasudevan A., Ji Z., Frey R. R., Wada C. K., Steinman D., Heyman H. R., Guo Y., Curtin M. L., Guo J., Li J., Pease L., Glaser K. B., Marcotte P. A., Bouska J. J., Davidsen S. K. and Michaelides M. R. Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett, 2003; 13: 3909\u20133913.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "12_CR101", "doi-asserted-by": "publisher", "first-page": "5745", "DOI": "10.1021/jm030377q", "volume": "46", "author": "D. K. Kim", "year": "2003", "unstructured": "Kim D. K., Lee J. Y., Kim J. S., Ryu J. H., Choi J. Y., Lee J. W., Im G. J., Kim T. K., Seo J. W., Park H. J., Yoo J., Park J. H., Kim T. Y. and Bang, Y. J. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J Med Chem, 2003; 46: 5745\u20135751.", "journal-title": "J Med Chem"}, {"key": "12_CR102", "doi-asserted-by": "publisher", "first-page": "3313", "DOI": "10.1016/j.bmcl.2004.03.063", "volume": "14", "author": "T. Suzuki", "year": "2004", "unstructured": "Suzuki T., Kouketsu A., Matsuura A., Kohara A., Ninomiya S., Kohda K. and Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg Med Chem Lett, 2004; 14: 3313\u20133317.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "12_CR103", "doi-asserted-by": "publisher", "first-page": "4321", "DOI": "10.1016/j.bmcl.2003.09.048", "volume": "13", "author": "T. Suzuki", "year": "2003", "unstructured": "Suzuki T., Nagano Y., Matsuura A., Kohara A., Ninomiya S., Kohda K. and Miyata N. Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates. Bioorg Med Chem Lett, 2003; 13: 4321\u20134326.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "12_CR104", "doi-asserted-by": "publisher", "first-page": "720", "DOI": "10.1124/jpet.103.055541", "volume": "307", "author": "E. Hu", "year": "2003", "unstructured": "Hu E., Dul E., Sung C. M., Chen Z., Kirkpatrick R., Zhang G. F., Johanson K., Liu R., Lago A., Hofmann G., Macarron R., de los Frailes M., Perez P., Krawiec J., Winkler J. and Jaye M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther, 2003; 307: 720\u2013728.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "12_CR105", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1038/43710", "volume": "401", "author": "M. S. Finnin", "year": "1999", "unstructured": "Finnin M. S., Donigian J. R., Cohen A., Richon V. M., Rifkind R. A., Marks P. A., Breslow R. and Pavletich N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999; 401: 188\u2013193.", "journal-title": "Nature"}, {"key": "12_CR106", "doi-asserted-by": "publisher", "first-page": "138", "DOI": "10.1016/j.ymgme.2003.08.008", "volume": "80", "author": "D. Wegener", "year": "2003", "unstructured": "Wegener D., Hildmann C., and Schwienhorst A. Recent progress in the development of assays suited for histone deacetylase inhibitor screening. Mol Genet Metab, 2003; 80: 138\u2013147.", "journal-title": "Mol Genet Metab"}, {"key": "12_CR107", "doi-asserted-by": "publisher", "first-page": "6820", "DOI": "10.1093/emboj/cdf682", "volume": "21", "author": "A. Matsuyama", "year": "2002", "unstructured": "Matsuyama A., Shimazu T., Sumida Y., Saito A., Yoshimatsu Y., Seigneurin-Berny D., Osada H., Komatsu Y., Nishino N., Khochbin S., Horinouchi S. and Yoshida M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. Embo J, 2002; 21: 6820\u20136831.", "journal-title": "Embo J"}, {"key": "12_CR108", "doi-asserted-by": "publisher", "first-page": "11700", "DOI": "10.1073/pnas.182372299", "volume": "99", "author": "L. M. Butler", "year": "2002", "unstructured": "Butler L. M., Zhou X., Xu W.-S., Scher H. I., Rifkind R. A., Marks P. A. and Richon V. M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, upregulates thioredoxin-binding protein-2, and down-regulates thioredoxin. PNAS, 2002; 99: 11700\u201311705.", "journal-title": "PNAS"}, {"key": "12_CR109", "first-page": "773", "volume": "24", "author": "S. G. Gray", "year": "2004", "unstructured": "Gray S. G., Qian C. N., Furge K., Guo X. and Teh B. T. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol, 2004; 24: 773\u2013795.", "journal-title": "Int J Oncol"}, {"key": "12_CR110", "doi-asserted-by": "publisher", "first-page": "10014", "DOI": "10.1073/pnas.180316197", "volume": "97", "author": "V. M. Richon", "year": "2000", "unstructured": "Richon V. M., Sandhoff T. W., Rifkind R. A. and Marks P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A, 2000; 97: 10014\u201310019.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR111", "doi-asserted-by": "publisher", "first-page": "1165", "DOI": "10.1016/S0959-8049(03)00072-8", "volume": "39", "author": "A. E. Chambers", "year": "2003", "unstructured": "Chambers A. E., Banerjee S., Chaplin T., Dunne J., Debernardi S., Joel S. P. and Young B. D. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer, 2003; 39: 1165\u20131175.", "journal-title": "Eur J Cancer"}, {"key": "12_CR112", "doi-asserted-by": "publisher", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "volume": "101", "author": "C. S. Mitsiades", "year": "2004", "unstructured": "Mitsiades C. S., Mitsiades N. S., McMullan C. J., Poulaki V., Shringarpure R., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X., Bailey C., Joseph M., Libermann T. A., Richon V. M., Marks P. A. and Anderson K. C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A, 2004; 101: 540\u2013545.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR113", "doi-asserted-by": "publisher", "first-page": "4162", "DOI": "10.1128/MCB.23.12.4162-4173.2003", "volume": "23", "author": "A. Rascle", "year": "2003", "unstructured": "Rascle A., Johnston J. A. and Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol, 2003; 23: 4162\u20134173.", "journal-title": "Mol Cell Biol"}, {"key": "12_CR114", "doi-asserted-by": "crossref", "first-page": "1550", "DOI": "10.1096/fj.02-1003fje", "volume": "17", "author": "R. Warrener", "year": "2003", "unstructured": "Warrener R., Beamish H., Burgess A., Waterhouse N. J., Giles N., Fairlie D. and Gabrielli B. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. Faseb J, 2003; 17: 1550\u20131552.", "journal-title": "Faseb J"}, {"key": "12_CR115", "doi-asserted-by": "publisher", "first-page": "1252", "DOI": "10.1038/sj.bjc.6690493", "volume": "80", "author": "L. Qiu", "year": "1999", "unstructured": "Qiu L., Kelso M. J., Hansen C., West M. L., Fairlie D. P. and Parsons P. G. Antitumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer, 1999; 80: 1252\u20131258.", "journal-title": "Br J Cancer"}, {"key": "12_CR116", "unstructured": "Polevoda B. and Sherman F. The diversity of acetylated proteins. Genome Biol, 2002; 3: reviews 0006."}, {"key": "12_CR117", "doi-asserted-by": "publisher", "first-page": "4389", "DOI": "10.1073/pnas.0430973100", "volume": "100", "author": "S. J. Haggarty", "year": "2003", "unstructured": "Haggarty S. J., Koeller K. M., Wong J. C., Grozinger C. M. and Schreiber S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A, 2003; 100: 4389\u20134394.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "12_CR118", "doi-asserted-by": "publisher", "first-page": "2009", "DOI": "10.1097/01.ASN.0000024253.59665.F1", "volume": "13", "author": "Z. Yu", "year": "2002", "unstructured": "Yu Z., Zhang W. and Kone B. C. Histone deacetylases augment cytokine induction of the iNOS gene. J Am Soc Nephrol, 2002; 13: 2009\u20132017.", "journal-title": "J Am Soc Nephrol"}, {"key": "12_CR119", "doi-asserted-by": "crossref", "first-page": "612", "DOI": "10.4161/cbt.3.7.931", "volume": "3", "author": "L. Paoluzzi", "year": "2004", "unstructured": "Paoluzzi L. and Figg W. D. Histone Deacetylase Inhibitors are Potent Radiation Protectants. Cancer Biol Ther, 2004; 3: 612\u2013613.", "journal-title": "Cancer Biol Ther"}, {"key": "12_CR120", "doi-asserted-by": "publisher", "first-page": "1174", "DOI": "10.1016/j.ijrobp.2004.03.001", "volume": "59", "author": "J. H. Kim", "year": "2004", "unstructured": "Kim J. H., Shin J. H. and Kim I. H. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys, 2004; 59: 1174\u20131180.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "12_CR121", "doi-asserted-by": "publisher", "first-page": "301", "DOI": "10.1002/ijc.20117", "volume": "110", "author": "Y. Zhang", "year": "2004", "unstructured": "Zhang Y., Adachi M., Zhao X., Kawamura R. and Imai, K. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer, 2004;110: 301\u2013308.", "journal-title": "Int J Cancer"}, {"key": "12_CR122", "first-page": "7291", "volume": "63", "author": "M. S. Kim", "year": "2003", "unstructured": "Kim M. S., Blake M., Baek J. H., Kohlhagen G., Pommier Y. and Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res, 2003; 63: 7291\u20137300.", "journal-title": "Cancer Res"}, {"key": "12_CR123", "doi-asserted-by": "crossref", "first-page": "719", "DOI": "10.4161/cbt.3.8.1065", "volume": "3", "author": "M. R. Acharya", "year": "2004", "unstructured": "Acharya M. R. and Figg W. D. Histone Deacetylase Inhibitor Enhances the Anti-Leukemic Activity of an Established Nucleoside Analogue. Cancer Biol Ther, 2004; 3: 719\u2013720.", "journal-title": "Cancer Biol Ther"}, {"key": "12_CR124", "doi-asserted-by": "publisher", "first-page": "2590", "DOI": "10.1158/0008-5472.CAN-03-2631", "volume": "64", "author": "S. C. Maggio", "year": "2004", "unstructured": "Maggio S. C., Rosato R. R., Kramer L. B., Dai Y. Rahmani M., Paik D. S., Czarnik A. C., Payne S. G., Spiegel S. and Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res, 2004; 64: 2590\u20132600.", "journal-title": "Cancer Res"}, {"key": "12_CR125", "doi-asserted-by": "publisher", "first-page": "571", "DOI": "10.1124/mol.65.3.571", "volume": "65", "author": "R. R. Rosato", "year": "2004", "unstructured": "Rosato R. R., Almenara J. A., Yu C. and Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol, 2004; 65: 571\u2013581.", "journal-title": "Mol Pharmacol"}, {"key": "12_CR126", "doi-asserted-by": "publisher", "first-page": "420", "DOI": "10.1532/IJH97.04032", "volume": "79", "author": "C. Yoshida", "year": "2004", "unstructured": "Yoshida C. and Melo J. V. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol, 2004; 79: 420\u2013433.", "journal-title": "Int J Hematol"}, {"key": "12_CR127", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1016/j.bcp.2004.02.028", "volume": "68", "author": "A. Brieger", "year": "2004", "unstructured": "Brieger A., Boehrer S., Schaaf S., Nowak D., Ruthardt M., Kim S. Z., Atadja P., Hoelzer D., Mitrou P. S., Weidmann E. and Chow K. U. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Biochem Pharmacol, 2004; 68: 85\u201393.", "journal-title": "Biochem Pharmacol"}, {"key": "12_CR128", "doi-asserted-by": "publisher", "first-page": "166", "DOI": "10.1046/j.1365-2141.2003.04759.x", "volume": "124", "author": "J. S. Kim", "year": "2004", "unstructured": "Kim J. S., Jeung H. K., Cheong J. W., Maeng H., Lee S. T., Hahn J. S., Ko Y. W. and Min Y. H. Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br J Haematol, 2004; 124: 166\u2013178.", "journal-title": "Br J Haematol"}, {"key": "12_CR129", "doi-asserted-by": "publisher", "first-page": "3839", "DOI": "10.1158/1078-0432.CCR-03-0561", "volume": "10", "author": "X. Y. Pei", "year": "2004", "unstructured": "Pei X. Y., Dai Y. and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res, 2004; 10: 3839\u20133852.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR130", "doi-asserted-by": "publisher", "first-page": "3853", "DOI": "10.1158/1078-0432.CCR-03-0806", "volume": "10", "author": "M. Adachi", "year": "2004", "unstructured": "Adachi M., Zhang, Y., Zhao X., Minami T., Kawamura R., Hinoda Y. and Imai K. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res, 2004; 10: 3853\u20133862.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR131", "doi-asserted-by": "publisher", "first-page": "2580", "DOI": "10.1158/0008-5472.CAN-03-2629", "volume": "64", "author": "F. Guo", "year": "2004", "unstructured": "Guo F., Sigua C., Tao J., Bali P., George P., Li Y., Wittmann S., Moscinski L., Atadja P. and Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res, 2004; 64: 2580\u20132589.", "journal-title": "Cancer Res"}, {"key": "12_CR132", "doi-asserted-by": "publisher", "first-page": "186", "DOI": "10.1016/j.bbrc.2003.12.074", "volume": "314", "author": "J. Neuzil", "year": "2004", "unstructured": "Neuzil J., Swettenham E. and Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun, 2004; 314: 186\u2013191.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR133", "doi-asserted-by": "publisher", "first-page": "1537", "DOI": "10.1016/S0006-2952(03)00509-4", "volume": "66", "author": "X. D. Zhang", "year": "2003", "unstructured": "Zhang X. D., Gillespie S. K., Borrow J. M. and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol, 2003; 66: 1537\u20131545.", "journal-title": "Biochem Pharmacol"}, {"key": "12_CR134", "doi-asserted-by": "publisher", "first-page": "6261", "DOI": "10.1038/sj.onc.1207830", "volume": "23", "author": "S. Nakata", "year": "2004", "unstructured": "Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M. and Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene, 2004; 23:6261\u20136271.", "journal-title": "Oncogene"}, {"key": "12_CR135", "doi-asserted-by": "publisher", "first-page": "560", "DOI": "10.1016/j.yexcr.2004.04.038", "volume": "298", "author": "V. Chopin", "year": "2004", "unstructured": "Chopin V., Slomianny C., Hondermarck H. and Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors\u2019 signaling and requires P21(waf1). Exp Cell Res, 2004; 298: 560\u2013573.", "journal-title": "Exp Cell Res"}, {"key": "12_CR136", "first-page": "8420", "volume": "63", "author": "M. Rahmani", "year": "2003", "unstructured": "Rahmani M., Yu C., Dai Y., Reese E., Ahmed W., Dent P. and Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res, 2003; 63: 8420\u20138427.", "journal-title": "Cancer Res"}, {"key": "12_CR137", "doi-asserted-by": "publisher", "first-page": "7016", "DOI": "10.1038/sj.onc.1203176", "volume": "18", "author": "J. A. Vrana", "year": "1999", "unstructured": "Vrana J. A., Decker R. H., Johnson C. R., Wang Z., Jarvis W. D., Richon V. M., Ehinger M., Fisher P. B. and Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 1999; 18: 7016\u20137025.", "journal-title": "Oncogene"}, {"key": "12_CR138", "first-page": "3578", "volume": "9", "author": "W. K. Kelly", "year": "2003", "unstructured": "Kelly W. K., Richon V. M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J. H., Rifkind R., Marks P. A. and Scher H. Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously. Clin Cancer Res, 2003; 9: 3578\u20133588.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR139", "unstructured": "Duvic M., Rakhshandra T., Chiao J. and Chiao N. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Proc Amer Soc of Hem, 2003."}, {"key": "12_CR140", "doi-asserted-by": "publisher", "first-page": "523", "DOI": "10.1007/s00401-004-0841-3", "volume": "107", "author": "H. Sawa", "year": "2004", "unstructured": "Sawa H., Murakami H., Kumagai M., Nakasato M., Yamauchi S., Matsuyama N., Tamura Y., Satone A., Ide W., Hashimoto I. and Kamada H. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol (Berl), 2004; 107: 523\u2013531.", "journal-title": "Acta Neuropathol (Berl)"}, {"key": "12_CR141", "first-page": "718", "volume": "8", "author": "V. Sandor", "year": "2002", "unstructured": "Sandor V., Bakke S., Robey R. W., Kang M. H., Blagosklonny M. V., Bender J., Brooks R., Piekarz R. L., Tucker E., Figg W. D., Chan K. K., Goldspiel B., Fojo A. T., Balcerzak S. P. and Bates S. E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res, 2002; 8: 718\u2013728.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR142", "doi-asserted-by": "publisher", "first-page": "2289", "DOI": "10.2174/1381612043383980", "volume": "10", "author": "R. Piekarz", "year": "2004", "unstructured": "Piekarz R. and Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des, 2004; 10: 2289\u20132298.", "journal-title": "Curr Pharm Des"}, {"key": "12_CR143", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1073/pnas.0408732102", "volume": "102", "author": "J. Ungerstedt", "year": "2005", "unstructured": "Ungerstedt J., Sowa Y, Xu W-S, Shao Y., Perez G., Ngo L., Holmgren A., Jiang X., Marks P. A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitor. Proc. Natl. Acad. Sci. USA, 2005; 102:673\u2013678.", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "12_CR144", "first-page": "419", "volume": "89", "author": "A. Romanski", "year": "2004", "unstructured": "Romanski A., Bacic B., Bug G., Pfeifer H., Gul H., Remiszewski S., Hoelzer D., Atadja P., Ruthardt M. and Ottmann O. G. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica, 2004; 89: 419\u2013426.", "journal-title": "Haematologica"}, {"key": "12_CR145", "doi-asserted-by": "publisher", "first-page": "1207", "DOI": "10.1038/sj.leu.2403388", "volume": "18", "author": "D. M. Lucas", "year": "2004", "unstructured": "Lucas D. M., Davis M. E., Parthun M. R., Mone A. P., Kitada S., Cunningham K. D., Flax E. L., Wickham J., Reed J. C., Byrd J. C. and Grever M. R. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia, 2004; 18: 1207\u20131214.", "journal-title": "Leukemia"}, {"key": "12_CR146", "first-page": "4460", "volume": "63", "author": "M. J. Peart", "year": "2003", "unstructured": "Peart M. J., Tainton K. M., Ruefli A. A., Dear A. E., Sedelies K. A., O'Reilly L. A., Waterhouse N. J., Trapani J. A. and Johnstone R. W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res, 2003; 63: 4460\u20134471.", "journal-title": "Cancer Res"}, {"key": "12_CR147", "first-page": "4392", "volume": "59", "author": "R. D. Glick", "year": "1999", "unstructured": "Glick R. D., Swendeman S. L., Coffey D. C., Rifkind R. A., Marks P. A., Richon V. M. and La Quaglia M. P. Hybrid Polar Histone Deacetylase Inhibitor Induces Apoptosis and CD95/CD95 Ligand Expression in Human Neuroblastoma. Cancer Res, 1999; 59: 4392\u20134399.", "journal-title": "Cancer Res"}, {"key": "12_CR148", "first-page": "5165", "volume": "60", "author": "L. M. Butler", "year": "2000", "unstructured": "Butler L. M., Agus D. B., Scher H. I., Higgins B., Rose A., Cordon-Cardo C., Thaler H. T., Rifkind R. A., Marks P. A. and Richon V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res, 2000; 60: 5165\u20135170.", "journal-title": "Cancer Res"}, {"key": "12_CR149", "doi-asserted-by": "publisher", "first-page": "866", "DOI": "10.1006/bbrc.2001.4434", "volume": "281", "author": "J. S. Kim", "year": "2001", "unstructured": "Kim J. S., Lee S., Lee T., Lee Y. W. and Trepel J. B. Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun, 2001; 281: 866\u2013871.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR150", "doi-asserted-by": "publisher", "first-page": "290", "DOI": "10.1002/ijc.1602", "volume": "97", "author": "H. J. Kwon", "year": "2002", "unstructured": "Kwon H. J., Kim M. S., Kim M. J., Nakajima H., and Kim K. W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer, 2002; 97: 290\u2013296.", "journal-title": "Int J Cancer"}, {"key": "12_CR151", "doi-asserted-by": "publisher", "first-page": "427", "DOI": "10.1038/sj.onc.1205108", "volume": "21", "author": "C. F. Deroanne", "year": "2002", "unstructured": "Deroanne C. F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J. M., Nusgens B. V. and Castronovo V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 2002; 21: 427\u2013436.", "journal-title": "Oncogene"}, {"key": "12_CR152", "doi-asserted-by": "publisher", "first-page": "964", "DOI": "10.1016/j.bbrc.2004.01.149", "volume": "315", "author": "S. H. Kim", "year": "2004", "unstructured": "Kim S. H., Ahn S., Han J. W., Lee H. W., Lee H. Y., Lee Y. W., Kim M. R., Kim K. W., Kim W. B. and Hong S. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun, 2004; 315: 964\u2013970.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR153", "doi-asserted-by": "publisher", "first-page": "693", "DOI": "10.1016/j.bbrc.2004.02.105", "volume": "316", "author": "D. Zgouras", "year": "2004", "unstructured": "Zgouras D., Becker U., Loitsch S. and Stein J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun, 2004; 316: 693\u2013697.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR154", "first-page": "1690", "volume": "54", "author": "A. Thibault", "year": "1994", "unstructured": "Thibault A., Cooper M. R., Figg W. D., Venzon D. J., Sartor A. O., Tompkins A. C., Weinberger M. S., Headlee D. J., McCall N. A., Samid D. and et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res, 1994; 54: 1690\u20131694, 1994.", "journal-title": "Cancer Res"}, {"key": "12_CR155", "doi-asserted-by": "crossref", "first-page": "2932", "DOI": "10.1002/1097-0142(19950615)75:12<2932::AID-CNCR2820751221>3.0.CO;2-P", "volume": "75", "author": "A. Thibault", "year": "1995", "unstructured": "Thibault A., Samid D., Cooper M. R., Figg W. D., Tompkins A. C., Patronas N., Headlee D. J., Kohler D. R., Venzon D. J. and Myers C. E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer, 1995; 75: 2932\u20132938.", "journal-title": "Cancer"}, {"key": "12_CR156", "doi-asserted-by": "crossref", "first-page": "984", "DOI": "10.1200/JCO.1999.17.3.984", "volume": "17", "author": "S. M. Chang", "year": "1999", "unstructured": "Chang S. M., Kuhn J. G., Robins H. I., Schold S. C., Spence A. M., Berger M. S., Mehta M. P., Bozik M. E., Pollack I., Schiff D., Gilbert M., Rankin C. and Prados M. D. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol, 1999; 17: 984\u2013990.", "journal-title": "J Clin Oncol"}, {"key": "12_CR157", "first-page": "3047", "volume": "7", "author": "M. A. Carducci", "year": "2001", "unstructured": "Carducci M. A., Gilbert J., Bowling M. K., Noe D., Eisenberger M. A., Sinibaldi V., Zabelina Y., Chen T. L., Grochow L. B. and Donehower R. C. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res, 2001; 7: 3047\u20133055.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR158", "first-page": "2330", "volume": "7", "author": "S. D. Gore", "year": "2001", "unstructured": "Gore S. D., Weng L. J., Zhai S., Figg W. D., Donehower R. C., Dover G. J., Grever M., Griffin C. A., Grochow L. B., Rowinsky E. K., Zabalena Y., Hawkins A. L., Burks K. and Miller C. B. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res, 2001; 7: 2330\u20132339.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR159", "first-page": "963", "volume": "8", "author": "S. D. Gore", "year": "2002", "unstructured": "Gore S. D., Weng L. J., Figg W. D., Zhai S., Donehower R. C., Dover G., Grever M. R., Griffin C., Grochow L. B., Hawkins A., Burks K., Zabelena Y. and Miller C. B. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res, 2002; 8: 963\u2013970.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR160", "first-page": "2292", "volume": "7", "author": "J. Gilbert", "year": "2001", "unstructured": "Gilbert J., Baker S. D., Bowling M. K., Grochow L., Figg W. D., Zabelina Y., Donehower R. C. and Carducci M. A. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res, 2001; 7: 2292\u20132300.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR161", "doi-asserted-by": "publisher", "first-page": "1621", "DOI": "10.1093/jnci/90.21.1621", "volume": "90", "author": "R. P. Warrell Jr.", "year": "1998", "unstructured": "Warrell R. P., Jr., He L. Z., Richon V., Calleja E. and Pandolfi P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst, 1998; 90: 1621\u20131625.", "journal-title": "J Natl Cancer Inst"}, {"key": "12_CR162", "doi-asserted-by": "publisher", "first-page": "381", "DOI": "10.1016/j.lungcan.2004.03.002", "volume": "45", "author": "T. Reid", "year": "2004", "unstructured": "Reid T., Valone F., Lipera W., Irwin D., Paroly W., Natale R., Sreedharan S., Keer H., Lum B., Scappaticci F. and Bhatnagar A. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer, 2004; 45: 381\u2013386.", "journal-title": "Lung Cancer"}, {"key": "12_CR163", "doi-asserted-by": "crossref", "first-page": "3169", "DOI": "10.1200/jco.2004.22.14_suppl.3169", "volume": "22", "author": "A. Atmaca", "year": "2004", "unstructured": "Atmaca A., Maurer A. B., Heinzel T., Gottlicher M., Neumann A., Al-Bartran S., Martin E., Bartsch I., Knuth A., Jaeger E. and Nordwest K. A dose escalating phase I study with valproic acid (VPA) in patients with advanced cancer. Proc Am Soc Clin Onc, 2004; 22: 3169.", "journal-title": "Proc Am Soc Clin Onc"}, {"key": "12_CR164", "doi-asserted-by": "publisher", "first-page": "325", "DOI": "10.1046/j.1359-4117.2002.01039.x", "volume": "2", "author": "J. L. Marshall", "year": "2002", "unstructured": "Marshall J. L., Rizvi N., Kauh J., Dahut W., Figuera M., Kang M. H., Figg W. D., Wainer I., Chaissang C., Li M. Z. and Hawkins M. J. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol, 2002; 2: 325\u2013332.", "journal-title": "J Exp Ther Oncol"}, {"key": "12_CR165", "doi-asserted-by": "crossref", "first-page": "3028", "DOI": "10.1200/jco.2004.22.14_suppl.3028", "volume": "22", "author": "R. Piekarz", "year": "2004", "unstructured": "Piekarz R., Frye R. A., Turner M. L., Wright J., Leonard J., Allen S. and Bates S. Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Proc Am Soc Clin Onc, 2004; 22: 3028.", "journal-title": "Proc Am Soc Clin Onc"}, {"key": "12_CR166", "doi-asserted-by": "publisher", "first-page": "959", "DOI": "10.1182/blood-2004-05-1693", "volume": "105", "author": "J. Byrd", "year": "2005", "unstructured": "Byrd J., Marcucci G., Parthun M., Xiao J., Klisovic R. B., Moran M., Lin T., Liu S., Sklenar A. R., David M. E., Lucas D. M., Fischer B., Shank R., Tejaswi S. L., Binkley P., Wright J., Chan K. K. and Grever M. A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2005; 105: 959\u2013967.", "journal-title": "Blood"}, {"key": "12_CR167", "unstructured": "Kelly W. K., O'Connor O., Richon V., Curley T., Richardson S., Thapi D., Chiao J., Rifkind R., Marks P. and Scher H. Phase I clinical trial of an oral histone deacetylase inhibitor: suberoylanilide hyroxamic acid (SAHA). 15th AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Boston MA 226, 2003."}, {"key": "12_CR168", "doi-asserted-by": "crossref", "first-page": "3027", "DOI": "10.1200/jco.2004.22.14_suppl.3027", "volume": "22", "author": "G. Garcia-Manero", "year": "2004", "unstructured": "Garcia-Manero G., Issa J. P., Cortes J., Koller C., O'Brien S., Estey E., Canalli A., Chiao J., Richon V. and Kantarjian H. Phase I study of oral suberoylanilide lydroxamic acid (SAHA) a histone deacetylase inhibitor. Proc Amer Soc Clin Oncol, 2004; 22: 3027.", "journal-title": "Proc Amer Soc Clin Oncol"}, {"key": "12_CR169", "doi-asserted-by": "crossref", "first-page": "5578", "DOI": "10.1200/jco.2004.22.14_suppl.5578", "volume": "22", "author": "G. Blumenschein", "year": "2004", "unstructured": "Blumenschein G., Lu C., Kies M., Glisson B., Papadimitrakopoulou V., Zinner R., Kim E., Gillenwater A., Chiao J. and Hong W. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients with recurrent and/or metastatic head and neck cancer. Proc Amer Soc Clin Oncol, 2004; 22: 5578.", "journal-title": "Proc Amer Soc Clin Oncol"}, {"key": "12_CR170", "doi-asserted-by": "crossref", "first-page": "3024", "DOI": "10.1200/jco.2004.22.14_suppl.3024", "volume": "22", "author": "O. G. Ottmann", "year": "2004", "unstructured": "Ottmann O. G., Deangelo D. J., Stone R., Preifer H., Lowenberg B., Atadja P., Peng B., Scott J., Dugan M., Sonneveld P. and Wolfgang J. A. A phase I pharmacokinetic and pharmacodynamic study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. Proc Amer Soc Clin Oncol, 2004; 22: 3024.", "journal-title": "Proc Amer Soc Clin Oncol"}, {"key": "12_CR171", "doi-asserted-by": "crossref", "first-page": "3022", "DOI": "10.1200/jco.2004.22.14_suppl.3022", "volume": "22", "author": "E. K. Rowinsky", "year": "2004", "unstructured": "Rowinsky E. K., Pacey S., Patnaik A., O'Donnell A., Mita M., Atadja P., Peng B., Dugan M., Scott J. W. and DeBono J. S. A phase I pharmacokinetic and Pharmacodynamic study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors. Proc Amer Soc Clin Oncol, 2004; 22: 3022.", "journal-title": "Proc Amer Soc Clin Oncol"}, {"key": "12_CR172", "doi-asserted-by": "crossref", "first-page": "3025", "DOI": "10.1200/jco.2004.22.14_suppl.3025", "volume": "22", "author": "J. Beck", "year": "2004", "unstructured": "Beck J., Fischer T., Rowinsky E. K., Huber C., Mita M., Atadja P., Peng B., Kwong C., Dugan M. and Patnaik A. Phase I pharmacokinetic and pharmacodynamic study of LBH589A: A histone deacetylase inhibitor. Proc Amer Soc Clin Oncol, 2004; 22: 3025.", "journal-title": "Proc Amer Soc Clin Oncol"}, {"key": "12_CR173", "first-page": "200", "volume": "22", "author": "Q. C. Ryan", "year": "2003", "unstructured": "Ryan Q. C., Headlee D. J., Sparreboom A., Figg W. D., Zhai S., Trepel J. B., Murgo A., Elsayed Y., Karp J. E. and Sausville E. A. A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. Proc Amer Soc Clin Oncol, 2003; 22:200.", "journal-title": "Proc Amer Soc Clin Oncol"}, {"key": "12_CR174", "unstructured": "O'shaughnessy J., Flaherty L., Fiorica J. and Grove W. Phase II trial of CI-994 in patients with metastatic renal cell carcinoma. Proc Amer Soc Clin Oncol, 1999."}, {"key": "12_CR175", "unstructured": "Kimmel K. A., Kindler H. L., Janisch S., Olson E. N. and Grove W. Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors. Proc Amer Soc Clin Oncol, 87a, 2001."}, {"key": "12_CR176", "first-page": "S52", "volume": "1", "author": "A. Ardizzoni", "year": "2002", "unstructured": "Ardizzoni A. and Loprevite M. Histone deacetylation inhibitors. Suppl Tumori, 2002; 1: S52\u201354.", "journal-title": "Suppl Tumori"}, {"key": "12_CR177", "unstructured": "Wozniak A., O'shaughnessy J., Fiorica J. and Grove W. Phase II trial of CI-994 in patients with advanced nonsmall cell lung cancer. Proc Amer Soc Clin Oncol, 1999; 487a."}], "container-title": ["Cancer Metastasis \u2014 Biology and Treatment", "DNA Methylation, Epigenetics and Metastasis"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/1-4020-3642-6_12", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 2, 4]], "date-time": "2019-02-04T02:54:12Z", "timestamp": 1549248852000}, "score": 40.674465, "issued": {"date-parts": [[null]]}, "ISBN": ["1402036418"], "references-count": 177, "URL": "http://dx.doi.org/10.1007/1-4020-3642-6_12", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T18:11:32Z", "timestamp": 1575137492591}, "reference-count": 47, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 3, 1]], "date-time": "2005-03-01T00:00:00Z", "timestamp": 1109635200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Clin Oncol"], "published-print": {"date-parts": [[2005, 3]]}, "DOI": "10.1038/ncponc0106", "type": "journal-article", "created": {"date-parts": [[2005, 3, 22]], "date-time": "2005-03-22T10:16:03Z", "timestamp": 1111486563000}, "page": "150-157", "source": "Crossref", "is-referenced-by-count": 208, "title": ["Drug Insight: histone deacetylase inhibitors\u2014development of the new targeted anticancer agent suberoylanilide hydroxamic acid"], "prefix": "10.1038", "volume": "2", "author": [{"given": "William Kevin", "family": "Kelly", "sequence": "first", "affiliation": []}, {"given": "Paul A", "family": "Marks", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "BFncponc0106_CR1", "doi-asserted-by": "publisher", "first-page": "5097", "DOI": "10.1021/jm0303094", "volume": "46", "author": "TA Miller", "year": "2003", "unstructured": "Miller TA et al. (2003) Histone deacetylase inhibitors. J Med Chem 46: 5097\u20135116", "journal-title": "J Med Chem"}, {"key": "BFncponc0106_CR2", "doi-asserted-by": "publisher", "first-page": "137", "DOI": "10.1016/S0065-230X(04)91004-4", "volume": "91", "author": "PA Marks", "year": "2004", "unstructured": "Marks PA et al. (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137\u2013168", "journal-title": "Adv Cancer Res"}, {"key": "BFncponc0106_CR3", "first-page": "17174", "volume": "265", "author": "M Yoshida", "year": "1990", "unstructured": "Yoshida M et al. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174\u201317179", "journal-title": "J Biol Chem"}, {"key": "BFncponc0106_CR4", "doi-asserted-by": "publisher", "first-page": "1990", "DOI": "10.1007/s00018-003-3090-z", "volume": "60", "author": "S Kyrylenko", "year": "2003", "unstructured": "Kyrylenko S et al. (2003) Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci 60: 1990\u20131997", "journal-title": "Cell Mol Life Sci"}, {"key": "BFncponc0106_CR5", "doi-asserted-by": "publisher", "first-page": "2393", "DOI": "10.2174/0929867033456675", "volume": "10", "author": "SW Remiszewski", "year": "2003", "unstructured": "Remiszewski SW (2003) The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem 10: 2393\u20132402", "journal-title": "Curr Med Chem"}, {"key": "BFncponc0106_CR6", "first-page": "4916", "volume": "62", "author": "R Furumai", "year": "2002", "unstructured": "Furumai R et al. (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916\u20134921", "journal-title": "Cancer Res"}, {"key": "BFncponc0106_CR7", "doi-asserted-by": "publisher", "first-page": "2289", "DOI": "10.2174/1381612043383980", "volume": "10", "author": "R Piekarz", "year": "2004", "unstructured": "Piekarz R and Bates S (2004) A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10: 2289\u20132298", "journal-title": "Curr Pharm Des"}, {"key": "BFncponc0106_CR8", "first-page": "1690", "volume": "54", "author": "A Thibault", "year": "1994", "unstructured": "Thibault A et al. (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690\u20131694", "journal-title": "Cancer Res"}, {"key": "BFncponc0106_CR9", "doi-asserted-by": "publisher", "first-page": "984", "DOI": "10.1200/JCO.1999.17.3.984", "volume": "17", "author": "SM Chang", "year": "1999", "unstructured": "Chang SM et al. (1999) Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17: 984\u2013990", "journal-title": "J Clin Oncol"}, {"key": "BFncponc0106_CR10", "doi-asserted-by": "publisher", "first-page": "381", "DOI": "10.1016/j.lungcan.2004.03.002", "volume": "45", "author": "T Reid", "year": "2004", "unstructured": "Reid T et al. (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45: 381\u2013386", "journal-title": "Lung Cancer"}, {"key": "BFncponc0106_CR11", "unstructured": "Atmaca A et al. (2004) A dose escalating phase I study with valproic acid (VPA) in patients with advanced cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition) [abstract #3169] J Clin Oncol 22 (Suppl)"}, {"key": "BFncponc0106_CR12", "doi-asserted-by": "publisher", "first-page": "1207", "DOI": "10.1038/sj.leu.2403388", "volume": "18", "author": "DM Lucas", "year": "2004", "unstructured": "Lucas DM et al. (2004) The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18: 1207\u20131214", "journal-title": "Leukemia"}, {"key": "BFncponc0106_CR13", "first-page": "a345", "volume": "87", "author": "KA Kimmel", "year": "2001", "unstructured": "Kimmel KA et al. (2001) A Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors. [abstract #345] Proc Am Soc Clin Oncol 87: a345", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "BFncponc0106_CR14", "doi-asserted-by": "publisher", "first-page": "58", "DOI": "10.1016/0168-9525(96)81401-6", "volume": "12", "author": "AP Wolffe", "year": "1996", "unstructured": "Wolffe AP and Pruss D (1996) Deviant nucleosomes: the functional specialization of chromatin. Trends Genet 12: 58\u201362", "journal-title": "Trends Genet"}, {"key": "BFncponc0106_CR15", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1038/38444", "volume": "389", "author": "K Luger", "year": "1997", "unstructured": "Luger K et al. (1997) Crystal structure of the nucleosome core particle at 2.8 \u00c5 resolution. Nature 389: 251\u2013260", "journal-title": "Nature"}, {"key": "BFncponc0106_CR16", "doi-asserted-by": "publisher", "first-page": "1074", "DOI": "10.1126/science.1063127", "volume": "293", "author": "T Jenuwein", "year": "2001", "unstructured": "Jenuwein T and Allis CD (2001) Translating the histone code. Science 293: 1074\u20131080", "journal-title": "Science"}, {"key": "BFncponc0106_CR17", "doi-asserted-by": "publisher", "first-page": "577", "DOI": "10.1172/JCI0216547", "volume": "110", "author": "HT Spotswood", "year": "2002", "unstructured": "Spotswood HT and Turner BM (2002) An increasingly complex code. J Clin Invest 110: 577\u2013582", "journal-title": "J Clin Invest"}, {"key": "BFncponc0106_CR18", "doi-asserted-by": "publisher", "first-page": "475", "DOI": "10.1038/nature02017", "volume": "425", "author": "W Fischle", "year": "2003", "unstructured": "Fischle W et al. (2003) Binary switches and modification cassettes in histone biology and beyond. Nature 425: 475\u2013479", "journal-title": "Nature"}, {"key": "BFncponc0106_CR19", "doi-asserted-by": "publisher", "first-page": "1241", "DOI": "10.1073/pnas.0307708100", "volume": "101", "author": "CY Gui", "year": "2004", "unstructured": "Gui CY et al. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101: 1241\u20131246", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "BFncponc0106_CR20", "doi-asserted-by": "publisher", "first-page": "2343", "DOI": "10.2174/0929867033456657", "volume": "10", "author": "J Arts", "year": "2003", "unstructured": "Arts J et al. (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10: 2343\u20132350", "journal-title": "Curr Med Chem"}, {"key": "BFncponc0106_CR21", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.1016/j.bbrc.2003.09.043", "volume": "310", "author": "KB Glaser", "year": "2003", "unstructured": "Glaser KB et al. (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529\u2013536", "journal-title": "Biochem Biophys Res Commun"}, {"key": "BFncponc0106_CR22", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7", "volume": "184", "author": "WD Cress", "year": "2000", "unstructured": "Cress WD and Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184: 1\u201316", "journal-title": "J Cell Physiol"}, {"key": "BFncponc0106_CR23", "doi-asserted-by": "publisher", "first-page": "737", "DOI": "10.1042/bj20021321", "volume": "370", "author": "AJ de Ruijter", "year": "2003", "unstructured": "de Ruijter AJ et al. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 (Part 3): 737\u2013749", "journal-title": "Biochem J"}, {"key": "BFncponc0106_CR24", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1038/nrg816", "volume": "3", "author": "PA Jones", "year": "2002", "unstructured": "Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415\u2013428", "journal-title": "Nat Rev Genet"}, {"key": "BFncponc0106_CR25", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.1016/S1535-6108(03)00165-X", "volume": "4", "author": "RW Johnstone", "year": "2003", "unstructured": "Johnstone RW and Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13\u201318", "journal-title": "Cancer Cell"}, {"key": "BFncponc0106_CR26", "doi-asserted-by": "publisher", "first-page": "1321", "DOI": "10.1172/JCI200111537", "volume": "108", "author": "LZ He", "year": "2001", "unstructured": "He LZ et al. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321\u20131330", "journal-title": "J Clin Invest"}, {"key": "BFncponc0106_CR27", "doi-asserted-by": "publisher", "first-page": "1071", "DOI": "10.1093/hmg/10.10.1071", "volume": "10", "author": "T Murata", "year": "2001", "unstructured": "Murata T et al. (2001) Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein\u2013Taybi syndrome. Hum Mol Genet 10: 1071\u20131076", "journal-title": "Hum Mol Genet"}, {"key": "BFncponc0106_CR28", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1038/43710", "volume": "401", "author": "MS Finnin", "year": "1999", "unstructured": "Finnin MS (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188\u2013193", "journal-title": "Nature"}, {"key": "BFncponc0106_CR29", "first-page": "773", "volume": "24", "author": "SG Gray", "year": "2004", "unstructured": "Gray SG et al. (2004) Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24: 773\u2013795", "journal-title": "Int J Oncol"}, {"key": "BFncponc0106_CR30", "doi-asserted-by": "publisher", "first-page": "10014", "DOI": "10.1073/pnas.180316197", "volume": "97", "author": "VM Richon", "year": "2000", "unstructured": "Richon VM et al. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014\u201310019", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "BFncponc0106_CR31", "doi-asserted-by": "publisher", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "volume": "101", "author": "CS Mitsiades", "year": "2004", "unstructured": "Mitsiades CS et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101: 540\u2013545", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "BFncponc0106_CR32", "doi-asserted-by": "publisher", "first-page": "11700", "DOI": "10.1073/pnas.182372299", "volume": "99", "author": "LM Butler", "year": "2002", "unstructured": "Butler LM et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700\u201311705", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "BFncponc0106_CR33", "doi-asserted-by": "publisher", "first-page": "1550", "DOI": "10.1096/fj.02-1003fje", "volume": "17", "author": "R Warrener", "year": "2003", "unstructured": "Warrener R et al. (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17: 1550\u20131552", "journal-title": "FASEB J"}, {"key": "BFncponc0106_CR34", "doi-asserted-by": "publisher", "first-page": "1252", "DOI": "10.1038/sj.bjc.6690493", "volume": "80", "author": "L Qiu", "year": "1999", "unstructured": "Qiu L et al. (1999) Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 1252\u20131258", "journal-title": "Br J Cancer"}, {"key": "BFncponc0106_CR35", "doi-asserted-by": "publisher", "first-page": "0006", "DOI": "10.1186/gb-2002-3-5-reviews0006", "volume": "3", "author": "B Polevoda", "year": "2002", "unstructured": "Polevoda B and Sherman F (2002) The diversity of acetylated proteins. Genome Biol 3: reviews 0006", "journal-title": "Genome Biol"}, {"key": "BFncponc0106_CR36", "doi-asserted-by": "publisher", "first-page": "1176", "DOI": "10.1093/emboj/19.6.1176", "volume": "19", "author": "T Kouzarides", "year": "2000", "unstructured": "Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176\u20131179", "journal-title": "EMBO J"}, {"key": "BFncponc0106_CR37", "doi-asserted-by": "publisher", "first-page": "3839", "DOI": "10.1158/1078-0432.CCR-03-0561", "volume": "10", "author": "XY Pei", "year": "2004", "unstructured": "Pei XY et al. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839\u20133852", "journal-title": "Clin Cancer Res"}, {"key": "BFncponc0106_CR38", "first-page": "8420", "volume": "63", "author": "M Rahmani", "year": "2003", "unstructured": "Rahmani M et al. (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63: 8420\u20138427", "journal-title": "Cancer Res"}, {"key": "BFncponc0106_CR39", "first-page": "3578", "volume": "9", "author": "WK Kelly", "year": "2003", "unstructured": "Kelly WK et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578\u20133588", "journal-title": "Clin Cancer Res"}, {"key": "BFncponc0106_CR40", "unstructured": "Duvic M et al. (2003) Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). [abstract #625] Proc Am Soc Hematol"}, {"key": "BFncponc0106_CR41", "unstructured": "Marks PA and Kelly WK Histone deacetylase inhibitors: novel targeted anti-cancer agents. In DNA Methylation Epigenetics and Metastasis. (Ed. Esteller M) Boston, Dordrecht, London: Kluwer Academic Publisher, in press"}, {"key": "BFncponc0106_CR42", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1073/pnas.0408732102", "volume": "102", "author": "JS Ungerstedt", "year": "2005", "unstructured": "Ungerstedt JS et al. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 102: 673\u2013678", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "BFncponc0106_CR43", "first-page": "4460", "volume": "63", "author": "MJ Peart", "year": "2003", "unstructured": "Peart MJ et al. (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460\u20134471", "journal-title": "Cancer Res"}, {"key": "BFncponc0106_CR44", "first-page": "5165", "volume": "60", "author": "LM Butler", "year": "2000", "unstructured": "Butler LM et al. (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165\u20135170", "journal-title": "Cancer Res"}, {"key": "BFncponc0106_CR45", "unstructured": "Kelly WK et al. Phase I study of the oral histone deacetylase inhibitor: suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J Clin Oncol, in press", "DOI": "10.1200/JCO.2005.14.167", "doi-asserted-by": "crossref"}, {"key": "BFncponc0106_CR46", "doi-asserted-by": "publisher", "first-page": "2865", "DOI": "10.1182/blood.V98.9.2865", "volume": "98", "author": "RL Piekarz", "year": "2001", "unstructured": "Piekarz RL et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865\u20132868", "journal-title": "Blood"}, {"key": "BFncponc0106_CR47", "doi-asserted-by": "publisher", "first-page": "4636", "DOI": "10.1182/blood-2003-09-3068", "volume": "103", "author": "RL Piekarz", "year": "2004", "unstructured": "Piekarz RL et al. (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103: 4636\u20134643", "journal-title": "Blood"}], "container-title": ["Nature Clinical Practice Oncology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/ncponc0106.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/ncponc0106", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/doifinder/10.1038/ncponc0106", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}, {"URL": "http://www.nature.com/articles/ncponc0106.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 16]], "date-time": "2019-03-16T18:25:30Z", "timestamp": 1552760730000}, "score": 40.427338, "issued": {"date-parts": [[2005, 3]]}, "references-count": 47, "journal-issue": {"published-print": {"date-parts": [[2005, 3]]}, "issue": "3"}, "alternative-id": ["BFncponc0106"], "URL": "http://dx.doi.org/10.1038/ncponc0106", "relation": {"cites": []}, "ISSN": ["1743-4254", "1743-4262"], "issn-type": [{"value": "1743-4254", "type": "print"}, {"value": "1743-4262", "type": "electronic"}], "subject": ["Oncology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T16:43:59Z", "timestamp": 1576860239666}, "reference-count": 250, "publisher": "Elsevier", "isbn-type": [{"value": "9780123943873", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012]]}, "DOI": "10.1016/b978-0-12-394387-3.00002-1", "type": "book-chapter", "created": {"date-parts": [[2014, 1, 14]], "date-time": "2014-01-14T19:30:59Z", "timestamp": 1389727859000}, "page": "39-86", "source": "Crossref", "is-referenced-by-count": 45, "title": ["Mechanisms of Resistance to Histone Deacetylase Inhibitors"], "prefix": "10.1016", "author": [{"given": "Ju-Hee", "family": "Lee", "sequence": "first", "affiliation": []}, {"given": "Megan L.", "family": "Choy", "sequence": "additional", "affiliation": []}, {"given": "Paul A.", "family": "Marks", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Advances in Cancer Research", "Histone Deacetylase Inhibitors as Cancer Therapeutics"], "deposited": {"date-parts": [[2018, 10, 7]], "date-time": "2018-10-07T09:58:04Z", "timestamp": 1538906284000}, "score": 37.530506, "issued": {"date-parts": [[2012]]}, "ISBN": ["9780123943873"], "references-count": 250, "URL": "http://dx.doi.org/10.1016/b978-0-12-394387-3.00002-1", "ISSN": ["0065-230X"], "issn-type": [{"value": "0065-230X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T16:05:26Z", "timestamp": 1574265926385}, "reference-count": 51, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2007, 1, 1]], "date-time": "2007-01-01T00:00:00Z", "timestamp": 1167609600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Biotechnol"], "published-print": {"date-parts": [[2007, 1]]}, "DOI": "10.1038/nbt1272", "type": "journal-article", "created": {"date-parts": [[2007, 1, 8]], "date-time": "2007-01-08T18:52:39Z", "timestamp": 1168282359000}, "page": "84-90", "source": "Crossref", "is-referenced-by-count": 704, "title": ["Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug"], "prefix": "10.1038", "volume": "25", "author": [{"given": "Paul A", "family": "Marks", "sequence": "first", "affiliation": []}, {"given": "Ronald", "family": "Breslow", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2007, 1, 8]]}, "reference": [{"key": "BFnbt1272_CR1", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.1038/35106079", "volume": "1", "author": "P Marks", "year": "2001", "unstructured": "Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194\u2013202 (2001).", "journal-title": "Nat. Rev. Cancer"}, {"key": "BFnbt1272_CR2", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1016/S0065-230X(02)86002-X", "volume": "86", "author": "H Lehrmann", "year": "2002", "unstructured": "Lehrmann, H., Pritchard, L.L. & Harel-Bellan, A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86, 41\u201365 (2002).", "journal-title": "Adv. Cancer Res."}, {"key": "BFnbt1272_CR3", "doi-asserted-by": "publisher", "first-page": "1497", "DOI": "10.1517/13543784.14.12.1497", "volume": "14", "author": "PA Marks", "year": "2005", "unstructured": "Marks, P.A. & Dokmanovic, M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497\u20131511 (2005).", "journal-title": "Expert Opin. Investig. Drugs"}, {"key": "BFnbt1272_CR4", "doi-asserted-by": "publisher", "first-page": "769", "DOI": "10.1038/nrd2133", "volume": "5", "author": "JE Bolden", "year": "2006", "unstructured": "Bolden, J.E., Peart, M.J. & Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769\u2013784 (2006).", "journal-title": "Nat. Rev. Drug Discov."}, {"key": "BFnbt1272_CR5", "doi-asserted-by": "publisher", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "volume": "101", "author": "CS Mitsiades", "year": "2004", "unstructured": "Mitsiades, C.S. et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA 101, 540\u2013545 (2004).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR6", "doi-asserted-by": "publisher", "first-page": "3697", "DOI": "10.1073/pnas.0500369102", "volume": "102", "author": "MJ Peart", "year": "2005", "unstructured": "Peart, M.J. et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102, 3697\u20133702 (2005).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR7", "doi-asserted-by": "publisher", "first-page": "1277", "DOI": "10.1158/0008-5472.CAN-05-3632", "volume": "66", "author": "GK Scott", "year": "2006", "unstructured": "Scott, G.K., Mattie, M.D., Berger, C.E., Benz, S.C. & Benz, C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66, 1277\u20131281 (2006).", "journal-title": "Cancer Res."}, {"key": "BFnbt1272_CR8", "first-page": "1273", "volume": "2", "author": "RR Rosato", "year": "2003", "unstructured": "Rosato, R.R., Almenara, J.A., Dai, Y. & Grant, S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2, 1273\u20131284 (2003).", "journal-title": "Mol. Cancer Ther."}, {"key": "BFnbt1272_CR9", "doi-asserted-by": "publisher", "first-page": "18030", "DOI": "10.1073/pnas.0408345102", "volume": "101", "author": "Y Shao", "year": "2004", "unstructured": "Shao, Y., Gao, Z., Marks, P.A. & Jiang, X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 101, 18030\u201318035 (2004).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR10", "doi-asserted-by": "publisher", "first-page": "3923", "DOI": "10.1200/JCO.2005.14.167", "volume": "23", "author": "WK Kelly", "year": "2005", "unstructured": "Kelly, W.K. et al. Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J. Clin. Oncol. 23, 3923\u20133931 (2005).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnbt1272_CR11", "doi-asserted-by": "publisher", "first-page": "166", "DOI": "10.1200/JCO.2005.01.9679", "volume": "24", "author": "OA O'Connor", "year": "2005", "unstructured": "O'Connor, O.A. et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24, 166\u2013173 (2005).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnbt1272_CR12", "first-page": "759", "volume": "7", "author": "PA Marks", "year": "2001", "unstructured": "Marks, P.A., Rifkind, R.A., Richon, V.M. & Breslow, R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. 7, 759\u2013760 (2001).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnbt1272_CR13", "doi-asserted-by": "publisher", "first-page": "3971", "DOI": "10.1200/JCO.2005.16.600", "volume": "23", "author": "KN Bhalla", "year": "2005", "unstructured": "Bhalla, K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23, 3971\u20133993 (2005).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnbt1272_CR14", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.ejmech.2004.10.001", "volume": "40", "author": "C Monneret", "year": "2005", "unstructured": "Monneret, C. Histone deacetylase inhibitors. Eur. J. Med. Chem. 40, 1\u201313 (2005).", "journal-title": "Eur. J. Med. Chem."}, {"key": "BFnbt1272_CR15", "doi-asserted-by": "publisher", "first-page": "109", "DOI": "10.1016/j.ejcb.2004.12.010", "volume": "84", "author": "H Hess-Stumpp", "year": "2005", "unstructured": "Hess-Stumpp, H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell Biol. 84, 109\u2013121 (2005).", "journal-title": "Eur. J. Cell Biol."}, {"key": "BFnbt1272_CR16", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.2174/1568011054866946", "volume": "5", "author": "O Moradei", "year": "2005", "unstructured": "Moradei, O., Maroun, C.R., Paquin, I. & Vaisburg, A. Histone deacetylase inhibitors: latest developments, trends and prospects. Curr. Med. Chem. Anticancer Agents 5, 529\u2013560 (2005).", "journal-title": "Curr. Med. Chem. Anticancer Agents"}, {"key": "BFnbt1272_CR17", "first-page": "27", "volume": "93", "author": "P Peixoto", "year": "2006", "unstructured": "Peixoto, P. & Lansiaux, A. Histone-deacetylases inhibitors: from TSA to SAHA. Bull. Cancer 93, 27\u201336 (2006).", "journal-title": "Bull. Cancer"}, {"key": "BFnbt1272_CR18", "doi-asserted-by": "publisher", "first-page": "37", "DOI": "10.1038/nrd1930", "volume": "5", "author": "CB Yoo", "year": "2006", "unstructured": "Yoo, C.B. & Jones, P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5, 37\u201350 (2006).", "journal-title": "Nat. Rev. Drug Discov."}, {"key": "BFnbt1272_CR19", "doi-asserted-by": "publisher", "first-page": "38", "DOI": "10.1038/nrc1779", "volume": "6", "author": "S Minucci", "year": "2006", "unstructured": "Minucci, S. & Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38\u201351 (2006).", "journal-title": "Nat. Rev. Cancer"}, {"key": "BFnbt1272_CR20", "doi-asserted-by": "publisher", "first-page": "378", "DOI": "10.1073/pnas.68.2.378", "volume": "68", "author": "C Friend", "year": "1971", "unstructured": "Friend, C., Scher, W., Holland, J.G. & Sato, T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc. Natl. Acad. Sci. USA 68, 378\u2013382 (1971).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR21", "doi-asserted-by": "publisher", "first-page": "1198", "DOI": "10.1038/2121198a0", "volume": "212", "author": "A Bank", "year": "1966", "unstructured": "Bank, A. & Marks, P.A. Excess \u03b1 chain synthesis relative to \u03b2 chain synthesis in thalassemia major and minor. Nature 212, 1198\u20132000 (1966).", "journal-title": "Nature"}, {"key": "BFnbt1272_CR22", "doi-asserted-by": "publisher", "first-page": "1003", "DOI": "10.1073/pnas.72.3.1003", "volume": "72", "author": "M Tanaka", "year": "1975", "unstructured": "Tanaka, M. et al. Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc. Natl. Acad. Sci. USA 72, 1003\u20131006 (1975).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR23", "doi-asserted-by": "publisher", "first-page": "862", "DOI": "10.1073/pnas.73.3.862", "volume": "73", "author": "RC Reuben", "year": "1976", "unstructured": "Reuben, R.C., Wife, R.L., Breslow, R., Rifkind, R.A. & Marks, P.A. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc. Natl. Acad. Sci. USA 73, 862\u2013866 (1976).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR24", "doi-asserted-by": "publisher", "first-page": "419", "DOI": "10.1146/annurev.bi.47.070178.002223", "volume": "47", "author": "PA Marks", "year": "1978", "unstructured": "Marks, P.A. & Rifkind, R.A. Erythroleukemic differentiation. Annu. Rev. Biochem. 47, 419\u2013448 (1978).", "journal-title": "Annu. Rev. Biochem."}, {"key": "BFnbt1272_CR25", "first-page": "659", "volume": "47", "author": "PA Marks", "year": "1987", "unstructured": "Marks, P.A., Sheffery, M. & Rifkind, R.A. Induction of transformed cells to terminal differentiation and the modulation of gene expression. Cancer Res. 47, 659\u2013666 (1987).", "journal-title": "Cancer Res."}, {"key": "BFnbt1272_CR26", "first-page": "165", "volume": "4", "author": "VM Richon", "year": "1989", "unstructured": "Richon, V.M., Ramsay, R.G., Rifkind, R.A. & Marks, P.A. Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation. Oncogene 4, 165\u2013173 (1989).", "journal-title": "Oncogene"}, {"key": "BFnbt1272_CR27", "first-page": "2604", "volume": "80", "author": "M Andreeff", "year": "1992", "unstructured": "Andreeff, M. et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80, 2604\u20132609 (1992).", "journal-title": "Blood"}, {"key": "BFnbt1272_CR28", "doi-asserted-by": "publisher", "first-page": "5542", "DOI": "10.1073/pnas.88.13.5542", "volume": "88", "author": "R Breslow", "year": "1991", "unstructured": "Breslow, R. et al. Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc. Natl. Acad. Sci. USA 88, 5542\u20135546 (1991).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR29", "doi-asserted-by": "publisher", "first-page": "5705", "DOI": "10.1073/pnas.93.12.5705", "volume": "93", "author": "VM Richon", "year": "1996", "unstructured": "Richon, V.M. et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 93, 5705\u20135708 (1996).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR30", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.2174/0929867013373787", "volume": "8", "author": "PT Meinke", "year": "2001", "unstructured": "Meinke, P.T. & Liberator, P. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr. Med. Chem. 8, 211\u2013235 (2001).", "journal-title": "Curr. Med. Chem."}, {"key": "BFnbt1272_CR31", "doi-asserted-by": "publisher", "first-page": "3003", "DOI": "10.1073/pnas.95.6.3003", "volume": "95", "author": "VM Richon", "year": "1998", "unstructured": "Richon, V.M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 95, 3003\u20133007 (1998).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR32", "first-page": "17174", "volume": "265", "author": "M Yoshida", "year": "1990", "unstructured": "Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174\u201317179 (1990).", "journal-title": "J. Biol. Chem."}, {"key": "BFnbt1272_CR33", "doi-asserted-by": "publisher", "first-page": "5097", "DOI": "10.1021/jm0303094", "volume": "46", "author": "TA Miller", "year": "2003", "unstructured": "Miller, T.A., Witter, D.J. & Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 46, 5097\u20135116 (2003).", "journal-title": "J. Med. Chem."}, {"key": "BFnbt1272_CR34", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1038/43710", "volume": "401", "author": "MS Finnin", "year": "1999", "unstructured": "Finnin, M.S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188\u2013193 (1999).", "journal-title": "Nature"}, {"key": "BFnbt1272_CR35", "doi-asserted-by": "publisher", "first-page": "495", "DOI": "10.1146/annurev.pharmtox.45.120403.095825", "volume": "45", "author": "DC Drummond", "year": "2005", "unstructured": "Drummond, D.C. et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495\u20135280 (2005).", "journal-title": "Annu. Rev. Pharmacol. Toxicol."}, {"key": "BFnbt1272_CR36", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.1016/S1535-6108(03)00165-X", "volume": "4", "author": "RW Johnstone", "year": "2003", "unstructured": "Johnstone, R.W. & Licht, J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13\u201318 (2003).", "journal-title": "Cancer Cell"}, {"key": "BFnbt1272_CR37", "doi-asserted-by": "publisher", "first-page": "2580", "DOI": "10.1158/0008-5472.CAN-03-2629", "volume": "64", "author": "F Guo", "year": "2004", "unstructured": "Guo, F. et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64, 2580\u20132589 (2004).", "journal-title": "Cancer Res."}, {"key": "BFnbt1272_CR38", "doi-asserted-by": "publisher", "first-page": "549", "DOI": "10.4161/cc.4.4.1564", "volume": "4", "author": "PA Marks", "year": "2005", "unstructured": "Marks, P.A. & Jiang, X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4, 549\u2013551 (2005).", "journal-title": "Cell Cycle"}, {"key": "BFnbt1272_CR39", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1073/pnas.0408732102", "volume": "102", "author": "JS Ungerstedt", "year": "2005", "unstructured": "Ungerstedt, J.S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102, 673\u2013678 (2005).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR40", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.2174/1568011054866946", "volume": "5", "author": "O Moradei", "year": "2005", "unstructured": "Moradei, O., Maroun, C.R., Paquin, I. & Vaisburg, A. Histone deacetylase inhibitors: latest developments, trends and prospects. Curr. Med. Chem. Anticancer Agents 5, 529\u2013560 (2005).", "journal-title": "Curr. Med. Chem. Anticancer Agents"}, {"key": "BFnbt1272_CR41", "doi-asserted-by": "publisher", "first-page": "10014", "DOI": "10.1073/pnas.180316197", "volume": "97", "author": "VM Richon", "year": "2000", "unstructured": "Richon, V.M., Sandhoff, T.W., Rifkind, R.A. & Marks, P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014\u201310019 (2000).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR42", "doi-asserted-by": "publisher", "first-page": "11700", "DOI": "10.1073/pnas.182372299", "volume": "99", "author": "LM Butler", "year": "2002", "unstructured": "Butler, L.M. et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99, 11700\u201311705 (2002).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR43", "doi-asserted-by": "publisher", "first-page": "1241", "DOI": "10.1073/pnas.0307708100", "volume": "101", "author": "CY Gui", "year": "2004", "unstructured": "Gui, C.Y., Ngo, L., Xu, W.S., Richon, V.M. & Marks, P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101, 1241\u20131246 (2004).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnbt1272_CR44", "first-page": "5165", "volume": "60", "author": "LM Butler", "year": "2000", "unstructured": "Butler, L.M. et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165\u20135170 (2000).", "journal-title": "Cancer Res."}, {"key": "BFnbt1272_CR45", "doi-asserted-by": "publisher", "first-page": "420", "DOI": "10.1532/IJH97.04032", "volume": "79", "author": "C Yoshida", "year": "2004", "unstructured": "Yoshida, C. & Melo, J.V. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. J. Hematol. 79, 420\u2013433 (2004).", "journal-title": "Int. J. Hematol."}, {"key": "BFnbt1272_CR46", "first-page": "971", "volume": "2", "author": "L Fuino", "year": "2003", "unstructured": "Fuino, L. et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2, 971\u2013984 (2003).", "journal-title": "Mol. Cancer Ther."}, {"key": "BFnbt1272_CR47", "doi-asserted-by": "publisher", "first-page": "6382", "DOI": "10.1158/1078-0432.CCR-05-0344", "volume": "11", "author": "P Bali", "year": "2005", "unstructured": "Bali, P. et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 11, 6382\u20136389 (2005).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnbt1272_CR48", "doi-asserted-by": "publisher", "first-page": "150", "DOI": "10.1038/ncponc0106", "volume": "2", "author": "WK Kelly", "year": "2005", "unstructured": "Kelly, W.K. & Marks, P. Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2, 150\u2013157 (2005).", "journal-title": "Nat. Clin. Pract. Oncol."}, {"key": "BFnbt1272_CR49", "first-page": "3578", "volume": "9", "author": "WK Kelly", "year": "2003", "unstructured": "Kelly, W.K. et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578\u20133588 (2003).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnbt1272_CR50", "author": "E Olsen", "first-page": "7500", "year": "2006", "unstructured": "Olsen, E. et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): results of phase IIB trial. ASCO Annual Meeting Proceedings Part 1. (June 20 Suppl.) 24, 7500 (2006).", "volume-title": "ASCO Annual Meeting Proceedings Part 1"}, {"key": "BFnbt1272_CR51", "doi-asserted-by": "publisher", "first-page": "1045", "DOI": "10.1111/j.0022-202X.2005.23925.x", "volume": "125", "author": "C Zhang", "year": "2005", "unstructured": "Zhang, C., Richon, V., Ni, X., Talpur, R. & Duvic, M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 125, 1045\u20131052 (2005).", "journal-title": "J. Invest. Dermatol."}], "container-title": ["Nature Biotechnology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nbt1272.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nbt1272", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nbt1272.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 19]], "date-time": "2019-03-19T01:20:57Z", "timestamp": 1552958457000}, "score": 35.533867, "issued": {"date-parts": [[2007, 1]]}, "references-count": 51, "journal-issue": {"published-print": {"date-parts": [[2007, 1]]}, "issue": "1"}, "alternative-id": ["BFnbt1272"], "URL": "http://dx.doi.org/10.1038/nbt1272", "relation": {"cites": []}, "ISSN": ["1087-0156", "1546-1696"], "issn-type": [{"value": "1087-0156", "type": "print"}, {"value": "1546-1696", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T06:24:02Z", "timestamp": 1574231042553}, "reference-count": 93, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2006, 12, 1]], "date-time": "2006-12-01T00:00:00Z", "timestamp": 1164931200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Seminars in Cancer Biology"], "published-print": {"date-parts": [[2006, 12]]}, "DOI": "10.1016/j.semcancer.2006.09.005", "type": "journal-article", "created": {"date-parts": [[2006, 9, 27]], "date-time": "2006-09-27T11:39:02Z", "timestamp": 1159357142000}, "page": "436-443", "source": "Crossref", "is-referenced-by-count": 39, "title": ["Thioredoxin in cancer\u2014Role of histone deacetylase inhibitors"], "prefix": "10.1016", "volume": "16", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Seminars in Cancer Biology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1044579X06000939?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1044579X06000939?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 12]], "date-time": "2019-01-12T22:51:31Z", "timestamp": 1547333491000}, "score": 34.968452, "issued": {"date-parts": [[2006, 12]]}, "references-count": 93, "journal-issue": {"published-print": {"date-parts": [[2006, 12]]}, "issue": "6"}, "alternative-id": ["S1044579X06000939"], "URL": "http://dx.doi.org/10.1016/j.semcancer.2006.09.005", "ISSN": ["1044-579X"], "issn-type": [{"value": "1044-579X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T00:54:21Z", "timestamp": 1574297661054}, "reference-count": 1, "publisher": "Wiley", "issue": "26", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2989, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["ChemInform"], "published-print": {"date-parts": [[2007, 6, 26]]}, "DOI": "10.1002/chin.200726258", "type": "journal-article", "created": {"date-parts": [[2007, 6, 6]], "date-time": "2007-06-06T10:20:02Z", "timestamp": 1181125202000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Thioredoxin in Cancer \u2014 The Role of Histone Deacetylase Inhibitors"], "prefix": "10.1002", "volume": "38", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}], "member": "311", "reference": [{"key": "10.1002/chin.200726258-BIB1", "author": "Marks", "volume": "16", "first-page": "436", "year": "2006", "journal-title": "Semin. Cancer Biol.", "DOI": "10.1016/j.semcancer.2006.09.005", "doi-asserted-by": "crossref"}], "container-title": ["ChemInform"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fchin.200726258", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/chin.200726258", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 31]], "date-time": "2019-01-31T05:29:56Z", "timestamp": 1548912596000}, "score": 34.968452, "issued": {"date-parts": [[2007, 6, 26]]}, "references-count": 1, "journal-issue": {"published-print": {"date-parts": [[2007, 6, 26]]}, "issue": "26"}, "URL": "http://dx.doi.org/10.1002/chin.200726258", "relation": {"cites": []}, "ISSN": ["0931-7597", "1522-2667"], "issn-type": [{"value": "0931-7597", "type": "print"}, {"value": "1522-2667", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T07:31:41Z", "timestamp": 1574580701000}, "publisher-location": "Cambridge", "reference-count": 0, "publisher": "Cambridge University Press", "isbn-type": [{"value": "9781139046947", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1017/cbo9781139046947.088", "type": "book-chapter", "created": {"date-parts": [[2015, 2, 9]], "date-time": "2015-02-09T05:06:40Z", "timestamp": 1423458400000}, "page": "912-920", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Histone deacetylase inhibitors"], "prefix": "10.1017", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}], "member": "56", "container-title": ["Molecular Oncology"], "deposited": {"date-parts": [[2018, 4, 13]], "date-time": "2018-04-13T01:53:18Z", "timestamp": 1523584398000}, "score": 34.968452, "editor": [{"given": "Edward P.", "family": "Gelmann", "sequence": "additional", "affiliation": []}, {"given": "Charles L.", "family": "Sawyers", "sequence": "additional", "affiliation": []}, {"given": "Frank J.", "family": "Rauscher III", "sequence": "additional", "affiliation": []}], "issued": {"date-parts": [[null]]}, "ISBN": ["9781139046947"], "references-count": 0, "URL": "http://dx.doi.org/10.1017/cbo9781139046947.088"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T02:22:27Z", "timestamp": 1575166947862}, "reference-count": 51, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3895, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J. Cell. Biochem."], "published-print": {"date-parts": [[2005, 10, 1]]}, "DOI": "10.1002/jcb.20532", "type": "journal-article", "created": {"date-parts": [[2005, 8, 8]], "date-time": "2005-08-08T20:48:52Z", "timestamp": 1123534132000}, "page": "293-304", "source": "Crossref", "is-referenced-by-count": 292, "title": ["Prospects: Histone deacetylase inhibitors"], "prefix": "10.1002", "volume": "96", "author": [{"given": "Milos", "family": "Dokmanovic", "sequence": "first", "affiliation": []}, {"given": "Paul A.", "family": "Marks", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2005]]}, "reference": [{"key": "10.1002/jcb.20532-BIB1", "author": "Allfrey", "volume": "51", "first-page": "786", "year": "1964", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.51.5.786", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB2", "author": "Arner", "volume": "267", "first-page": "6102", "year": "2000", "journal-title": "Eur J Biochem", "DOI": "10.1046/j.1432-1327.2000.01701.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB3", "author": "Blander", "volume": "73", "first-page": "417", "year": "2004", "journal-title": "Annu Rev Biochem", "DOI": "10.1146/annurev.biochem.73.011303.073651", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB4", "author": "Butler", "volume": "99", "first-page": "11700", "year": "2002", "journal-title": "Proc Natl Acad Sci", "DOI": "10.1073/pnas.182372299", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB5", "author": "Choi", "volume": "92", "first-page": "1300", "year": "2001", "journal-title": "Jpn J Cancer Res", "DOI": "10.1111/j.1349-7006.2001.tb02153.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB6", "author": "Curtin", "volume": "10", "first-page": "2373", "year": "2003", "journal-title": "Curr Med Chem", "DOI": "10.2174/0929867033456576", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB7", "author": "De Ruijter", "volume": "370", "first-page": "737", "year": "2002", "journal-title": "Biochem J", "DOI": "10.1042/bj20021321", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB8", "author": "Di Gennaro", "volume": "26", "first-page": "435", "year": "2004", "journal-title": "Amino Acids", "DOI": "10.1007/s00726-004-0087-3", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB9", "author": "Drummond", "volume": "45", "first-page": "495", "year": "2005", "journal-title": "Annu Rev Pharmacol Toxicol", "DOI": "10.1146/annurev.pharmtox.45.120403.095825", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB10", "author": "Finnin", "volume": "401", "first-page": "188", "year": "1999", "journal-title": "Nature", "DOI": "10.1038/43710", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB11", "author": "Fischle", "volume": "425", "first-page": "475", "year": "2003", "journal-title": "Nature", "DOI": "10.1038/nature02017", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB12", "author": "Glaser", "volume": "310", "first-page": "529", "year": "2003", "journal-title": "Biochem Biophys Res Commun", "DOI": "10.1016/j.bbrc.2003.09.043", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB13", "author": "Gray", "volume": "24", "first-page": "773", "year": "2004", "journal-title": "Int J Oncol"}, {"key": "10.1002/jcb.20532-BIB14", "author": "Gregoretti", "volume": "338", "first-page": "17", "year": "2004", "journal-title": "J Mol Biol", "DOI": "10.1016/j.jmb.2004.02.006", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB15", "author": "Gui", "volume": "101", "first-page": "1241", "year": "2004", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.0307708100", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB16", "author": "Haggarty", "volume": "100", "first-page": "4389", "year": "2003", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.0430973100", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB17", "author": "Halkidou", "volume": "59", "first-page": "177", "year": "2004", "journal-title": "Prostate", "DOI": "10.1002/pros.20022", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB18", "author": "Hu", "volume": "307", "first-page": "720", "year": "2003", "journal-title": "J Pharmacol Exp Ther", "DOI": "10.1124/jpet.103.055541", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB19", "author": "Johnstone", "volume": "4", "first-page": "13", "year": "2003", "journal-title": "Cancer Cell", "DOI": "10.1016/S1535-6108(03)00165-X", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB20", "author": "Jose", "volume": "14", "first-page": "5343", "year": "2004", "journal-title": "Bioorg Med Chem Lett", "DOI": "10.1016/j.bmcl.2004.08.016", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB21", "author": "Kelly", "volume": "2", "first-page": "1", "year": "2005", "journal-title": "Nat Clinc Prac", "DOI": "10.1038/ncpcardio0070", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB22", "author": "Kelly", "volume": "23", "first-page": "3923", "year": "2005", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2005.14.167", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB23", "author": "Lehrmann", "volume": "86", "first-page": "41", "year": "2002", "journal-title": "Adv Cancer Res", "DOI": "10.1016/S0065-230X(02)86002-X", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB24", "author": "Lindemann", "volume": "3", "first-page": "779", "year": "2004", "journal-title": "Cell Cycle", "DOI": "10.4161/cc.3.6.927", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB25", "author": "Luger", "volume": "389", "first-page": "251", "year": "1997", "journal-title": "Nature", "DOI": "10.1038/38444", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB26", "author": "Marks", "volume": "1", "first-page": "194", "year": "2001", "journal-title": "Nat Rev Cancer", "DOI": "10.1038/35106079", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB27", "author": "Marks", "volume": "91", "first-page": "137", "year": "2004", "journal-title": "Adv Cancer Res", "DOI": "10.1016/S0065-230X(04)91004-4", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB28", "author": "Miller", "volume": "46", "first-page": "5097", "year": "2003", "journal-title": "J Med Chem", "DOI": "10.1021/jm0303094", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB29", "author": "Mitsiades", "volume": "101", "first-page": "540", "year": "2004", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.2536759100", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB30", "author": "Osada", "volume": "112", "first-page": "26", "year": "2004", "journal-title": "Int J Cancer", "DOI": "10.1002/ijc.20395", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB31", "author": "Park", "volume": "10", "first-page": "5271", "year": "2004", "journal-title": "Clin Cancer Res", "DOI": "10.1158/1078-0432.CCR-03-0709", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB32", "author": "Peart", "volume": "102", "first-page": "3697", "year": "2005", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.0500369102", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB33", "author": "Pei", "volume": "10", "first-page": "3839", "year": "2004", "journal-title": "Clin Cancer Res", "DOI": "10.1158/1078-0432.CCR-03-0561", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB34", "author": "Piekarz", "volume": "10", "first-page": "2289", "year": "2004", "journal-title": "Curr Pharm Des", "DOI": "10.2174/1381612043383980", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB35", "author": "Piekarz", "volume": "22", "first-page": "2", "year": "2004a", "journal-title": "Proc Am Soc Clin Onc", "DOI": "10.1200/jco.2004.22.14_suppl.2", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB36", "author": "Piekarz", "volume": "103", "first-page": "4636", "year": "2004b", "journal-title": "Blood", "DOI": "10.1182/blood-2003-09-3068", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB37", "author": "Rascle", "volume": "23", "first-page": "4162", "year": "2003", "journal-title": "Mol Cell Biol", "DOI": "10.1128/MCB.23.12.4162-4173.2003", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB38", "author": "Richon", "volume": "93", "first-page": "5705", "year": "1996", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.93.12.5705", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB39", "author": "Richon", "volume": "95", "first-page": "3003", "year": "1998", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.95.6.3003", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB40", "author": "Rosato", "volume": "2", "first-page": "30", "year": "2003", "journal-title": "Cancer Biol Ther", "DOI": "10.4161/cbt.190", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB41", "author": "Rosato", "volume": "13", "first-page": "21", "year": "2004", "journal-title": "Expert Opin Investig Drugs", "DOI": "10.1517/13543784.13.1.21", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB42", "author": "Sengupta", "volume": "93", "first-page": "57", "year": "2004", "journal-title": "J Cell Biochem", "DOI": "10.1002/jcb.20179", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB43", "author": "Somoza", "volume": "12", "first-page": "1325", "year": "2004", "journal-title": "Structure", "DOI": "10.1016/j.str.2004.04.012", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB44", "author": "Spotswood", "volume": "110", "first-page": "577", "year": "2002", "journal-title": "J Clin Invest", "DOI": "10.1172/JCI0216547", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB45", "author": "Ungerstedt", "volume": "102", "first-page": "673", "year": "2005", "journal-title": "Proc Natl Acad Sci USA", "DOI": "10.1073/pnas.0408732102", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB46", "author": "Vega", "volume": "119", "first-page": "555", "year": "2004", "journal-title": "Cell", "DOI": "10.1016/j.cell.2004.10.024", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB47", "author": "Verdin", "volume": "19", "first-page": "286", "year": "2003", "journal-title": "Trends Genet", "DOI": "10.1016/S0168-9525(03)00073-8", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB48", "author": "Warrener", "volume": "17", "first-page": "1550", "year": "2003", "journal-title": "Faseb J", "DOI": "10.1096/fj.02-1003fje", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB49", "author": "Yoshida", "volume": "79", "first-page": "420", "year": "2004", "journal-title": "Int J Hematol", "DOI": "10.1532/IJH97.04032", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB50", "author": "Yoshida", "volume": "10", "first-page": "2351", "year": "2003", "journal-title": "Curr Med Chem", "DOI": "10.2174/0929867033456602", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.20532-BIB51", "author": "Zhang", "volume": "15", "first-page": "2343", "year": "2001", "journal-title": "Genes Dev", "DOI": "10.1101/gad.927301", "doi-asserted-by": "crossref"}], "container-title": ["Journal of Cellular Biochemistry"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjcb.20532", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/jcb.20532", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 13]], "date-time": "2019-03-13T05:27:25Z", "timestamp": 1552454845000}, "score": 34.23704, "issued": {"date-parts": [[2005]]}, "references-count": 51, "journal-issue": {"published-print": {"date-parts": [[2005, 10, 1]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1002/jcb.20532", "relation": {"cites": []}, "ISSN": ["0730-2312", "1097-4644"], "issn-type": [{"value": "0730-2312", "type": "print"}, {"value": "1097-4644", "type": "electronic"}], "subject": ["Cell Biology", "Biochemistry", "Molecular Biology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T06:00:59Z", "timestamp": 1574316059148}, "reference-count": 115, "publisher": "Springer Science and Business Media LLC", "issue": "37", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2007, 8, 1]], "date-time": "2007-08-01T00:00:00Z", "timestamp": 1185926400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncogene"], "published-print": {"date-parts": [[2007, 8]]}, "DOI": "10.1038/sj.onc.1210620", "type": "journal-article", "created": {"date-parts": [[2007, 8, 13]], "date-time": "2007-08-13T09:17:57Z", "timestamp": 1186996677000}, "page": "5541-5552", "source": "Crossref", "is-referenced-by-count": 822, "title": ["Histone deacetylase inhibitors: molecular mechanisms of action"], "prefix": "10.1038", "volume": "26", "author": [{"given": "W S", "family": "Xu", "sequence": "first", "affiliation": []}, {"given": "R B", "family": "Parmigiani", "sequence": "additional", "affiliation": []}, {"given": "P A", "family": "Marks", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2007, 8, 13]]}, "reference": [{"key": "BF1210620_CR1", "doi-asserted-by": "crossref", "first-page": "1331", "DOI": "10.1038/sj.leu.2402535", "volume": "16", "author": "J Almenara", "year": "2002", "unstructured": "Almenara J, Rosato R, Grant S . (2002). Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16: 1331\u20131343.", "journal-title": "Leukemia"}, {"key": "BF1210620_CR2", "doi-asserted-by": "crossref", "first-page": "431", "DOI": "10.1016/S1054-3589(08)61042-X", "volume": "27", "author": "MW Anders", "year": "1994", "unstructured": "Anders MW, Dekant W . (1994). Aminoacylases. Adv Pharmacol 27: 431\u2013448.", "journal-title": "Adv Pharmacol"}, {"key": "BF1210620_CR3", "doi-asserted-by": "crossref", "first-page": "565", "DOI": "10.1016/j.tcb.2005.09.003", "volume": "15", "author": "S Aoyagi", "year": "2005", "unstructured": "Aoyagi S, Archer TK . (2005). Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15: 565\u2013567.", "journal-title": "Trends Cell Biol"}, {"key": "BF1210620_CR4", "doi-asserted-by": "crossref", "first-page": "6791", "DOI": "10.1073/pnas.95.12.6791", "volume": "95", "author": "SY Archer", "year": "1998", "unstructured": "Archer SY, Meng S, Shei A, Hodin RA . (1998). p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791\u20136796.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR5", "doi-asserted-by": "crossref", "first-page": "420", "DOI": "10.1038/nrc821", "volume": "2", "author": "A Ashkenazi", "year": "2002", "unstructured": "Ashkenazi A . (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420\u2013430.", "journal-title": "Nat Rev Cancer"}, {"key": "BF1210620_CR6", "doi-asserted-by": "crossref", "first-page": "26729", "DOI": "10.1074/jbc.C500186200", "volume": "280", "author": "P Bali", "year": "2005", "unstructured": "Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. (2005). Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729\u201326734.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR7", "doi-asserted-by": "crossref", "first-page": "3971", "DOI": "10.1200/JCO.2005.16.600", "volume": "23", "author": "KN Bhalla", "year": "2005", "unstructured": "Bhalla KN . (2005). Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971\u20133993.", "journal-title": "J Clin Oncol"}, {"key": "BF1210620_CR8", "doi-asserted-by": "crossref", "first-page": "417", "DOI": "10.1146/annurev.biochem.73.011303.073651", "volume": "73", "author": "G Blander", "year": "2004", "unstructured": "Blander G, Guarente L . (2004). The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417\u2013435.", "journal-title": "Annu Rev Biochem"}, {"key": "BF1210620_CR9", "doi-asserted-by": "crossref", "first-page": "769", "DOI": "10.1038/nrd2133", "volume": "5", "author": "JE Bolden", "year": "2006", "unstructured": "Bolden JE, Peart MJ, Johnstone RW . (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769\u2013784.", "journal-title": "Nat Rev Drug Discov"}, {"key": "BF1210620_CR10", "doi-asserted-by": "crossref", "first-page": "3357", "DOI": "10.1038/sj.emboj.7601210", "volume": "25", "author": "C Boyault", "year": "2006", "unstructured": "Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W et al. (2006). HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25: 3357\u20133366.", "journal-title": "EMBO J"}, {"key": "BF1210620_CR11", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.1038/nrc1367", "volume": "4", "author": "JM Brown", "year": "2004", "unstructured": "Brown JM, Wilson WR . (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437\u2013447.", "journal-title": "Nat Rev Cancer"}, {"key": "BF1210620_CR12", "doi-asserted-by": "crossref", "first-page": "7685", "DOI": "10.1074/jbc.M310997200", "volume": "279", "author": "MH Brush", "year": "2004", "unstructured": "Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S . (2004). Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279: 7685\u20137691.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR13", "doi-asserted-by": "crossref", "first-page": "2717", "DOI": "10.1002/cncr.21589", "volume": "104", "author": "G Bug", "year": "2005", "unstructured": "Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K et al. (2005). Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104: 2717\u20132725.", "journal-title": "Cancer"}, {"key": "BF1210620_CR14", "doi-asserted-by": "crossref", "first-page": "6693", "DOI": "10.1038/sj.onc.1207893", "volume": "23", "author": "A Burgess", "year": "2004", "unstructured": "Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R et al. (2004). Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23: 6693\u20136701.", "journal-title": "Oncogene"}, {"key": "BF1210620_CR15", "first-page": "5165", "volume": "60", "author": "LM Butler", "year": "2000", "unstructured": "Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C et al. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165\u20135170.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR16", "doi-asserted-by": "crossref", "first-page": "11700", "DOI": "10.1073/pnas.182372299", "volume": "99", "author": "LM Butler", "year": "2002", "unstructured": "Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA et al. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700\u201311705.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR17", "doi-asserted-by": "crossref", "first-page": "1165", "DOI": "10.1016/S0959-8049(03)00072-8", "volume": "39", "author": "AE Chambers", "year": "2003", "unstructured": "Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP et al. (2003). Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39: 1165\u20131175.", "journal-title": "Eur J Cancer"}, {"key": "BF1210620_CR18", "doi-asserted-by": "crossref", "first-page": "22", "DOI": "10.1186/1476-4598-4-22", "volume": "4", "author": "A Chavez-Blanco", "year": "2005", "unstructured": "Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M et al. (2005). Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 4: 22.", "journal-title": "Mol Cancer"}, {"key": "BF1210620_CR19", "doi-asserted-by": "crossref", "first-page": "38879", "DOI": "10.1074/jbc.M505733200", "volume": "280", "author": "CS Chen", "year": "2005", "unstructured": "Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS . (2005). Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879\u201338887.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR20", "first-page": "1129", "volume": "21", "author": "YM Chung", "year": "2001", "unstructured": "Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ . (2001). Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res 21: 1129\u20131133.", "journal-title": "Anticancer Res"}, {"key": "BF1210620_CR21", "doi-asserted-by": "crossref", "first-page": "3821", "DOI": "10.1091/mbc.e03-01-0860", "volume": "14", "author": "D Cimini", "year": "2003", "unstructured": "Cimini D, Mattiuzzo M, Torosantucci L, Degrassi F . (2003). Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell 14: 3821\u20133833.", "journal-title": "Mol Biol Cell"}, {"key": "BF1210620_CR22", "doi-asserted-by": "crossref", "first-page": "427", "DOI": "10.1038/sj.onc.1205108", "volume": "21", "author": "CF Deroanne", "year": "2002", "unstructured": "Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427\u2013436.", "journal-title": "Oncogene"}, {"key": "BF1210620_CR23", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.4161/cbt.4.2.1441", "volume": "4", "author": "M Dowling", "year": "2005", "unstructured": "Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD . (2005). Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 4: 197\u2013206.", "journal-title": "Cancer Biol Ther"}, {"key": "BF1210620_CR24", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1182/blood-2006-06-025999", "volume": "109", "author": "M Duvic", "year": "2007", "unstructured": "Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C et al. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31\u201339.", "journal-title": "Blood"}, {"issue": "Suppl 1", "key": "BF1210620_CR25", "doi-asserted-by": "crossref", "first-page": "S13", "DOI": "10.1038/sj.bjc.6603465", "volume": "95", "author": "M Duvic", "year": "2006", "unstructured": "Duvic M, Zhang C . (2006). Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 95(Suppl 1): S13\u2013S19.", "journal-title": "Br J Cancer"}, {"key": "BF1210620_CR26", "doi-asserted-by": "crossref", "first-page": "13612", "DOI": "10.1074/jbc.M600456200", "volume": "281", "author": "DM Fath", "year": "2006", "unstructured": "Fath DM, Kong X, Liang D, Lin Z, Chou A, Jiang Y et al. (2006). Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem 281: 13612\u201313619.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR27", "doi-asserted-by": "crossref", "first-page": "188", "DOI": "10.1038/43710", "volume": "401", "author": "MS Finnin", "year": "1999", "unstructured": "Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188\u2013193.", "journal-title": "Nature"}, {"key": "BF1210620_CR28", "doi-asserted-by": "crossref", "first-page": "8563", "DOI": "10.1128/MCB.23.23.8563-8575.2003", "volume": "23", "author": "M Fu", "year": "2003", "unstructured": "Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D et al. (2003). Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23: 8563\u20138575.", "journal-title": "Mol Cell Biol"}, {"key": "BF1210620_CR29", "doi-asserted-by": "crossref", "first-page": "25748", "DOI": "10.1074/jbc.M111871200", "volume": "277", "author": "L Gao", "year": "2002", "unstructured": "Gao L, Cueto MA, Asselbergs F, Atadja P . (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 25748\u201325755.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR30", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1038/nbt0107-17", "volume": "25", "author": "K Garber", "year": "2007", "unstructured": "Garber K . (2007). HDAC inhibitors overcome first hurdle. Nat Biotechnol 25: 17\u201319.", "journal-title": "Nat Biotechnol"}, {"key": "BF1210620_CR31", "doi-asserted-by": "crossref", "first-page": "651", "DOI": "10.1016/j.leukres.2005.10.016", "volume": "30", "author": "KB Glaser", "year": "2006", "unstructured": "Glaser KB . (2006). Defining the role of gene regulation in resistance to HDAC inhibitors \u2013 mechanisms beyond P-glycoprotein. Leuk Res 30: 651\u2013652.", "journal-title": "Leuk Res"}, {"key": "BF1210620_CR32", "first-page": "151", "volume": "2", "author": "KB Glaser", "year": "2003", "unstructured": "Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK . (2003). Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151\u2013163.", "journal-title": "Mol Cancer Ther"}, {"key": "BF1210620_CR33", "first-page": "4392", "volume": "59", "author": "RD Glick", "year": "1999", "unstructured": "Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM et al. (1999). Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 59: 4392\u20134399.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR34", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.1016/j.gene.2005.09.010", "volume": "363", "author": "MA Glozak", "year": "2005", "unstructured": "Glozak MA, Sengupta N, Zhang X, Seto E . (2005). Acetylation and deacetylation of non-histone proteins. Gene 363: 15\u201323.", "journal-title": "Gene"}, {"key": "BF1210620_CR35", "first-page": "773", "volume": "24", "author": "SG Gray", "year": "2004", "unstructured": "Gray SG, Qian CN, Furge K, Guo X, Teh BT . (2004). Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24: 773\u2013795.", "journal-title": "Int J Oncol"}, {"key": "BF1210620_CR36", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1016/j.jmb.2004.02.006", "volume": "338", "author": "IV Gregoretti", "year": "2004", "unstructured": "Gregoretti IV, Lee YM, Goodson HV . (2004). Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17\u201331.", "journal-title": "J Mol Biol"}, {"key": "BF1210620_CR37", "doi-asserted-by": "crossref", "first-page": "1241", "DOI": "10.1073/pnas.0307708100", "volume": "101", "author": "CY Gui", "year": "2004", "unstructured": "Gui CY, Ngo L, Xu WS, Richon VM, Marks PA . (2004). Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241\u20131246.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR38", "doi-asserted-by": "crossref", "first-page": "4389", "DOI": "10.1073/pnas.0430973100", "volume": "100", "author": "SJ Haggarty", "year": "2003", "unstructured": "Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL . (2003). Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100: 4389\u20134394.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR39", "doi-asserted-by": "crossref", "first-page": "347", "DOI": "10.1016/S0014-5793(03)01186-4", "volume": "554", "author": "T Hitomi", "year": "2003", "unstructured": "Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T . (2003). p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett 554: 347\u2013350.", "journal-title": "FEBS Lett"}, {"key": "BF1210620_CR40", "doi-asserted-by": "crossref", "first-page": "720", "DOI": "10.1124/jpet.103.055541", "volume": "307", "author": "E Hu", "year": "2003", "unstructured": "Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF et al. (2003). Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307: 720\u2013728.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "BF1210620_CR41", "doi-asserted-by": "crossref", "first-page": "849", "DOI": "10.1007/BF03401823", "volume": "6", "author": "L Huang", "year": "2000", "unstructured": "Huang L, Pardee AB . (2000). Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849\u2013866.", "journal-title": "Mol Med"}, {"key": "BF1210620_CR42", "doi-asserted-by": "crossref", "first-page": "455", "DOI": "10.1038/417455a", "volume": "417", "author": "C Hubbert", "year": "2002", "unstructured": "Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417: 455\u2013458.", "journal-title": "Nature"}, {"key": "BF1210620_CR43", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1038/nm1160", "volume": "11", "author": "A Insinga", "year": "2005", "unstructured": "Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. (2005). Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71\u201376.", "journal-title": "Nat Med"}, {"key": "BF1210620_CR44", "doi-asserted-by": "crossref", "first-page": "4653", "DOI": "10.1002/pmic.200500042", "volume": "5", "author": "H Iwabata", "year": "2005", "unstructured": "Iwabata H, Yoshida M, Komatsu Y . (2005). Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies. Proteomics 5: 4653\u20134664.", "journal-title": "Proteomics"}, {"key": "BF1210620_CR45", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1016/S0092-8674(02)01085-1", "volume": "111", "author": "JW Jeong", "year": "2002", "unstructured": "Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH et al. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709\u2013720.", "journal-title": "Cell"}, {"key": "BF1210620_CR46", "doi-asserted-by": "crossref", "first-page": "87", "DOI": "10.1146/annurev.biochem.73.011303.073706", "volume": "73", "author": "X Jiang", "year": "2004", "unstructured": "Jiang X, Wang X . (2004). Cytochrome c-mediated apoptosis. Annu Rev Biochem 73: 87\u2013106.", "journal-title": "Annu Rev Biochem"}, {"key": "BF1210620_CR47", "doi-asserted-by": "crossref", "first-page": "26", "DOI": "10.1002/cm.10057", "volume": "53", "author": "JA Johnston", "year": "2002", "unstructured": "Johnston JA, Illing ME, Kopito RR . (2002). Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 53: 26\u201338.", "journal-title": "Cell Motil Cytoskeleton"}, {"key": "BF1210620_CR48", "doi-asserted-by": "crossref", "first-page": "6297", "DOI": "10.1074/jbc.273.11.6297", "volume": "273", "author": "SW Kang", "year": "1998", "unstructured": "Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG . (1998). Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273: 6297\u20136302.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR49", "doi-asserted-by": "crossref", "first-page": "41966", "DOI": "10.1074/jbc.M406320200", "volume": "279", "author": "H Kato", "year": "2004", "unstructured": "Kato H, Tamamizu-Kato S, Shibasaki F . (2004). Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279: 41966\u201341974.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR50", "doi-asserted-by": "crossref", "first-page": "727", "DOI": "10.1016/S0092-8674(03)00939-5", "volume": "115", "author": "Y Kawaguchi", "year": "2003", "unstructured": "Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP . (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727\u2013738.", "journal-title": "Cell"}, {"key": "BF1210620_CR51", "doi-asserted-by": "crossref", "first-page": "150", "DOI": "10.1038/ncponc0106", "volume": "2", "author": "W Kelly", "year": "2005", "unstructured": "Kelly W, Marks P . (2005). Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150\u2013157.", "journal-title": "Nat Clin Pract Oncol"}, {"key": "BF1210620_CR52", "doi-asserted-by": "crossref", "first-page": "5745", "DOI": "10.1021/jm030377q", "volume": "46", "author": "DK Kim", "year": "2003", "unstructured": "Kim DK, Lee JY, Kim JS, Ryu JH, Choi JY, Lee JW et al. (2003a). Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J Med Chem 46: 5745\u20135751.", "journal-title": "J Med Chem"}, {"key": "BF1210620_CR53", "first-page": "7291", "volume": "63", "author": "MS Kim", "year": "2003", "unstructured": "Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F . (2003b). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291\u20137300.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR54", "doi-asserted-by": "crossref", "first-page": "607", "DOI": "10.1016/j.molcel.2006.06.026", "volume": "23", "author": "SC Kim", "year": "2006", "unstructured": "Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J et al. (2006). Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607\u2013618.", "journal-title": "Mol Cell"}, {"key": "BF1210620_CR55", "doi-asserted-by": "crossref", "first-page": "2019", "DOI": "10.1128/MCB.26.6.2019-2028.2006", "volume": "26", "author": "X Kong", "year": "2006", "unstructured": "Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J . (2006). Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019\u20132028.", "journal-title": "Mol Cell Biol"}, {"key": "BF1210620_CR56", "doi-asserted-by": "crossref", "first-page": "601", "DOI": "10.1016/j.molcel.2005.04.021", "volume": "18", "author": "JJ Kovacs", "year": "2005", "unstructured": "Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al. (2005). HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601\u2013607.", "journal-title": "Mol Cell"}, {"key": "BF1210620_CR57", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1016/S0065-230X(02)86002-X", "volume": "86", "author": "H Lehrmann", "year": "2002", "unstructured": "Lehrmann H, Pritchard LL, Harel-Bellan A . (2002). Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86: 41\u201365.", "journal-title": "Adv Cancer Res"}, {"key": "BF1210620_CR58", "doi-asserted-by": "crossref", "first-page": "2430", "DOI": "10.4161/cc.5.21.3409", "volume": "5", "author": "D Liang", "year": "2006", "unstructured": "Liang D, Kong X, Sang N . (2006). Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 5: 2430\u20132435.", "journal-title": "Cell Cycle"}, {"key": "BF1210620_CR59", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1089/ars.2007.9.25", "volume": "9", "author": "CH Lillig", "year": "2007", "unstructured": "Lillig CH, Holmgren A . (2007). Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal 9: 25\u201347.", "journal-title": "Antioxid Redox Signal"}, {"key": "BF1210620_CR60", "doi-asserted-by": "crossref", "first-page": "8071", "DOI": "10.1073/pnas.0702294104", "volume": "104", "author": "RK Lindemann", "year": "2007", "unstructured": "Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. (2007). Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model B cell lymophoma. Proc Natl Acad Sci USA 104: 8071\u20138076.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR61", "doi-asserted-by": "crossref", "first-page": "1207", "DOI": "10.1038/sj.leu.2403388", "volume": "18", "author": "DM Lucas", "year": "2004", "unstructured": "Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD et al. (2004). The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18: 1207\u20131214.", "journal-title": "Leukemia"}, {"key": "BF1210620_CR62", "doi-asserted-by": "crossref", "first-page": "261", "DOI": "10.1002/med.20024", "volume": "25", "author": "A Mai", "year": "2005", "unstructured": "Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R et al. (2005). Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261\u2013309.", "journal-title": "Med Res Rev"}, {"key": "BF1210620_CR63", "doi-asserted-by": "crossref", "first-page": "8467", "DOI": "10.1158/1078-0432.CCR-05-1073", "volume": "11", "author": "DC Marchion", "year": "2005", "unstructured": "Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN . (2005). Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 11: 8467\u20138475.", "journal-title": "Clin Cancer Res"}, {"key": "BF1210620_CR64", "doi-asserted-by": "crossref", "first-page": "84", "DOI": "10.1038/nbt1272", "volume": "25", "author": "PA Marks", "year": "2007", "unstructured": "Marks PA, Breslow R . (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84\u201390.", "journal-title": "Nat Biotechnol"}, {"key": "BF1210620_CR65", "doi-asserted-by": "crossref", "first-page": "1497", "DOI": "10.1517/13543784.14.12.1497", "volume": "14", "author": "PA Marks", "year": "2005", "unstructured": "Marks PA, Dokmanovic M . (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497\u20131511.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "BF1210620_CR66", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/0925-5710(95)00428-9", "volume": "63", "author": "PA Marks", "year": "1996", "unstructured": "Marks PA, Richon VM, Rifkind RA . (1996). Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: molecular and clinical studies employing hybrid polar compounds. Int J Hematol 63: 1\u201317.", "journal-title": "Int J Hematol"}, {"key": "BF1210620_CR67", "doi-asserted-by": "crossref", "first-page": "5097", "DOI": "10.1021/jm0303094", "volume": "46", "author": "TA Miller", "year": "2003", "unstructured": "Miller TA, Witter DJ, Belvedere S . (2003). Histone deacetylase inhibitors. J Med Chem 46: 5097\u20135116.", "journal-title": "J Med Chem"}, {"key": "BF1210620_CR68", "doi-asserted-by": "crossref", "first-page": "38", "DOI": "10.1038/nrc1779", "volume": "6", "author": "S Minucci", "year": "2006", "unstructured": "Minucci S, Pelicci PG . (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38\u201351.", "journal-title": "Nat Rev Cancer"}, {"key": "BF1210620_CR69", "doi-asserted-by": "crossref", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "volume": "101", "author": "CS Mitsiades", "year": "2004", "unstructured": "Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. (2004). Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540\u2013545.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR70", "doi-asserted-by": "crossref", "first-page": "4055", "DOI": "10.1182/blood-2002-11-3514", "volume": "101", "author": "N Mitsiades", "year": "2003", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. (2003). Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055\u20134062.", "journal-title": "Blood"}, {"key": "BF1210620_CR71", "first-page": "8492", "volume": "61", "author": "PN Munster", "year": "2001", "unstructured": "Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM . (2001). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492\u20138497.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR72", "doi-asserted-by": "crossref", "first-page": "6261", "DOI": "10.1038/sj.onc.1207830", "volume": "23", "author": "S Nakata", "year": "2004", "unstructured": "Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T . (2004). Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261\u20136271.", "journal-title": "Oncogene"}, {"key": "BF1210620_CR73", "doi-asserted-by": "crossref", "first-page": "3236", "DOI": "10.1182/blood-2002-08-2675", "volume": "101", "author": "R Nimmanapalli", "year": "2003", "unstructured": "Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K . (2003). Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101: 3236\u20133239.", "journal-title": "Blood"}, {"key": "BF1210620_CR74", "doi-asserted-by": "crossref", "first-page": "21645", "DOI": "10.1074/jbc.274.31.21645", "volume": "274", "author": "A Nishiyama", "year": "1999", "unstructured": "Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H et al. (1999). Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645\u201321650.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR75", "doi-asserted-by": "crossref", "first-page": "3697", "DOI": "10.1073/pnas.0500369102", "volume": "102", "author": "MJ Peart", "year": "2005", "unstructured": "Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. (2005). Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697\u20133702.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR76", "first-page": "4460", "volume": "63", "author": "MJ Peart", "year": "2003", "unstructured": "Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. (2003). Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460\u20134471.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR77", "doi-asserted-by": "crossref", "first-page": "2934", "DOI": "10.1038/sj.onc.1207515", "volume": "23", "author": "Y Pommier", "year": "2004", "unstructured": "Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW . (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934\u20132949.", "journal-title": "Oncogene"}, {"key": "BF1210620_CR78", "doi-asserted-by": "crossref", "first-page": "312", "DOI": "10.1016/S0891-5849(00)00313-0", "volume": "29", "author": "G Powis", "year": "2000", "unstructured": "Powis G, Mustacich D, Coon A . (2000). The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312\u2013322.", "journal-title": "Free Radic Biol Med"}, {"key": "BF1210620_CR79", "doi-asserted-by": "crossref", "first-page": "8814", "DOI": "10.1158/0008-5472.CAN-05-4598", "volume": "66", "author": "DZ Qian", "year": "2006", "unstructured": "Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P et al. (2006). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1{alpha}. Cancer Res 66: 8814\u20138821.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR80", "doi-asserted-by": "crossref", "first-page": "2069", "DOI": "10.1091/mbc.11.6.2069", "volume": "11", "author": "L Qiu", "year": "2000", "unstructured": "Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG . (2000). Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11: 2069\u20132083.", "journal-title": "Mol Biol Cell"}, {"key": "BF1210620_CR81", "doi-asserted-by": "crossref", "first-page": "4162", "DOI": "10.1128/MCB.23.12.4162-4173.2003", "volume": "23", "author": "A Rascle", "year": "2003", "unstructured": "Rascle A, Johnston JA, Amati B . (2003). Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 23: 4162\u20134173.", "journal-title": "Mol Cell Biol"}, {"key": "BF1210620_CR82", "doi-asserted-by": "crossref", "first-page": "3003", "DOI": "10.1073/pnas.95.6.3003", "volume": "95", "author": "VM Richon", "year": "1998", "unstructured": "Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95: 3003\u20133007.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR83", "doi-asserted-by": "crossref", "first-page": "10014", "DOI": "10.1073/pnas.180316197", "volume": "97", "author": "VM Richon", "year": "2000", "unstructured": "Richon VM, Sandhoff TW, Rifkind RA, Marks PA . (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014\u201310019.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR84", "doi-asserted-by": "crossref", "first-page": "717", "DOI": "10.4161/cc.4.5.1690", "volume": "4", "author": "AR Robbins", "year": "2005", "unstructured": "Robbins AR, Jablonski SA, Yen TJ, Yoda K, Robey R, Bates SE et al. (2005). Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4: 717\u2013726.", "journal-title": "Cell Cycle"}, {"key": "BF1210620_CR85", "first-page": "3637", "volume": "63", "author": "RR Rosato", "year": "2003", "unstructured": "Rosato RR, Almenara JA, Grant S . (2003). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637\u20133645.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR86", "doi-asserted-by": "crossref", "first-page": "21", "DOI": "10.1517/13543784.13.1.21", "volume": "13", "author": "RR Rosato", "year": "2004", "unstructured": "Rosato RR, Grant S . (2004). Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13: 21\u201338.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "BF1210620_CR87", "doi-asserted-by": "crossref", "first-page": "809", "DOI": "10.1517/14728222.9.4.809", "volume": "9", "author": "RR Rosato", "year": "2005", "unstructured": "Rosato RR, Grant S . (2005). Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 9: 809\u2013824.", "journal-title": "Expert Opin Ther Targets"}, {"key": "BF1210620_CR88", "first-page": "216", "volume": "69", "author": "RR Rosato", "year": "2006", "unstructured": "Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S et al. (2006). The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 69: 216\u2013225.", "journal-title": "Mol Pharmacol"}, {"key": "BF1210620_CR89", "first-page": "181", "volume": "19", "author": "RR Rosato", "year": "2001", "unstructured": "Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S . (2001). Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol 19: 181\u2013191.", "journal-title": "Int J Oncol"}, {"key": "BF1210620_CR90", "doi-asserted-by": "crossref", "first-page": "10833", "DOI": "10.1073/pnas.191208598", "volume": "98", "author": "AA Ruefli", "year": "2001", "unstructured": "Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. (2001). The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833\u201310838.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR91", "doi-asserted-by": "crossref", "first-page": "292", "DOI": "10.1002/ijc.10327", "volume": "99", "author": "AA Ruefli", "year": "2002", "unstructured": "Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW . (2002). Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 99: 292\u2013298.", "journal-title": "Int J Cancer"}, {"key": "BF1210620_CR92", "doi-asserted-by": "crossref", "first-page": "2596", "DOI": "10.1093/emboj/17.9.2596", "volume": "17", "author": "M Saitoh", "year": "1998", "unstructured": "Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y et al. (1998). Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596\u20132606.", "journal-title": "EMBO J"}, {"key": "BF1210620_CR93", "doi-asserted-by": "crossref", "first-page": "1079", "DOI": "10.1016/S0006-2952(02)01261-3", "volume": "64", "author": "Y Sasakawa", "year": "2002", "unstructured": "Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T et al. (2002). Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64: 1079\u20131090.", "journal-title": "Biochem Pharmacol"}, {"key": "BF1210620_CR94", "doi-asserted-by": "crossref", "first-page": "603", "DOI": "10.1016/j.bcp.2004.11.008", "volume": "69", "author": "Y Sasakawa", "year": "2005", "unstructured": "Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M et al. (2005). Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69: 603\u2013616.", "journal-title": "Biochem Pharmacol"}, {"key": "BF1210620_CR95", "doi-asserted-by": "crossref", "first-page": "18030", "DOI": "10.1073/pnas.0408345102", "volume": "101", "author": "Y Shao", "year": "2004", "unstructured": "Shao Y, Gao Z, Marks PA, Jiang X . (2004). Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030\u201318035.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR96", "doi-asserted-by": "crossref", "first-page": "1205", "DOI": "10.2174/156802606777812068", "volume": "6", "author": "DB Solit", "year": "2006", "unstructured": "Solit DB, Rosen N . (2006). Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6: 1205\u20131214.", "journal-title": "Curr Top Med Chem"}, {"key": "BF1210620_CR97", "doi-asserted-by": "crossref", "first-page": "1325", "DOI": "10.1016/j.str.2004.04.012", "volume": "12", "author": "JR Somoza", "year": "2004", "unstructured": "Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ et al. (2004). Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Cambridge) 12: 1325\u20131334.", "journal-title": "Structure (Cambridge)"}, {"key": "BF1210620_CR98", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.3816/CGC.2006.n.018", "volume": "5", "author": "WM Stadler", "year": "2006", "unstructured": "Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA . (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical genitourinary cancer 5: 57\u201360.", "journal-title": "Clinical genitourinary cancer"}, {"key": "BF1210620_CR99", "doi-asserted-by": "crossref", "first-page": "387", "DOI": "10.1002/jcp.20235", "volume": "203", "author": "K Sutheesophon", "year": "2005", "unstructured": "Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K et al. (2005). Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 203: 387\u2013397.", "journal-title": "J Cell Physiol"}, {"key": "BF1210620_CR100", "doi-asserted-by": "crossref", "first-page": "114", "DOI": "10.1038/35055010", "volume": "3", "author": "A Taddei", "year": "2001", "unstructured": "Taddei A, Maison C, Roche D, Almouzni G . (2001). Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 3: 114\u2013120.", "journal-title": "Nat Cell Biol"}, {"key": "BF1210620_CR101", "doi-asserted-by": "crossref", "first-page": "10508", "DOI": "10.1074/jbc.M512719200", "volume": "281", "author": "J Tan", "year": "2006", "unstructured": "Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q . (2006). Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem 281: 10508\u201310515.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR102", "doi-asserted-by": "crossref", "first-page": "673", "DOI": "10.1073/pnas.0408732102", "volume": "102", "author": "JS Ungerstedt", "year": "2005", "unstructured": "Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al. (2005). Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673\u2013678.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR103", "first-page": "245", "volume": "5", "author": "C Van Lint", "year": "1996", "unstructured": "Van Lint C, Emiliani S, Verdin E . (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245\u2013253.", "journal-title": "Gene Expr"}, {"key": "BF1210620_CR104", "doi-asserted-by": "crossref", "first-page": "15064", "DOI": "10.1073/pnas.0404603101", "volume": "101", "author": "A Vannini", "year": "2004", "unstructured": "Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D et al. (2004). Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101: 15064\u201315069.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR105", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/S0378-1119(00)00092-5", "volume": "247", "author": "A Vidal", "year": "2000", "unstructured": "Vidal A, Koff A . (2000). Cell-cycle inhibitors: three families united by a common cause. Gene 247: 1\u201315.", "journal-title": "Gene"}, {"key": "BF1210620_CR106", "doi-asserted-by": "crossref", "first-page": "5175", "DOI": "10.1038/sj.onc.1207654", "volume": "23", "author": "LG Wang", "year": "2004", "unstructured": "Wang LG, Ossowski L, Ferrari AC . (2004). Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23: 5175\u20135184.", "journal-title": "Oncogene"}, {"key": "BF1210620_CR107", "doi-asserted-by": "crossref", "first-page": "7982", "DOI": "10.1128/MCB.22.22.7982-7992.2002", "volume": "22", "author": "JJ Westendorf", "year": "2002", "unstructured": "Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB et al. (2002). Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22: 7982\u20137992.", "journal-title": "Mol Cell Biol"}, {"key": "BF1210620_CR108", "doi-asserted-by": "crossref", "first-page": "15540", "DOI": "10.1073/pnas.0607518103", "volume": "103", "author": "W Xu", "year": "2006", "unstructured": "Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA . (2006). Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103: 15540\u201315545.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR109", "doi-asserted-by": "crossref", "first-page": "7832", "DOI": "10.1158/0008-5472.CAN-04-4608", "volume": "65", "author": "WS Xu", "year": "2005", "unstructured": "Xu WS, Perez G, Ngo L, Gui CY, Marks PA . (2005). Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65: 7832\u20137839.", "journal-title": "Cancer Res"}, {"key": "BF1210620_CR110", "doi-asserted-by": "crossref", "first-page": "2351", "DOI": "10.2174/0929867033456602", "volume": "10", "author": "M Yoshida", "year": "2003", "unstructured": "Yoshida M, Matsuyama A, Komatsu Y, Nishino N . (2003). From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10: 2351\u20132358.", "journal-title": "Curr Med Chem"}, {"key": "BF1210620_CR111", "doi-asserted-by": "crossref", "first-page": "425", "DOI": "10.4161/cbt.3.5.985", "volume": "3", "author": "XD Zhang", "year": "2004", "unstructured": "Zhang XD, Gillespie SK, Borrow JM, Hersey P . (2004). The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 3: 425\u2013435.", "journal-title": "Mol Cancer Ther"}, {"key": "BF1210620_CR112", "doi-asserted-by": "crossref", "first-page": "2401", "DOI": "10.1074/jbc.C500241200", "volume": "281", "author": "Y Zhang", "year": "2006", "unstructured": "Zhang Y, Gilquin B, Khochbin S, Matthias P . (2006). Two catalytic domains are required for protein deacetylation. J Biol Chem 281: 2401\u20132404.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR113", "doi-asserted-by": "crossref", "first-page": "4183", "DOI": "10.1074/jbc.M509051200", "volume": "281", "author": "LJ Zhao", "year": "2006", "unstructured": "Zhao LJ, Subramanian T, Zhou Y, Chinnadurai G . (2006). Acetylation by p300 regulates nuclear localization and function of the transcriptional corepressor CtBP2. J Biol Chem 281: 4183\u20134189.", "journal-title": "J Biol Chem"}, {"key": "BF1210620_CR114", "doi-asserted-by": "crossref", "first-page": "16090", "DOI": "10.1073/pnas.0505585102", "volume": "102", "author": "Y Zhao", "year": "2005", "unstructured": "Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q . (2005). Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102: 16090\u201316095.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1210620_CR115", "doi-asserted-by": "crossref", "first-page": "45", "DOI": "10.1016/j.bbrc.2005.12.144", "volume": "341", "author": "H Zou", "year": "2006", "unstructured": "Zou H, Wu Y, Navre M, Sang BC . (2006). Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun 341: 45\u201350.", "journal-title": "Biochem Biophys Res Commun"}], "container-title": ["Oncogene"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1210620.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1210620", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1210620.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 20]], "date-time": "2019-04-20T05:26:00Z", "timestamp": 1555737960000}, "score": 32.10517, "issued": {"date-parts": [[2007, 8]]}, "references-count": 115, "journal-issue": {"published-print": {"date-parts": [[2007, 8]]}, "issue": "37"}, "alternative-id": ["BF1210620"], "URL": "http://dx.doi.org/10.1038/sj.onc.1210620", "relation": {"cites": []}, "ISSN": ["0950-9232", "1476-5594"], "issn-type": [{"value": "0950-9232", "type": "print"}, {"value": "1476-5594", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T15:09:43Z", "timestamp": 1574435383876}, "reference-count": 141, "publisher": "Elsevier BV", "issue": "10-12", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2010, 10, 1]], "date-time": "2010-10-01T00:00:00Z", "timestamp": 1285891200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"], "published-print": {"date-parts": [[2010, 10]]}, "DOI": "10.1016/j.bbagrm.2010.05.008", "type": "journal-article", "created": {"date-parts": [[2010, 6, 9]], "date-time": "2010-06-09T09:06:22Z", "timestamp": 1276074382000}, "page": "717-725", "source": "Crossref", "is-referenced-by-count": 104, "title": ["Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions"], "prefix": "10.1016", "volume": "1799", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1874939910000696?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1874939910000696?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 29]], "date-time": "2019-05-29T23:17:16Z", "timestamp": 1559171836000}, "score": 31.37447, "issued": {"date-parts": [[2010, 10]]}, "references-count": 141, "journal-issue": {"published-print": {"date-parts": [[2010, 10]]}, "issue": "10-12"}, "alternative-id": ["S1874939910000696"], "URL": "http://dx.doi.org/10.1016/j.bbagrm.2010.05.008", "ISSN": ["1874-9399"], "issn-type": [{"value": "1874-9399", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:29:10Z", "timestamp": 1574486950869}, "reference-count": 57, "publisher": "Wiley", "issue": "7", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1642, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 4]]}, "DOI": "10.1111/j.1476-5381.2010.01188.x", "type": "journal-article", "created": {"date-parts": [[2010, 12, 30]], "date-time": "2010-12-30T13:06:18Z", "timestamp": 1293714378000}, "page": "1590-1602", "source": "Crossref", "is-referenced-by-count": 51, "title": ["The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells"], "prefix": "10.1111", "volume": "162", "author": [{"given": "CE", "family": "Tiffon", "sequence": "first", "affiliation": []}, {"given": "JE", "family": "Adams", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "van der Fits", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Wen", "sequence": "additional", "affiliation": []}, {"given": "PA", "family": "Townsend", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Ganesan", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Hodges", "sequence": "additional", "affiliation": []}, {"given": "MH", "family": "Vermeer", "sequence": "additional", "affiliation": []}, {"given": "G", "family": "Packham", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 3, 4]]}, "reference": [{"key": "10.1111/j.1476-5381.2010.01188.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "607", "DOI": "10.1146/annurev.immunol.23.021704.115821", "article-title": "Regulation of Th2 differentiation and IL-4 locus accessibility", "volume": "24", "author": "Ansel", "year": "2006", "journal-title": "Annu Rev Immunol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "833", "DOI": "10.1111/1523-1747.ep12330869", "article-title": "Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA", "volume": "107", "author": "Asadullah", "year": "1996", "journal-title": "J Invest Dermatol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB3|cit3", "first-page": "2929", "article-title": "The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells", "volume": "99", "author": "Berger", "year": "2002", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1640", "DOI": "10.1182/blood-2004-06-2181", "article-title": "Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells", "volume": "105", "author": "Berger", "year": "2005", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB5|cit5", "first-page": "1270", "article-title": "Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice", "volume": "63", "author": "Blaskovich", "year": "2003", "journal-title": "Cancer Res"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "769", "DOI": "10.1038/nrd2133", "article-title": "Anticancer activities of histone deacetylase inhibitors", "volume": "5", "author": "Bolden", "year": "2006", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "1424", "DOI": "10.1182/blood-2008-01-133769", "article-title": "Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines", "volume": "112", "author": "Buglio", "year": "2008", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "195", "DOI": "10.1111/j.1600-0625.1997.tb00205.x", "article-title": "Immunohistochemical expression of IL-10 in mycosis fungoides", "volume": "6", "author": "Buhl", "year": "1997", "journal-title": "Exp Dermatol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "12", "DOI": "10.1002/jcb.240630503", "article-title": "T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL)", "volume": "24", "author": "Bunn", "year": "1996", "journal-title": "J Cell Biochem Suppl"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "767", "DOI": "10.1182/blood-2009-11-251926", "article-title": "Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors", "volume": "116", "author": "Campbell", "year": "2010", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "4038", "DOI": "10.1182/blood-2008-08-176024", "article-title": "Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism", "volume": "113", "author": "Chen", "year": "2009", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "834", "DOI": "10.1126/science.1175371", "article-title": "Lysine acetylation targets protein complexes and co-regulates major cellular functions", "volume": "325", "author": "Choudhary", "year": "2009", "journal-title": "Science"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "463", "DOI": "10.1016/j.bcp.2008.06.004", "article-title": "Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A", "volume": "76", "author": "Crabb", "year": "2008", "journal-title": "Biochem Pharmacol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1182/blood-2006-06-025999", "article-title": "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)", "volume": "109", "author": "Duvic", "year": "2007", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "3785", "DOI": "10.1158/0008-5472.CAN-07-6091", "article-title": "Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma", "volume": "68", "author": "Fantin", "year": "2008", "journal-title": "Cancer Res"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB16|cit16", "first-page": "4916", "article-title": "FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases", "volume": "62", "author": "Furumai", "year": "2002", "journal-title": "Cancer Res"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1080/08916930601095148", "article-title": "Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration", "volume": "40", "author": "Harada", "year": "2007", "journal-title": "Autoimmunity"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "9630", "DOI": "10.1158/0008-5472.CAN-07-1243", "article-title": "A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients", "volume": "67", "author": "Hussain", "year": "2007", "journal-title": "Cancer Res"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "293", "DOI": "10.1007/BF00431220", "article-title": "A continuous T-cell line from a patient with Sezary syndrome", "volume": "279", "author": "Kaltoft", "year": "1987", "journal-title": "Arch Dermatol Res"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "2506", "DOI": "10.4049/jimmunol.181.4.2506", "article-title": "Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes", "volume": "181", "author": "Kasprzycka", "year": "2008", "journal-title": "J Immunol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB46|cit21", "doi-asserted-by": "crossref", "first-page": "1691", "DOI": "10.1038/sj.jid.5701246", "article-title": "Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells", "volume": "128", "author": "van Kester", "year": "2008", "journal-title": "J Invest Dermatol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB21|cit22", "doi-asserted-by": "crossref", "first-page": "581", "DOI": "10.1042/BJ20070779", "article-title": "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors", "volume": "409", "author": "Khan", "year": "2008", "journal-title": "Biochem J"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB22|cit23", "doi-asserted-by": "crossref", "first-page": "798", "DOI": "10.1172/JCI200524826", "article-title": "Immunopathogenesis and therapy of cutaneous T cell lymphoma", "volume": "115", "author": "Kim", "year": "2005", "journal-title": "J Clin Invest"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB23|cit24", "doi-asserted-by": "crossref", "first-page": "376", "DOI": "10.1007/s11912-006-0061-1", "article-title": "Mycosis fungoides and sezary syndrome: an update", "volume": "8", "author": "Kim", "year": "2006", "journal-title": "Curr Oncol Rep"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB24|cit25", "doi-asserted-by": "crossref", "first-page": "2230", "DOI": "10.1038/leu.2008.224", "article-title": "Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome", "volume": "22", "author": "Krejsgaard", "year": "2008", "journal-title": "Leukemia"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB25|cit26", "doi-asserted-by": "crossref", "first-page": "1171", "DOI": "10.1046/j.1365-2133.2002.04994.x", "article-title": "Dendritic cells and apoptosis in mycosis fungoides", "volume": "147", "author": "Luftl", "year": "2002", "journal-title": "Br J Dermatol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB26|cit27", "doi-asserted-by": "crossref", "first-page": "137", "DOI": "10.1016/S0065-230X(04)91004-4", "article-title": "Histone deacetylase inhibitors", "volume": "91", "author": "Marks", "year": "2004", "journal-title": "Adv Cancer Res"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB27|cit28", "doi-asserted-by": "crossref", "first-page": "751", "DOI": "10.1016/S0092-8674(03)00934-6", "article-title": "Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter", "volume": "115", "author": "Metivier", "year": "2003", "journal-title": "Cell"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB28|cit29", "doi-asserted-by": "crossref", "first-page": "2628", "DOI": "10.1073/pnas.051507098", "article-title": "Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells", "volume": "98", "author": "Mishra", "year": "2001", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB29|cit30", "doi-asserted-by": "crossref", "first-page": "301", "DOI": "10.1111/j.1365-2567.2005.02091.x", "article-title": "Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas", "volume": "114", "author": "Mitchell", "year": "2005", "journal-title": "Immunology"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB30|cit31", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1111/j.1600-065X.2008.00706.x", "article-title": "Interleukin-10: new perspectives on an old cytokine", "volume": "226", "author": "Mosser", "year": "2008", "journal-title": "Immunol Rev"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB31|cit32", "doi-asserted-by": "crossref", "first-page": "3109", "DOI": "10.1200/JCO.2006.10.2434", "article-title": "Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma", "volume": "25", "author": "Olsen", "year": "2007", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB32|cit33", "doi-asserted-by": "crossref", "first-page": "1166", "DOI": "10.1038/sj.onc.1209897", "article-title": "Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells", "volume": "26", "author": "Pickering", "year": "2007", "journal-title": "Oncogene"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "4636", "DOI": "10.1182/blood-2003-09-3068", "article-title": "T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance", "volume": "103", "author": "Piekarz", "year": "2004", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB33|cit35", "doi-asserted-by": "crossref", "first-page": "5410", "DOI": "10.1200/JCO.2008.21.6150", "article-title": "Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma", "volume": "27", "author": "Piekarz", "year": "2009", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "824", "DOI": "10.1210/me.16.4.824", "article-title": "Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity", "volume": "16", "author": "Ray", "year": "2002", "journal-title": "Mol Endocrinol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB35|cit37", "doi-asserted-by": "crossref", "first-page": "4510", "DOI": "10.1093/nar/gkn419", "article-title": "Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution", "volume": "36", "author": "Ray", "year": "2008", "journal-title": "Nucleic Acids Res"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB37|cit38", "doi-asserted-by": "crossref", "first-page": "201", "DOI": "10.1016/j.canlet.2009.01.002", "article-title": "Development of vorinostat: current applications and future perspectives for cancer therapy", "volume": "280", "author": "Richon", "year": "2009", "journal-title": "Cancer Lett"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB38|cit39", "doi-asserted-by": "crossref", "first-page": "825", "DOI": "10.1084/jem.185.5.825", "article-title": "Selective expression of an interleukin-12 receptor component by human T helper 1 cells", "volume": "185", "author": "Rogge", "year": "1997", "journal-title": "J Exp Med"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB39|cit40", "doi-asserted-by": "crossref", "first-page": "170", "DOI": "10.1038/nri2711", "article-title": "The regulation of IL-10 production by immune cells", "volume": "10", "author": "Saraiva", "year": "2010", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB40|cit41", "doi-asserted-by": "crossref", "first-page": "181", "DOI": "10.1111/j.1365-2230.2005.02019.x", "article-title": "Staging and management of cutaneous T-cell lymphoma", "volume": "31", "author": "Scarisbrick", "year": "2006", "journal-title": "Clin Exp Dermatol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB41|cit42", "doi-asserted-by": "crossref", "first-page": "1235", "DOI": "10.1016/j.chembiol.2006.09.018", "article-title": "Stattic: a small-molecule inhibitor of STAT3 activation and dimerization", "volume": "13", "author": "Schust", "year": "2006", "journal-title": "Chem Biol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB42|cit43", "doi-asserted-by": "crossref", "first-page": "255", "DOI": "10.1080/00015550152572877", "article-title": "Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101", "volume": "81", "author": "Shohat", "year": "2001", "journal-title": "Acta Derm Venereol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB43|cit44", "doi-asserted-by": "crossref", "first-page": "1293", "DOI": "10.1093/annonc/mdn792", "article-title": "HDAC inhibitor-based therapies and haematological malignancy", "volume": "20", "author": "Stimson", "year": "2009", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB44|cit45", "doi-asserted-by": "crossref", "first-page": "817", "DOI": "10.1084/jem.185.5.817", "article-title": "Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells", "volume": "185", "author": "Szabo", "year": "1997", "journal-title": "J Exp Med"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB45|cit46", "doi-asserted-by": "crossref", "first-page": "616", "DOI": "10.1016/j.bbrc.2008.12.132", "article-title": "HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A", "volume": "379", "author": "Togi", "year": "2009", "journal-title": "Biochem Biophys Res Commun"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB47|cit47", "doi-asserted-by": "crossref", "first-page": "92", "DOI": "10.1038/ni.1673", "article-title": "The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance", "volume": "10", "author": "Villagra", "year": "2009", "journal-title": "Nat Immunol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "9353", "DOI": "10.1021/jo801866z", "article-title": "Macrolactamization versus macrolactonization: total synthesis of FK228, the depsipeptide histone deacetylase inhibitor", "volume": "73", "author": "Wen", "year": "2008", "journal-title": "J Org Chem"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB49|cit49", "doi-asserted-by": "crossref", "first-page": "3768", "DOI": "10.1182/blood-2004-09-3502", "article-title": "WHO-EORTC classification for cutaneous lymphomas", "volume": "105", "author": "Willemze", "year": "2005", "journal-title": "Blood"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB50|cit50", "doi-asserted-by": "crossref", "first-page": "613", "DOI": "10.3324/haematol.2009.013870", "article-title": "Vorinostat interferes with the signaling transduction pathway of T cell receptor and synergizes with PI3K inhibitors in cutaneous T-cell lymphoma", "volume": "95", "author": "Wozniak", "year": "2010", "journal-title": "Haematologica"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB51|cit51", "doi-asserted-by": "crossref", "first-page": "147", "DOI": "10.1002/eji.1830270122", "article-title": "Regulation of interleukin-12 receptor beta1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells", "volume": "27", "author": "Wu", "year": "1997", "journal-title": "Eur J Immunol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB52|cit52", "doi-asserted-by": "crossref", "first-page": "208", "DOI": "10.1067/mjd.2001.116345", "article-title": "Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity", "volume": "45", "author": "Yoo", "year": "2001", "journal-title": "J Am Acad Dermatol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB53|cit53", "doi-asserted-by": "crossref", "first-page": "798", "DOI": "10.1038/nrc2734", "article-title": "STATs in cancer inflammation and immunity: a leading role for STAT3", "volume": "9", "author": "Yu", "year": "2009", "journal-title": "Nat Rev Cancer"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB54|cit54", "doi-asserted-by": "crossref", "first-page": "269", "DOI": "10.1126/science.1105166", "article-title": "Stat3 dimerization regulated by reversible acetylation of a single lysine residue", "volume": "307", "author": "Yuan", "year": "2005", "journal-title": "Science"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB55|cit55", "doi-asserted-by": "crossref", "first-page": "5720", "DOI": "10.1021/jm0703800", "article-title": "The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor", "volume": "50", "author": "Yurek-George", "year": "2007", "journal-title": "J Med Chem"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB56|cit56", "doi-asserted-by": "crossref", "first-page": "119", "DOI": "10.1046/j.0022-202x.2001.01354.x", "article-title": "Dysregulation of lymphocyte interleukin-12 receptor expression in Sezary syndrome", "volume": "117", "author": "Zaki", "year": "2001", "journal-title": "J Invest Dermatol"}, {"key": "10.1111/j.1476-5381.2010.01188.x-BIB57|cit57", "doi-asserted-by": "crossref", "first-page": "1045", "DOI": "10.1111/j.0022-202X.2005.23925.x", "article-title": "Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action", "volume": "125", "author": "Zhang", "year": "2005", "journal-title": "J Invest Dermatol"}], "container-title": ["British Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1476-5381.2010.01188.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 19]], "date-time": "2017-06-19T17:53:40Z", "timestamp": 1497894820000}, "score": 30.963722, "subtitle": ["Histone deacetylase inhibitors in CTCL"], "issued": {"date-parts": [[2011, 3, 4]]}, "references-count": 57, "journal-issue": {"published-print": {"date-parts": [[2011, 4]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1111/j.1476-5381.2010.01188.x", "relation": {"cites": []}, "ISSN": ["0007-1188"], "issn-type": [{"value": "0007-1188", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T02:04:28Z", "timestamp": 1574301868226}, "reference-count": 47, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2253, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J. Cell. Biochem."], "published-print": {"date-parts": [[2009, 7, 1]]}, "DOI": "10.1002/jcb.22185", "type": "journal-article", "created": {"date-parts": [[2009, 5, 20]], "date-time": "2009-05-20T13:49:30Z", "timestamp": 1242827370000}, "page": "600-608", "source": "Crossref", "is-referenced-by-count": 416, "title": ["Histone deacetylase inhibitors: Potential in cancer therapy"], "prefix": "10.1002", "volume": "107", "author": [{"given": "P.A.", "family": "Marks", "sequence": "first", "affiliation": []}, {"given": "W.-S.", "family": "Xu", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "10.1002/jcb.22185-BIB1", "doi-asserted-by": "crossref", "first-page": "1050", "DOI": "10.1016/j.lfs.2008.03.004", "article-title": "The use of diversity profiling to characterize chemical modulators of the histone deacetylases", "volume": "82", "author": "Blackwell", "year": "2008", "journal-title": "Life Sci"}, {"key": "10.1002/jcb.22185-BIB2", "doi-asserted-by": "crossref", "first-page": "769", "DOI": "10.1038/nrd2133", "article-title": "Anticancer activities of histone deacetylase inhibitors", "volume": "5", "author": "Bolden", "year": "2006", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1002/jcb.22185-BIB3", "doi-asserted-by": "crossref", "first-page": "6693", "DOI": "10.1038/sj.onc.1207893", "article-title": "Histone deacetylase inhibitors specifically kill nonproliferating tumour cells", "volume": "23", "author": "Burgess", "year": "2004", "journal-title": "Oncogene"}, {"key": "10.1002/jcb.22185-BIB4", "doi-asserted-by": "crossref", "first-page": "505", "DOI": "10.2174/138161208783885353", "article-title": "Chemical origins of isoform selectivity in histone deacetylase inhibitors", "volume": "14", "author": "Butler", "year": "2008", "journal-title": "Curr Pharm Des"}, {"key": "10.1002/jcb.22185-BIB5", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1016/j.canlet.2008.03.037", "article-title": "Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy", "volume": "269", "author": "Carew", "year": "2008", "journal-title": "Cancer Lett"}, {"key": "10.1002/jcb.22185-BIB6", "doi-asserted-by": "crossref", "first-page": "256", "DOI": "10.1126/science.1166226", "article-title": "HDAC4 regulates neuronal survival in normal and diseased retinas", "volume": "323", "author": "Chen", "year": "2009", "journal-title": "Science"}, {"key": "10.1002/jcb.22185-BIB7", "doi-asserted-by": "crossref", "first-page": "1311", "DOI": "10.1158/1535-7163.MCT-04-0287", "article-title": "Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824", "volume": "4", "author": "Chen", "year": "2005", "journal-title": "Mol Cancer Ther"}, {"key": "10.1002/jcb.22185-BIB8", "doi-asserted-by": "crossref", "first-page": "981", "DOI": "10.1158/1541-7786.MCR-07-0324", "article-title": "Histone deacetylase inhibitors: Overview and perspectives", "volume": "5", "author": "Dokmanovic", "year": "2007", "journal-title": "Mol Cancer Res"}, {"key": "10.1002/jcb.22185-BIB9", "doi-asserted-by": "crossref", "first-page": "2525", "DOI": "10.1158/1535-7163.MCT-07-0251", "article-title": "Histone deacetylase inhibitors selectively suppress expression of HDAC7", "volume": "6", "author": "Dokmanovic", "year": "2007", "journal-title": "Mol Cancer Ther"}, {"key": "10.1002/jcb.22185-BIB10", "doi-asserted-by": "crossref", "first-page": "1111", "DOI": "10.1517/13543784.16.7.1111", "article-title": "Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma", "volume": "16", "author": "Duvic", "year": "2007", "journal-title": "Expert Opin Invest Drugs"}, {"key": "10.1002/jcb.22185-BIB11", "doi-asserted-by": "crossref", "first-page": "2898", "DOI": "10.1021/jm7015254", "article-title": "Structural origin of selectivity in class II-selective histone deacetylase inhibitors", "volume": "51", "author": "Estiu", "year": "2008", "journal-title": "J Med Chem"}, {"key": "10.1002/jcb.22185-BIB12", "doi-asserted-by": "crossref", "first-page": "7237", "DOI": "10.1158/1078-0432.CCR-07-2114", "article-title": "Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications", "volume": "13", "author": "Fantin", "year": "2007", "journal-title": "Clin Cancer Res"}, {"key": "10.1002/jcb.22185-BIB13", "doi-asserted-by": "crossref", "first-page": "188", "DOI": "10.1038/43710", "article-title": "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors", "volume": "401", "author": "Finnin", "year": "1999", "journal-title": "Nature"}, {"key": "10.1002/jcb.22185-BIB14", "doi-asserted-by": "crossref", "first-page": "5420", "DOI": "10.1038/sj.onc.1210610", "article-title": "Histone deacetylases and cancer", "volume": "26", "author": "Glozak", "year": "2007", "journal-title": "Oncogene"}, {"key": "10.1002/jcb.22185-BIB15", "doi-asserted-by": "crossref", "first-page": "1241", "DOI": "10.1073/pnas.0307708100", "article-title": "Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1", "volume": "101", "author": "Gui", "year": "2004", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB16", "doi-asserted-by": "crossref", "first-page": "4389", "DOI": "10.1073/pnas.0430973100", "article-title": "Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation", "volume": "100", "author": "Haggarty", "year": "2003", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB17", "doi-asserted-by": "crossref", "first-page": "8567", "DOI": "10.1073/pnas.0503221102", "article-title": "Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma", "volume": "102", "author": "Hideshima", "year": "2005", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB18", "doi-asserted-by": "crossref", "first-page": "683", "DOI": "10.1016/j.cell.2007.01.029", "article-title": "The epigenomics of cancer", "volume": "128", "author": "Jones", "year": "2007", "journal-title": "Cell"}, {"key": "10.1002/jcb.22185-BIB19", "doi-asserted-by": "crossref", "first-page": "3456", "DOI": "10.1016/j.bmcl.2008.02.026", "article-title": "2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors", "volume": "18", "author": "Jones", "year": "2008", "journal-title": "Bioorg Med Chem Lett"}, {"key": "10.1002/jcb.22185-BIB20", "doi-asserted-by": "crossref", "first-page": "1801", "DOI": "10.1126/science.1164368", "article-title": "Core signaling pathways in human pancreatic cancers revealed by global genomic analyses", "volume": "321", "author": "Jones", "year": "2008", "journal-title": "Science"}, {"key": "10.1002/jcb.22185-BIB21", "doi-asserted-by": "crossref", "first-page": "581", "DOI": "10.1042/BJ20070779", "article-title": "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors", "volume": "409", "author": "Khan", "year": "2008", "journal-title": "Biochem J"}, {"key": "10.1002/jcb.22185-BIB22", "doi-asserted-by": "crossref", "first-page": "3054", "DOI": "10.1021/jm070178x", "article-title": "Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies", "volume": "50", "author": "Kozikowski", "year": "2007", "journal-title": "J Med Chem"}, {"key": "10.1002/jcb.22185-BIB23", "doi-asserted-by": "crossref", "first-page": "84", "DOI": "10.1038/nbt1272", "article-title": "Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug", "volume": "25", "author": "Marks", "year": "2007", "journal-title": "Nat Biotechnol"}, {"key": "10.1002/jcb.22185-BIB24", "doi-asserted-by": "crossref", "first-page": "38", "DOI": "10.1038/nrc1779", "article-title": "Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer", "volume": "6", "author": "Minucci", "year": "2006", "journal-title": "Nat Rev Cancer"}, {"key": "10.1002/jcb.22185-BIB25", "doi-asserted-by": "crossref", "first-page": "841", "DOI": "10.2174/156802608784911581", "article-title": "Histone deacetylase inhibitors in cancer therapy: New compounds and clinical update of benzamide-type agents", "volume": "8", "author": "Moradei", "year": "2008", "journal-title": "Curr Top Med Chem"}, {"key": "10.1002/jcb.22185-BIB26", "doi-asserted-by": "crossref", "first-page": "689", "DOI": "10.1038/sj.bjc.6604557", "article-title": "Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?", "volume": "99", "author": "Nolan", "year": "2008", "journal-title": "Br J Cancer"}, {"key": "10.1002/jcb.22185-BIB27", "first-page": "682", "article-title": "Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis", "volume": "1", "author": "Nonn", "year": "2003", "journal-title": "Mol Cancer Res"}, {"key": "10.1002/jcb.22185-BIB28", "doi-asserted-by": "crossref", "first-page": "1179", "DOI": "10.1016/j.bbrc.2008.03.019", "article-title": "Inhibition of histone deacetylase1 induces autophagy", "volume": "369", "author": "Oh", "year": "2008", "journal-title": "Biochem Biophys Res Commun"}, {"key": "10.1002/jcb.22185-BIB29", "doi-asserted-by": "crossref", "first-page": "9633", "DOI": "10.1073/pnas.0803749105", "article-title": "HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation", "volume": "105", "author": "Parmigiani", "year": "2008", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB30", "doi-asserted-by": "crossref", "first-page": "3697", "DOI": "10.1073/pnas.0500369102", "article-title": "Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors", "volume": "102", "author": "Peart", "year": "2005", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB31", "doi-asserted-by": "crossref", "first-page": "8814", "DOI": "10.1158/0008-5472.CAN-05-4598", "article-title": "Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha", "volume": "66", "author": "Qian", "year": "2006", "journal-title": "Cancer Res"}, {"key": "10.1002/jcb.22185-BIB32", "doi-asserted-by": "crossref", "first-page": "659", "DOI": "10.1517/13543784.16.5.659", "article-title": "Histone deacetylase inhibitors in cancer therapy", "volume": "16", "author": "Rasheed", "year": "2007", "journal-title": "Expert Opin Invest Drugs"}, {"key": "10.1002/jcb.22185-BIB33", "doi-asserted-by": "crossref", "first-page": "717", "DOI": "10.4161/cc.4.5.1690", "article-title": "Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin", "volume": "4", "author": "Robbins", "year": "2005", "journal-title": "Cell Cycle"}, {"key": "10.1002/jcb.22185-BIB34", "first-page": "216", "article-title": "The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide", "volume": "69", "author": "Rosato", "year": "2006", "journal-title": "Mol Pharmacol"}, {"key": "10.1002/jcb.22185-BIB35", "author": "Schemies", "year": "2009", "article-title": "Histone deacetylase inhibitors that target tubulin", "journal-title": "Cancer Lett.", "DOI": "10.1016/j.canlet.2009.01.040", "doi-asserted-by": "crossref"}, {"key": "10.1002/jcb.22185-BIB36", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1002/jcb.20179", "article-title": "Regulation of histone deacetylase activities", "volume": "93", "author": "Sengupta", "year": "2004", "journal-title": "J Cell Biochem"}, {"key": "10.1002/jcb.22185-BIB37", "doi-asserted-by": "crossref", "first-page": "261", "DOI": "10.1007/978-1-4020-6554-5_13", "article-title": "Histone deacetylase inhibitors: Mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis", "volume": "615", "author": "Shankar", "year": "2008", "journal-title": "Adv Exp Med Biol"}, {"key": "10.1002/jcb.22185-BIB38", "doi-asserted-by": "crossref", "first-page": "1325", "DOI": "10.1016/j.str.2004.04.012", "article-title": "Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases", "volume": "12", "author": "Somoza", "year": "2004", "journal-title": "Structure"}, {"key": "10.1002/jcb.22185-BIB39", "doi-asserted-by": "crossref", "first-page": "10508", "DOI": "10.1074/jbc.M512719200", "article-title": "Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity", "volume": "281", "author": "Tan", "year": "2006", "journal-title": "J Biol Chem"}, {"key": "10.1002/jcb.22185-BIB40", "doi-asserted-by": "crossref", "first-page": "673", "DOI": "10.1073/pnas.0408732102", "article-title": "Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors", "volume": "102", "author": "Ungerstedt", "year": "2005", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB41", "doi-asserted-by": "crossref", "first-page": "15064", "DOI": "10.1073/pnas.0404603101", "article-title": "Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor", "volume": "101", "author": "Vannini", "year": "2004", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB42", "doi-asserted-by": "crossref", "first-page": "958", "DOI": "10.1158/0008-5472.CAN-08-2216", "article-title": "Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer", "volume": "69", "author": "Welsbie", "year": "2009", "journal-title": "Cancer Res"}, {"key": "10.1002/jcb.22185-BIB43", "doi-asserted-by": "crossref", "first-page": "15540", "DOI": "10.1073/pnas.0607518103", "article-title": "Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor", "volume": "103", "author": "Xu", "year": "2006", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/jcb.22185-BIB44", "doi-asserted-by": "crossref", "first-page": "5541", "DOI": "10.1038/sj.onc.1210620", "article-title": "Histone deacetylase inhibitors: Molecular mechanisms of action", "volume": "26", "author": "Xu", "year": "2007", "journal-title": "Oncogene"}, {"key": "10.1002/jcb.22185-BIB45", "first-page": "1585", "article-title": "Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines", "volume": "28", "author": "Yamamoto", "year": "2008", "journal-title": "Anticancer Res"}, {"key": "10.1002/jcb.22185-BIB46", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.1016/j.molcel.2007.05.033", "article-title": "HDAC6 modulates cell motility by altering the acetylation level of cortactin", "volume": "27", "author": "Zhang", "year": "2007", "journal-title": "Mol Cell"}, {"key": "10.1002/jcb.22185-BIB47", "doi-asserted-by": "crossref", "first-page": "1388", "DOI": "10.4161/cbt.7.9.6415", "article-title": "Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer", "volume": "7", "author": "Zhang", "year": "2008", "journal-title": "Cancer Biol Ther"}], "container-title": ["Journal of Cellular Biochemistry"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjcb.22185", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 20]], "date-time": "2019-02-20T11:17:16Z", "timestamp": 1550661436000}, "score": 30.643059, "issued": {"date-parts": [[2009, 7, 1]]}, "references-count": 47, "journal-issue": {"published-print": {"date-parts": [[2009, 7, 1]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1002/jcb.22185", "relation": {"cites": []}, "ISSN": ["0730-2312", "1097-4644"], "issn-type": [{"value": "0730-2312", "type": "print"}, {"value": "1097-4644", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:31:04Z", "timestamp": 1574490664183}, "reference-count": 0, "publisher": "Informa UK Limited", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cell Cycle"], "published-print": {"date-parts": [[2005, 4, 28]]}, "DOI": "10.4161/cc.4.4.1564", "type": "journal-article", "created": {"date-parts": [[2011, 1, 21]], "date-time": "2011-01-21T19:01:02Z", "timestamp": 1295636462000}, "page": "549-551", "source": "Crossref", "is-referenced-by-count": 99, "title": ["Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy"], "prefix": "10.1080", "volume": "4", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}, {"given": "Xuejun", "family": "Jiang", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2005, 1, 28]]}, "container-title": ["Cell Cycle"], "language": "en", "link": [{"URL": "https://www.tandfonline.com/doi/pdf/10.4161/cc.4.4.1564", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 7, 2]], "date-time": "2018-07-02T08:38:31Z", "timestamp": 1530520711000}, "score": 30.643059, "issued": {"date-parts": [[2005, 1, 28]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2005, 1, 28]]}, "published-print": {"date-parts": [[2005, 4, 28]]}, "issue": "4"}, "alternative-id": ["10.4161/cc.4.4.1564"], "URL": "http://dx.doi.org/10.4161/cc.4.4.1564", "ISSN": ["1538-4101", "1551-4005"], "issn-type": [{"value": "1538-4101", "type": "print"}, {"value": "1551-4005", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:11:51Z", "timestamp": 1574133111018}, "publisher-location": "Chichester, UK", "reference-count": 0, "publisher": "John Wiley & Sons, Ltd", "isbn-type": [{"value": "0470862610", "type": "print"}, {"value": "0470862637", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/0470862637.ch20", "type": "book-chapter", "created": {"date-parts": [[2004, 7, 23]], "date-time": "2004-07-23T15:00:36Z", "timestamp": 1090594836000}, "page": "269-284", "source": "Crossref", "is-referenced-by-count": 32, "title": ["Histone Deacetylase Inhibitors: Development as Cancer Therapy"], "prefix": "10.1002", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}, {"given": "Victoria M.", "family": "Richon", "sequence": "additional", "affiliation": []}, {"given": "Wm Kevin", "family": "Kelly", "sequence": "additional", "affiliation": []}, {"given": "Judy H.", "family": "Chiao", "sequence": "additional", "affiliation": []}, {"given": "Thomas", "family": "Miller", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2008, 10, 7]]}, "container-title": ["Reversible Protein Acetylation", "Novartis Foundation Symposia"], "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F0470862637.ch20", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/0470862637.ch20", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T23:34:05Z", "timestamp": 1533166445000}, "score": 30.62727, "issued": {"date-parts": [[2008, 10, 7]]}, "ISBN": ["9780470862612", "0470862610", "9780470862636", "0470862637"], "references-count": 0, "URL": "http://dx.doi.org/10.1002/0470862637.ch20", "ISSN": ["1935-4657"], "issn-type": [{"value": "1935-4657", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:55:08Z", "timestamp": 1574135708179}, "reference-count": 135, "publisher": "Elsevier", "isbn-type": [{"value": "9780120066919", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2004]]}, "DOI": "10.1016/s0065-230x(04)91004-4", "type": "book-chapter", "created": {"date-parts": [[2004, 8, 27]], "date-time": "2004-08-27T13:04:12Z", "timestamp": 1093611852000}, "page": "137-168", "source": "Crossref", "is-referenced-by-count": 295, "title": ["Histone Deacetylase Inhibitors"], "prefix": "10.1016", "author": [{"given": "Paul A.", "family": "Marks", "sequence": "first", "affiliation": []}, {"given": "Victoria M.", "family": "Richon", "sequence": "additional", "affiliation": []}, {"given": "Thomas", "family": "Miller", "sequence": "additional", "affiliation": []}, {"given": "William Kevin", "family": "Kelly", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Advances in Cancer Research"], "deposited": {"date-parts": [[2019, 2, 4]], "date-time": "2019-02-04T15:26:15Z", "timestamp": 1549293975000}, "score": 30.619802, "issued": {"date-parts": [[2004]]}, "ISBN": ["9780120066919"], "references-count": 135, "URL": "http://dx.doi.org/10.1016/s0065-230x(04)91004-4", "ISSN": ["0065-230X"], "issn-type": [{"value": "0065-230X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T08:50:19Z", "timestamp": 1574326219814}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Molecular Cancer Research"], "published-print": {"date-parts": [[2007, 10, 1]]}, "DOI": "10.1158/1541-7786.mcr-07-0324", "type": "journal-article", "created": {"date-parts": [[2007, 10, 19]], "date-time": "2007-10-19T14:46:06Z", "timestamp": 1192805166000}, "page": "981-989", "source": "Crossref", "is-referenced-by-count": 654, "title": ["Histone Deacetylase Inhibitors: Overview and Perspectives"], "prefix": "10.1158", "volume": "5", "author": [{"given": "M.", "family": "Dokmanovic", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Clarke", "sequence": "additional", "affiliation": []}, {"given": "P. A.", "family": "Marks", "sequence": "additional", "affiliation": []}], "member": "1086", "container-title": ["Molecular Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1541-7786.MCR-07-0324", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 22]], "date-time": "2016-12-22T23:24:59Z", "timestamp": 1482449099000}, "score": 29.705572, "issued": {"date-parts": [[2007, 10, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2007, 10, 1]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1158/1541-7786.mcr-07-0324", "ISSN": ["1541-7786", "1557-3125"], "issn-type": [{"value": "1541-7786", "type": "print"}, {"value": "1557-3125", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T04:48:06Z", "timestamp": 1574484486568}, "reference-count": 23, "publisher": "Future Medicine Ltd", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Epigenomics"], "published-print": {"date-parts": [[2010, 12]]}, "DOI": "10.2217/epi.10.59", "type": "journal-article", "created": {"date-parts": [[2010, 12, 15]], "date-time": "2010-12-15T14:11:29Z", "timestamp": 1292422289000}, "page": "723-725", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Histone deacetylase inhibitors in the therapy of cancer: much to learn"], "prefix": "10.2217", "volume": "2", "author": [{"given": "Ju-Hee", "family": "Lee", "sequence": "first", "affiliation": []}, {"given": "Paul A", "family": "Marks", "sequence": "additional", "affiliation": []}], "member": "1057", "reference": [{"key": "ref-1", "author": "Marks", "year": "2010", "journal-title": "Biochim. Biophys. Acta"}, {"key": "ref-2", "author": "Schrump", "volume": "15", "first-page": "3947", "year": "2009", "journal-title": "Clin. Cancer Res.", "DOI": "10.1158/1078-0432.CCR-08-2787", "doi-asserted-by": "crossref"}, {"key": "ref-3", "DOI": "10.1186/1756-8722-3-5", "doi-asserted-by": "publisher"}, {"key": "ref-4", "author": "Willyard", "volume": "16", "first-page": "18", "year": "2010", "journal-title": "Nat. Med.", "DOI": "10.1038/nm0110-18", "doi-asserted-by": "crossref"}, {"key": "ref-5", "DOI": "10.1517/13543784.2010.510514", "doi-asserted-by": "publisher"}, {"key": "ref-6", "DOI": "10.1146/annurev.biochem.76.052705.162114", "doi-asserted-by": "publisher"}, {"key": "ref-7", "author": "Struhl", "volume": "293", "first-page": "1054", "year": "2001", "journal-title": "Science", "DOI": "10.1126/science.1064050", "doi-asserted-by": "crossref"}, {"key": "ref-8", "DOI": "10.1016/j.cell.2007.01.029", "doi-asserted-by": "publisher"}, {"key": "ref-9", "DOI": "10.1016/j.jmb.2004.02.006", "doi-asserted-by": "publisher"}, {"key": "ref-10", "DOI": "10.1126/science.1175371", "doi-asserted-by": "publisher"}, {"key": "ref-11", "DOI": "10.1056/NEJMra072067", "doi-asserted-by": "publisher"}, {"key": "ref-12", "author": "Parmigiani", "volume": "105", "first-page": "9633", "year": "2008", "journal-title": "Proc. Natl Acad. Sci. USA", "DOI": "10.1073/pnas.0803749105", "doi-asserted-by": "crossref"}, {"key": "ref-13", "DOI": "10.1073/pnas.0430973100", "doi-asserted-by": "publisher"}, {"key": "ref-14", "author": "Zhang", "volume": "27", "first-page": "197", "year": "2007", "journal-title": "Mol. Cell", "DOI": "10.1016/j.molcel.2007.05.033", "doi-asserted-by": "crossref"}, {"key": "ref-15", "author": "Kovacs", "volume": "18", "first-page": "601", "year": "2005", "journal-title": "Mol. Cell", "DOI": "10.1016/j.molcel.2005.04.021", "doi-asserted-by": "crossref"}, {"key": "ref-16", "DOI": "10.1016/S0092-8674(03)00939-5", "doi-asserted-by": "publisher"}, {"key": "ref-17", "DOI": "10.1038/43710", "doi-asserted-by": "publisher"}, {"key": "ref-18", "author": "Ficner", "volume": "9", "first-page": "235", "year": "2009", "journal-title": "Curr. Top. Med. Chem.", "DOI": "10.2174/156802609788085304", "doi-asserted-by": "crossref"}, {"key": "ref-19", "author": "Lee", "volume": "107", "first-page": "14639", "year": "2010", "journal-title": "Proc. Natl Acad. Sci. USA", "DOI": "10.1073/pnas.1008522107", "doi-asserted-by": "crossref"}, {"key": "ref-20", "DOI": "10.1073/pnas.0408732102", "doi-asserted-by": "publisher"}, {"key": "ref-21", "author": "Kato", "volume": "69", "first-page": "3597", "year": "2009", "journal-title": "Cancer Res.", "DOI": "10.1158/0008-5472.CAN-08-4368", "doi-asserted-by": "crossref"}, {"key": "ref-22", "author": "Tan", "volume": "281", "first-page": "10508", "year": "2006", "journal-title": "J. Biol. Chem.", "DOI": "10.1074/jbc.M512719200", "doi-asserted-by": "crossref"}, {"key": "ref-23", "DOI": "10.2165/11315680-000000000-00000", "doi-asserted-by": "publisher"}], "container-title": ["Epigenomics"], "language": "en", "link": [{"URL": "https://www.futuremedicine.com/doi/pdf/10.2217/epi.10.59", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T09:53:32Z", "timestamp": 1574243612000}, "score": 29.705572, "issued": {"date-parts": [[2010, 12]]}, "references-count": 23, "journal-issue": {"published-print": {"date-parts": [[2010, 12]]}, "issue": "6"}, "alternative-id": ["10.2217/epi.10.59"], "URL": "http://dx.doi.org/10.2217/epi.10.59", "relation": {"cites": []}, "ISSN": ["1750-1911", "1750-192X"], "issn-type": [{"value": "1750-1911", "type": "print"}, {"value": "1750-192X", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}